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Abstract 
The development of a functional tissue-engineered human skeletal 
muscle model in vitro would provide an excellent platform on which to study the 
process of myogenesis, various musculoskeletal disease states, and drugs for 
muscle toxicity. The global hypothesis that motivated this research was that joint 
inhibition of microRNA (miR)-133a and miR-696 in isolated primary human 
skeletal myoblasts (HSkM) leads to accelerated differentiation of tissue-
engineered muscle constructs with higher proportion of Type I myofibers and 
that are capable of significantly increased active contractile forces when 
subjected to electrical stimulus. The proposed research tested the following 
specific hypotheses: (1) HSkM require different culture conditions than those 
optimal for C2C12 culture, as measured by differentiation and microRNA 
expression, (2) in 2D culture, joint inhibition of miR-133a and miR-696 
accelerates, (3) inhibition of miR-133a and/or miR-696 in 3D human skeletal 
muscle model results in active contractile forces significantly higher than control, 
and finally (4) co-culture of human cord blood-derived endothelial cells (ECs) on 
the surface of 3D HSkM bundles is capable of active contraction, as measured by 
isometric force testing and immunofluorescence.  
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Culture conditions of 100 μg/mL growth factor reduced-Matrigel-coated 
substrates and 2% equine serum in differentiation medium improve HSkM 
culture, compared to conditions optimal for C2C12 cell culture (uncoated 
substrates and 8% equine serum media). Liposomal transfection of HSkM with 
anti-miR-133a and anti-miR-696 led to increased presence of sarcomeric α-actinin 
and PGC-1α proteins when cells were cultured in 2D for 2 weeks. Presence of 
mitochondria and distribution of fiber type did not change with microRNA 
transfection in a 2D culture. Joint inhibition also resulted in increased 
PPARGC1A gene expression after 2 weeks of 2D culture. For muscle bundles in 
3D, there exists a myoblast seeding density threshold for the production of 
functional muscle. 5 x 106 HSkM/mL did not produce active contraction, while 10 
x 106 HSkM/mL and above were successful. Of the seeding densities studied, 15 x 
106 HSkM/mL produced constructs that exerted the highest twitch and tetanus 
forces. Treatment of human skeletal muscle with anti-miR-133a and anti-miR-696 
led to significant increases in force amplitude when both anti-miRs were added 
together compared to negative control (transfection with scrambled sequence). 
Joint inhibition in myoblasts seeded into 3D constructs led to decreased presence 
of slow myosin heavy chain and increased fast myosin heavy chain. Finally, co- 
  
  
vi 
culture of functional HSkM with ECs is possible in 3.3% FBS in  
DMEM culture conditions, with significant increases in force amplitudes after 48 
of co-culture. These results suggest the potential of delivering more than one 
microRNA for therapy and the feasibility of developing a functional HSkM-EC 
co-culture model. 
  
vii 
Dedication 
This dissertation is dedicated to my grandfather, Chen-Ho Wang, whose 
curiosity was infectious. We miss you dearly. 
 
  
viii 
Contents 
Abstract ............................................................................................................................ iv 
List of Tables ................................................................................................................. xiv 
List of Figures ................................................................................................................. xv 
Acknowledgements .................................................................................................... xviii 
CHAPTER 1.  INTRODUCTION ................................................................................... 1 
1.1. Research Overview ................................................................................................ 1 
1.2. Skeletal Muscle Development .............................................................................. 4 
1.2.1. Satellite Cells and Muscle Repair ................................................................... 4 
1.2.2. Structure and Function of Skeletal Muscle ................................................... 6 
1.3. Considerations for Skeletal Muscle Tissue Engineering ................................ 17 
1.3.1. Satellite Cells ................................................................................................... 18 
1.3.2. Scaffold ............................................................................................................ 19 
1.3.3. Metabolism and Myofiber Types ................................................................. 22 
1.3.4. Contractile Forces ........................................................................................... 24 
1.4. Methods to Increase Muscle Maturity and Force Production ....................... 26 
1.4.1. Mechanical and Electrical Stimulation ........................................................ 26 
1.4.2. MicroRNA’s .................................................................................................... 28 
1.5. Motivation and Significance ............................................................................... 34 
1.6. Hypothesis & Specific Aims ............................................................................... 35 
  
  
ix 
CHAPTER 2. Optimization and Characterization of Primary Human Skeletal 
Myoblasts (HSkM) (Specific Aim 1) ............................................................................ 38 
2.1. Introduction .......................................................................................................... 38 
2.2. Materials and Methods ....................................................................................... 40 
2.2.1. Primary Human Skeletal Myoblast Isolation ............................................. 40 
2.2.2. Cell Culture ..................................................................................................... 41 
2.2.3. Myoblast Size and Growth Rate ................................................................... 42 
2.2.4. Immunofluorescence ..................................................................................... 42 
2.2.5. MicroRNA/RNA Isolation and Quantitative Real-Time PCR .................. 44 
2.2.6. Cyclic Mechanical Stretch ............................................................................. 46 
2.2.7. Statistical Analysis ......................................................................................... 47 
2.3. Results ................................................................................................................... 47 
2.3.1. Comparison of C2C12 and HSkM growth, size, and differentiation 
under conditions optimal for C2C12 myofiber maturation ............................... 47 
2.3.2. Culture Conditions for HSkM ...................................................................... 53 
2.3.3. Effect of culture conditions on C2C12 and HSkM microRNA and MEF-
2C expression ............................................................................................................ 54 
2.3.4. Effect of stretch on HSkM differentiation ................................................... 59 
2.3.5. Comparison of microRNA levels in fresh muscle explants and culture 
HSkM ......................................................................................................................... 61 
2.4. Discussion ............................................................................................................. 62 
2.5. Chapter Acknowledgements .............................................................................. 68 
  
  
x 
CHAPTER 3: Joint Inhibition of miR-133a and miR-696 for Accelerated Type I 
Human Myofiber Differentiation In Vitro (Specific Aims 2 & 3) ............................ 69 
3.1. Introduction .......................................................................................................... 69 
3.2. Materials and Methods ....................................................................................... 71 
3.2.1. Primary HSkM Isolation................................................................................ 71 
3.2.2. Cell Culture ..................................................................................................... 72 
3.2.3. MicroRNA Transient Transfection .............................................................. 73 
3.2.4. Mold Preparation and Sterilization ............................................................. 74 
3.2.5. Engineered 3D Human Muscle Bundle Construction .............................. 75 
3.2.6. Immunofluorescence ..................................................................................... 76 
3.2.7. Quantitative Real-Time PCR of Mef-2C and PPARGC1A ........................ 77 
3.2.8. Western Blot .................................................................................................... 77 
3.2.9. Measurement of Contractile Force ............................................................... 79 
3.2.10. Statistical Analysis ....................................................................................... 80 
3.3. Results ................................................................................................................... 80 
3.3.1. Transient Transfection Efficiency and Lifetime of MicroRNA’s ............. 80 
3.3.2. MiR-133a and MiR-696 Inhibition in 2D Cultures Accelerates 
Myogenesis and Affects PGC-1α ........................................................................... 81 
3.3.3. Functional Three-Dimensional Human Skeletal Muscle Bundles ........... 87 
3.3.4. Effect of MicroRNA-133a and/or -696 Inhibitors upon 3D Human 
Skeletal Muscle Bundles .......................................................................................... 92 
  
  
xi 
3.4. Discussion ........................................................................................................... 107 
3.5. Chapter Acknowledgements ............................................................................ 117 
CHAPTER 4. Endothelialization of Human Skeletal Muscle Bundles (Specific 
Aim 4) ............................................................................................................................ 118 
4.1. Introduction ........................................................................................................ 118 
4.2. Materials and Methods ..................................................................................... 120 
4.2.1. Endothelial Progenitor Cell Isolation and Culture .................................. 120 
4.2.2. Human Skeletal Muscle and Endothelial Progenitor Cell Co-Culture in 
2D .............................................................................................................................. 121 
4.2.3. Human Skeletal Muscle and Endothelial Progenitor Cell Co-Culture in 
3D .............................................................................................................................. 122 
4.2.4. Isometric Force Testing ................................................................................ 122 
4.2.5 Immunofluorescence .................................................................................... 123 
4.2.6. Statistical Analysis ....................................................................................... 124 
4.3. Results ................................................................................................................. 124 
4.3.1. Endothelial Cell Coverage of Fused Skeletal Muscle in 2D Studies ..... 124 
4.3.2. Identification of Co-culture Media for Retention of HSkM Bundle 
Functionality ........................................................................................................... 128 
4.3.3. Co-culture Bundle Functionality is Retained in 3.3% FBS in DMEM ... 130 
4.3.4. Endothelial Cell Coverage of Muscle Bundle in 3.3% FBS in DMEM .. 132 
4.4. Discussion ........................................................................................................... 136 
4.5. Acknowledgements ........................................................................................... 140 
  
  
xii 
CHAPTER 5. Dissertation Summary & Future Work ............................................ 141 
5.1. Dissertation Summary ....................................................................................... 141 
5.2. Strengths & Weaknesses of Work .................................................................... 145 
5.3. Implications for Tissue Engineering ............................................................... 149 
APPENDICES .............................................................................................................. 152 
APPENDIX A. Antibodies .......................................................................................... 153 
APPENDIX B. Primer Sequences for Quantitative Real Time RT-PCR ............... 154 
APPENDIX C. MATLAB Code for Force Measurements ...................................... 155 
APPENDIX D. HSkM Culture Media Recipes ........................................................ 156 
APPENDIX E. Matrigel Coating Protocol ................................................................ 158 
APPENDIX F. HSkM Isolation Protocol .................................................................. 159 
APPENDIX G. HSkM Muscle Bundle Protocol ....................................................... 164 
APPENDIX H. Immunostaining Protocol ................................................................ 166 
APPENDIX I. HSkM miR Transfection Protocol .................................................... 167 
APPENDIX J. miR Isolation Protocol ....................................................................... 168 
APPENDIX K. TAQMAN qRT-PCR for miR Expression ...................................... 170 
APPENDIX L. SYBR Green qRT-PCR Protocol ....................................................... 174 
APPENDIX M. Western Blot Protocol ...................................................................... 177 
APPENDIX N. Copyright Releases ........................................................................... 184 
  
  
xiii 
REFERENCES .............................................................................................................. 185 
BIOGRAPHY ................................................................................................................ 210 
 
  
xiv 
List of Tables 
Table 1: Z- and M-line widths for humans [43] ......................................................... 16 
Table 2. MicroRNA Levels in Explant, C2C12, and HSkM. [1] ............................... 62 
 
 
  
xv 
List of Figures 
Figure 1. Schematic of satellite cell myogenesis and markers typical of each stage. 
[17] ..................................................................................................................................... 7 
Figure 2: Components of sarcomere. ............................................................................ 8 
Figure 3: Skeletal muscle force-length relationship. ................................................. 16 
Figure 4. MicroRNA Pathway for Proliferation and Differentiation of Skeletal 
Muscle. ............................................................................................................................ 31 
Figure 5. MicroRNA Pathway for Energy Metabolism in Skeletal Muscle. .......... 33 
Figure 6. C2C12 vs. HSkM Cell Area. ......................................................................... 49 
Figure 7. C2C12 vs. HSkM Growth Rates. ................................................................. 49 
Figure 8. Effect of DM on Cell Proliferation. ............................................................. 50 
Figure 9. C2C12 vs. HSkM Myofiber Morphology. .................................................. 52 
Figure 10. Effect of serum and Matrigel coating on formation of striated human 
muscle fibers 14 days after shifting to differentiation medium (DM) with the 
indicated level of serum. .............................................................................................. 54 
Figure 11. Comparison of microRNA and Mef-2C mRNA levels in mouse C2C12 
(reference) and HSkM cells. ......................................................................................... 58 
Figure 12. Effect of culture conditions on expression of microRNAs. ................... 59 
Figure 13. Cyclic Stretch Affects microRNA Levels. ................................................ 61 
Figure 14. Preparation of PDMS Molds for Engineered 3D human skeletal muscle 
bundle construction. ..................................................................................................... 75 
Figure 15: Schmatic of isometric force testing setup. ............................................... 79 
Figure 16: Transfection efficiency and lifetime of exogenous microRNA. ............ 81 
  
  
xvi 
Figure 17: Sarcomeric α-actinin and mitochondria presence in 2D cultures. ....... 84 
Figure 18: Expression of PPARGC1A gene at Day 14 post-differentiation. .......... 85 
Figure 19: Fiber Type in 2D Engineered Human Skeletal Muscle. ......................... 87 
Figure 20: Engineered human skeletal muscle bundles with  5 x 106 cell/mL. ..... 88 
Figure 21: Human skeletal muscle bundle ultrastructure in 3D cultures seeded 
with 10 x 106 cells/mL. ................................................................................................... 89 
Figure 22: HSkM seeding density for muscle bundles. ............................................ 90 
Figure 23: Human skeletal muscle bundle ultrastructure in 3D cultures. ............. 91 
Figure 24: Bundle diameters and fiber density. ........................................................ 94 
Figure 25: Active and passive forces generated by engineered human skeletal 
muscle. ............................................................................................................................ 96 
Figure 26. Isometric force testing of muscle bundles.. ............................................. 98 
Figure 27: Specific force per muscle fiber area. ....................................................... 101 
Figure 28. Half Relaxation Time. ............................................................................... 102 
Figure 29: Myosin heavy chain presence.. ............................................................... 104 
Figure 30: Immunofluorescence for slow and fast fibers. ...................................... 106 
Figure 31: Mef-2C expression of engineered human skeletal muscle. ................. 107 
Figure 32: Role of Mef-2 in development of fiber type. ......................................... 116 
Figure 33: 2D Co-Culture Media Studies. ................................................................ 126 
Figure 34: Percent Coverage of EC and HSkM. ...................................................... 127 
Figure 35: Testing co-culture media in muscle-only engineered constructs. ...... 129 
  
  
xvii 
Figure 36: Ultrastructure of muscle-only bundles in tested co-culture media. .. 130 
Figure 37: Twitch and tetanus force amplitude for co-culture bundles. ............. 131 
Figure 38: Endothelial cell coverage on engineered muscle bundles. .................. 134 
Figure 39: Orthogonal views of co-culture bundles. .............................................. 135 
 
  
xviii 
Acknowledgements 
I would like to acknowledge my advisor Dr. Truskey for his guidance 
and encouragement through this process. As an advisor who has mentored me 
through my undergraduate and graduate time at Duke, he has truly shaped me 
as a researcher. I am hugely grateful for his time, dedication, and faith in my 
abilities. I would also like to thank my committee members for their invaluable 
insight and feedback. I truly believe that with their help my project has become 
more complete and cohesive. 
 Next, I would like to thank my friend and graduate mentor Caroline 
Rhim for her constant guidance in lab and also in life. Thank you for agreeing to 
mentor me – otherwise, I would likely not be where I am now! Thank you for 
being such a caring colleague and friend. I also extend my most heartfelt thanks 
to the ladies of the Truskey Lab: Tracy Cheung, Alexandra Jantzen, and Brittany 
Davis. You all made coming to work such an enjoyable time. I could not have 
asked for a better support system through the stresses of graduate school and for 
that I am hugely grateful. 
  
  
  
xix 
Many individuals contributed to the success of this project, and without them, 
this would not be possible. I would like to thank: Yasheng Gao for his expertise 
and guidance with confocal microscopy, Mark Juhas for his knowledge and 
guidance for tissue-engineered skeletal muscle, Chris Jackman for his help with 
the force transducer setup, Lauran Madden for her contribution to the isolated 
human skeletal myoblast cell stock, and Lydia Ran for her tremendous work 
ethic and dedication to the co-culture project. Thank you all for your help and 
contributions to the project; this is truly a collaborative effort! 
 I would like to thank my parents, Chann and Yingya, and my sister Faye 
for their support. Thank you for understanding that some holidays needed to be 
sacrificed in the pursuit of experiments. And thank you for your constant 
reassurance that I was almost there! 
 Finally, I would like to thank Mehran Chowdhury, my rock through my 
entire graduate school career. Your support and reassurance kept me going 
through the tough times, and your company during late-night and weekend 
experiments was extremely touching and appreciated! You inspire me to go after 
my dreams, and with your unwavering support and love, I know I can achieve 
them. Thank you (and fuzzy puppy Winston!) for always standing by me and 
believing in me.
  
1 
CHAPTER 1.  INTRODUCTION   
1.1.Research Overview 
Skeletal muscle is a major target for tissue engineering given that it comprises 
over 40% of human body mass [2] and can require up to 80% of cardiac output 
during heavy exercise [3]. Additionally, skeletal muscle plays a key role in energy 
metabolism and diabetes. Muscular diseases, such as muscular dystrophy and 
muscle wasting with age (sarcopenia), are debilitating and greatly affect one’s 
quality of life; therefore, the need for therapies targeting musculoskeletal diseases is 
tremendous. Tissue-engineered skeletal muscle has been largely studied using 
murine and rat models. However, human primary skeletal myoblasts provide a 
more physiologically-relevant model for testing drugs and therapies. The 
development of a functional human skeletal muscle model is important to the study 
of drug interactions within the body, as all drugs must pass through and may 
accumulate within the musculature.  Additionally, having a human model of skeletal 
muscle holds great translational potential as it would give insight into interactions of 
human cells with various drugs and therapies. However, the dearth of knowledge 
and experience with culturing human skeletal muscle in vitro presents many 
challenges. Requirements for functional engineered muscle include comparable gene 
expression, micromorphology, and contractile forces to those found in native muscle 
tissue.  
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The major goal of this research was to develop a protocol for engineering 
human skeletal muscle capable of active functional force output when stimulated. 
We hypothesized that joint inhibition of proliferation-promoting miR-133a and 
oxidative metabolism-repressing miR-696 will lead to accelerated differentiation and 
directed myofiber type development of functional tissue-engineered 3D human 
skeletal muscle. Thus far, a model that produces contractile human skeletal muscle 
without added stimuli and cultured in a static fashion has not been reported.  
The specific aims for this project are to (1) identify culture conditions for 
efficient human skeletal myoblast growth and differentiation and establish a 
temporal profile of microRNA expression during differentiation, (2) assess the effects 
of miR-133a and miR-696 inhibition on gene and protein expression in human 
muscle cultured in 2D and on contractile forces and ultrastructure of human muscle 
cultured in 3D, and (3) identify co-culture conditions to support HSkM and EC 
together and retain active contractile function in vitro.  
In Chapter 2, we addressed specific aim 1 and identified conditions for 
effective culture of HSkM in 2D culture. We measured myogenic microRNAs at the 
onset and through the progression of differentiation in C2C12 murine myoblasts and 
primary isolated human myoblasts (HSkM). HSkM expressed low levels of all 
measured microRNAs compared to C2C12, so culture conditions were tailored to 
increase these microRNA levels significantly compared to initial culture conditions 
(those optimal for C2C12 culture). Cyclic stretch and miR-133a inhibition were 
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explored as methods for improving myoblast differentiation. Using the Flexcell 
Tension System, we used a stretch regimen of ±10% at 1 Hz for 1 hour alternating 
with 5 hours of rest to promote differentiation of myoblasts [4] over a two-week 
period. Quantitative real-time PCR and immunostaining were utilized to measure 
gene expression and observe muscle morphology, respectively. While proper culture 
conditions for HSkM increased microRNA expression by over 20-times compared to 
baseline expression in C2C12 culture conditions, microRNA levels were still far 
removed from native human explant tissue.  
In Chapter 3, we addressed specific aims 2 and 3 and assessed the effects of 
joint miR-133a and miR-696 inhibition on human skeletal muscle differentiation and 
fiber type development. Joint inhibition was performed in 2D and 3D conformations 
– 2D served as proof of principle for 3D studies. We developed a protocol to culture 
functional 3D HSkM constructs in a fibrin hydrogel capable of active contraction. 
Proof of principle in 2D provided the basis for joint microRNA inhibition of 
functional skeletal muscle constructs cultured in 3D. In 2D, Western blots, qRT-PCR, 
and immunostaining were used to assess extent of HSkM differentiation and 
myofiber type. In 3D, isometric force testing, immunostaining, and qRT-PCR were 
used to demonstrate function, differentiation, and myofiber type. 
In Chapter 4, we addressed specific aim 4 and identified co-culture 
conditions to successfully endothelialize human muscle bundles while retaining 
active contractile function. In order to successfully co-culture HSkM with EC, a 
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common culture media was developed in order to maintain and support both cell 
types and allow functionality of engineered skeletal muscle. Functional force testing 
and immunostaining were used to observe differentiation and retention/spreading of 
EC on HSkM bundle, respectively. 
In Chapter 5, we summarize our main results and present conclusions from 
our work. We also present future directions and translational implications of this 
work. 
1.2. Skeletal Muscle Development 
1.2.1. Satellite Cells and Muscle Repair 
Satellite cells are a progenitor population of cells that are essential to skeletal 
muscle development and repair [5-7]. The regenerative potential of skeletal muscle 
fibers relies on this pool of undifferentiated myogenic progenitor cells [8], satellite 
cells, be found between the myofiber plasma membrane and basal lamina. They are 
characterized by expression of Pax7, which is important for self-renewal [9-11], but 
do not express muscle-specific transcription factors, making their characterization 
difficult. Under normal conditions, satellite cells remain quiescent in the periphery of 
the myofiber; while in this quiescent state, they exhibit limited gene expression and 
protein synthesis [5]. 
Satellite cells become activated in response to stresses that result from 
myotrauma and/or weight bearing [5, 7]. After injury, activation cues (i.e. growth 
factors, cytokines, etc.) released from injured myofibers signal satellite cells to leave 
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their niche and move outside the basal lamina. Here, they begin to proliferate [7, 12]; 
at this point in time, the cells are known as myoblasts and coexpress Pax7 and MyoD 
[5].  
As myoblasts continue to proliferate, they downregulate Pax7 and express 
MyoD and myogenin – a myogenic transcription factor that pushes cells towards 
differentiation [5-7]. As Pax7 expression decreases and myogenin is upregulated, 
myoblasts fuse to form multinucleated myotubes that either repair muscle damage 
(if fused to existing fibers) or reinforce muscle fibers (if fused to form new fibers). As 
sarcomeres develop, the new myotubes appear striated and are capable of 
contraction. In vivo, a fraction of myoblasts maintains their Pax7 expression and loses 
their myogenic marker expression. These cells ultimately leave the cell cycle and 
return to a self-renewing, quiescent satellite cell state. The renewed satellite cell pool, 
if activated, can reenter a new cycle of repair and regeneration [13]. 
Interestingly, not all myoblasts in culture fuse to form fibers and the extent of 
myofiber formation declines with continued satellite cell subculture [14].  To counter 
this decline and form high density myofiber cultures, forskolin, which activates 
cyclic AMP, can be added in culture to promote satellite cell proliferation without 
compromising the ability to form myotubes [15].  Other subpopulations of muscle 
stem cells can form myofibers but these stem cells are rare [16]. Induced pluripotent 
stem cells are another cell source that can differentiate into muscle cells hold the 
promise of providing a ready source of satellite cells and myoblasts, but further 
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work is needed to produce sufficient numbers of cells [15] and address potential 
safety concerns [16]. 
1.2.2. Structure and Function of Skeletal Muscle 
Skeletal muscle comprises over 40% of the human body’s total muscle mass. 
Abnormalities and diseases affecting skeletal muscle have profound systemic effects; 
therefore, it is important to understand the structure and function of this tissue 
organ system. Skeletal muscle is composed of bundles of myofibers running in 
parallel. This particular structure allows for the effective transmission of contraction 
and cumulative peak force generation. Myofibers are bound together by connective 
tissue that houses blood vessels and nerves. Within each myofiber, there are 
numerous mitochondria for energy production and many peripherally-located 
nuclei.  
Myofibers arise from the fusion and maturation of skeletal myoblasts. This 
process is guided by the selective and sequential expression of various myogenic cell 
markers, including CD34, Pax7, Myf5, MyoD, myogenin, and MLC3F-tg (Figure 1) 
[17]. CD34 and Pax7 are expressed during the satellite cell stage: from the change 
from quiescence to activation. Once the cells start to proliferation and become 
myoblasts, Myf5 and MyoD are expressed and CD34 and Pax7 are downregulated. 
As the myoblasts begin to fuse to myotubes and mature into myofibers, expression 
of myogenin and MLC3F-tg occur.  
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Figure 1. Schematic of satellite cell myogenesis and markers typical of each stage. [17] 
Sarcomeres are the basic functional units of muscle. They are separated by Z-
lines, and they contain myofibrillar proteins that allow muscles to contract, including 
myosin (the thick filament) and actin (the thin filament) [18]. Myosin has 6 
polypeptides: 2 heavy chains and 4 light chains. The heavy chains contain the 
myosin heads that interact with actin and allow muscle to contract (Fig. 2); this same 
area of the myosin heavy chain also binds ATP and converts it to ADP, providing 
the energy necessary for muscle contraction [18]. The thin filament is composed of 
actin and the regulatory proteins troponin and tropomyosin. When the myofiber 
receives a stimulus, Ca2+ is released from the sarcoplasmic reticulum and binds to 
troponin. This binding then causes tropomyosin to expose a myosin-binding site on 
the actin filament. When ATP is present, the myosin head pulls the actin along the 
myosin – which allows the sarcomere to shorten in contraction. The process of 
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myosin head attachment to actin, pulling, release, and reattachment is known as 
cross-bridge cycling. This process occurs at different speeds depending on the rate of 
ATP hydrolysis, which is in turn limited by the rate that the ATPase of the myosin 
head can hydrolyze ATP. [18] 
 
Figure 2: Components of sarcomere. Sarcomeres are componsed ot myosin and actin proteins. 
The actin-myosin overlap zone allows for generation of contractions. Cross bridges are the 
several actin-myosin overlap zones contained within a sarcomere. Each sarcomere is separated 
by Z-lines. [19] 
Skeletal muscle fibers are surrounded by the sarcolemma, which limits the 
entry and exit of ions into the intracellular environment. This selective permeability 
allows for the careful control of the electrical potential and membrane excitability of 
a skeletal muscle fiber. Action potentials are initiated by depolarization of the 
sarcolemma resulting from binding of acetylcholine (ACh) to acetylcholine receptors 
(AChR) at the neuromuscular junction. The binding of 2 ACh molecules to each 
AChR induces a conformational change in the AChR, which leads to opening of the 
central pore, allowing cations to flow into or from the muscle cell. Due to the 
electrochemical gradient, generally more Na+ flows into the cell than K+ out, 
resulting in depolarization of the muscle fiber. [20, 21] 
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  Depolarization of the muscle fiber leads to opening of L-type voltage-gated 
Ca2+ channels in the t-tubule of the membrane. T-tubules (or transverse tubules) are 
invaginations in the sarcolemma that run transverse to the length of the muscle fiber. 
T-tubules allow for the depolarization of the membrane to travel quickly to the 
interior of the cell (7 cm/sec [21]). The opening of the voltage-gated Ca2+ channels in 
the t-tubules induces conformational changes in adjacent Ca2+-release channels 
located in the membrane of the sarcoplasmic reticulum. This causes the Ca2+-release 
channels in the sarcoplasmic reticulum to open, resulting in an efflux of sequestered 
Ca2+ into the cytoplasm. The Ca2+ then binds to troponin C on the actin myofilament 
and leads to initiation of cross-bridge cycling of the muscle, also known as 
excitation-contraction coupling. [20, 21] Once bound to calcium, troponin undergoes 
a conformational change allowing the myosin head group to bind to the active site 
on actin.  The subsequent bending of the bound myosin initiates a power stroke in 
which myosin pulls the actin about 10 nm; this is also known as a cross-bridge cycle.  
After the power stroke, ATP binds to myosin, enabling the myosin head group to 
dissociate from actin; this also energizes the cross bridges and places myosin in the 
position to bind to actin for the next cycle.  The bound ATP is hydrolyzed to ADP 
releasing energy and detaching from myosin.  Calcium ions are pumped back into 
the sarcoplasmic reticulum, causing dissociation from troponin. Troponin then 
covers the myosin binding site on actin and the sarcomere returns to its initial 
condition.  
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Skeletal muscle is comprised of various types of myofibers that allow for the 
fast or slow contractions displayed by human muscle. There are several methods in 
which fiber types are classified, including protein myosin heavy chain (MHC) 
content, fiber metabolism, and presence of various ion channels. First, human muscle 
fiber types can be defined with the contractile protein MHC and the ATPase activity 
associated with each MHC classification [22]. The presence of various MHC isoforms 
as well as the temporally and spatially regulated expression of these isoforms is 
important for defining of specific muscle properties and functions [23]. Specifically, 
the ATPase activity of various MHC isoforms dictates the speed of shortening or 
contraction – thus, giving the fiber types their characteristic names: “fast” and 
“slow” [18, 24, 25]. The isoforms of MHC present in human skeletal muscle include 
1, 2A, and 2X, corresponding to Type I (slow), Type IIA (fast), and Type IIX (fast), 
respectively. Mouse and rat muscle contain these MHC isoforms and the additional 
2B isoform. Human skeletal muscle also differs from mouse skeletal muscle by the 
proportions of each fiber type in its musculature. Mouse muscle are composed 
primarily of MHC-2B and MHC-2X fibers, with very little MHC-2A and MHC-1 
fibers [26]. Human skeletal muscle contain mostly MHC-1 and MHC-2A in fibers, 
and less MHC-2X [26]. Given this important difference between mouse and human 
skeletal muscle, mouse skeletal muscle is not the best model for studying human 
skeletal muscle.  
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Metabolism is another method commonly used for classifying skeletal muscle 
fibers. Type I fibers are termed “slow twitch” due to the slow contraction speed of 
fibers utilizing oxidative metabolism. In close relation to the metabolism of fiber type 
is the content of myoglobin and mitochondria within each fiber: slow twitch fibers 
contain more myoglobin and mitochondria (giving the fibers their characteristic red 
hue), machinery necessary for the process of oxidative metabolism [26]. Human 
muscle fibers range in diameter from 10-100 µm [27], with Type I fibers being 
thinner to adapt for sustained activity, as slow fibers are fatigue “resistant.” [27]. 
Slow myosin cross-bridge cycling and a combination of both low abundance and 
activity of energy-consuming calcium pumps in the sarcoplasmic reticulum reduce 
the energy demands of Type I fibers [28]. Type I fibers sustain aerobic activity using 
fats and carbohydrates as fuel, and although oxidative phosphorylation is a slower 
process (1 mole of ATP per min), ATP synthesis is significantly more efficient, 
producing 36 molecules of ATP per molecule of glucose [29]. Type II fibers are 
generally classified as “fast twitch” due to the rapid contraction resulting from rapid 
calcium release and uptake during the contraction-relaxation cycle of these fibers 
utilizing glycolysis [26]. Type II fibers contain high levels of glycolytic enzymes, 
allowing for rapid firing of fibers. However, Type II fibers can further be classified 
into IIA and IIX based on the metabolism used, similar to the presence of different 
MHC isoforms presented above. Type IIA fibers are also known as fast-twitch 
oxidative glycolytic fibers, and IIX are called fast-twitch glycolytic fibers [29].  Type 
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IIA fibers contain more myoglobin and mitochondria than IIX fibers. Functionally, 
fast fibers are utilized for short bursts of near-maximal activity, but they do require 
more energy and fatigue quickly [30]. Rapid cross-bridge cycling and significant 
calcium fluxes are hallmarks in the fast twitch Type II fibers, resulting in much 
higher energy demands [28]. During anaerobic glycolysis, glucose is broken down to 
pyruvate and converted to lactic acid [31], producing 2.5 moles of ATP per minute 
[32].  Fibers utilizing glycolysis fatigue quickly because anaerobic metabolism is 
limited to the amount of glucose or glycogen accessible within muscle. 
Physiologically, Type II fibers are thicker, allowing for higher force amplitude 
generation than slow fibers. Since these fibers do not contain high levels of 
myoglobin and mitochondria, Type IIA and IIX fibers appear more white/pale in 
color compared to Type I fibers. 
Slow and fast twitch fibers can also be classified by their electrophysiological 
properties as well. Fast fibers have resting membrane potentials that are more 
negative than slow fibers (-90 to -95 mV compared -80 to -85 mV, respectively) [29]. 
Chloride ions play in important role in the stabilization of resting membrane 
potential in skeletal muscle cells: approximately 70% of the conductance of a muscle 
fiber membrane at rest relies on Cl- and 30% relies on K+. Fast fibers contain 3-5-times 
more L-type voltage-gated Ca2+ channels per volume than slow twitch fibers [29], 
which helps for the rapid firing that is characteristic of fast twitch fibers. Studies 
have shown that Cl- conductance is higher in fast fibers compared to slow fibers [29]. 
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K+ currents out of the skeletal muscle fibers are relatively small, resulting in their 
lower contribution to overall resting membrane potential. There exist many types of 
K+ channels in the human body; however, ATP-sensitive K+ are the most abundant 
within skeletal muscle. The density of K-ATP current is higher in fast twitch muscle 
fibers compared to slow twitch muscle fibers. [29] The excitability of the muscle fiber 
membrane is dependent on the number of Na+ channels and the proportion of these 
channels that are not inactivated [29]. Similar to Ca2+ channels, Na+ channels have 
higher densities in fast fibers than slow fibers. This greater density of Na+ channels 
leads to the rapid response and short-lasting contraction that are characteristic of fast 
fibers over their counterpart [29]. While there is no singular way to classify skeletal 
muscle fiber type, it is clear that these methods are all in agreement. The specific 
MHC isoforms, metabolism utilized, and ion channels present in muscle fibers all 
contribute to either the slow, sustained contraction or fast, maximal contraction 
phenotypes. 
Adult skeletal muscle may exhibit plasticity in response to sustained stimuli, 
including resistance exercise or immobilization. Reinnervation has been 
demonstrated to induce fast-to-slow transformations in the contractile properties of 
rabbit skeletal muscle [33, 34], and chronic low-frequency stimulation have been 
shown to change fast muscles towards slow muscles in various animal model studies 
[35]. However, such studies have not had as much success in human muscle tissue. 
Human skeletal muscle studies that have applied electrical stimulation protocols 
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similar to those in animal studies have not reported an increase in MHC-1 
composition within the tissue [36, 37]. Andersen et al. electrically stimulated skeletal 
muscle from spinal cord injury patients for 30 min/day 3 times per week for 1 year, 
but saw a reduction in MHC-2X isoforms and no change in MHC-1 isoforms [38]. In 
contrast, immobilization and disuse of human skeletal muscle leads to a slow-to-fast 
transition in MHC content. Individuals with spinal cord injuries showed almost no 
MHC-1 isoforms in the vastus lateralis, while healthy individuals express 
approximately 50% MHC-1 [39]. Their muscles are, instead, predominantly 
composed of MHC-2 isoforms, with over half being MHC-2X. Although the reason 
for slow-to-fast transition in conditions of muscle disuse is unclear, there is evidence 
suggesting that MHC-2X may be the default protein isoform [40]. Additionally, 
muscle fibers containing more than one MHC isoform have been reported, which 
may represent fibers that are in transition from one type to another. However, these 
hybrid muscle fibers are most commonly found in the muscle of older people [39]. 
While there is some evidence that human fiber type plasticity is possible, there still 
remains a large gap between what has been demonstrated in animal models and 
what can be done with human skeletal muscle. This presents further reason for 
human-specific studies of skeletal muscle to better understand its physiology and 
dynamic development. 
 The ability of skeletal muscle to contract is a hallmark of this tissue. 
However, the magnitude of contraction is dependent on the muscle length at 
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relaxation – this phenomenon is known as the force-length relationship: the force 
produced increases with the extent of stretch of sarcomeres at rest (Fig. 3, note this 
Figure considers frog muscle). Minimal stretch of sarcomeres leads to low force 
production due to minimal length of contraction. Within the optimal range of actin-
myosin overlap, as the sarcomeres are stretched, there will be increased force 
production due to optimal overlap between actin and myosin and adequate length of 
contraction to exert force. Finally, if the sarcomere is stretched too far and there exist 
no actin-myosin overlap, the force falls to zero. Therefore, there exists an optimal 
range in which force produced is greatest. In human skeletal muscle, actin and 
myosin lengths are approximately 1.30 μm and 1.66 μm, respectively [41]. Z-line 
widths range from 69-95 nm and M-line (midzone of the myosin filament that does 
not contain cross-bridges) widths range from 60-89 nm, depending on myofiber type 
[42]. Lengths of Z-lines and M-lines associated with each myofiber type are given in 
Table 1.  
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Figure 3: Skeletal muscle force-length relationship. The amount of force exerted by skeletal 
muscle is dependent on the length of the sarcomeres at rest. (1) Zero force is generated at 
complete overlap between actin and myosin. As the overlap decreases, force increases until the 
optimal range of overlap is reached (2). The optimal range is shown between (2) and (4). A 
plateau region exists between (3) and (4) since the midzone of the myosin filament does not 
form cross-bridges. There is a gradual decrease to zero of force from (4) to (5) as the sarcomere 
is stretched to an extent that cross-bridge formation declines due to separation of myosin and 
actin filaments. [19] 
Table 1: Z- and M-line widths for humans [43] 
Myofiber Type Z-lines M-lines 
Type I 95 nm 89 nm 
Type IIA 74 nm 79 nm 
Type IIX 69 nm 60 nm 
 
This phenomenon of length-tension is not a major factor for in vivo skeletal 
muscle physiology as individual sarcomeres are maintained near the optimal length 
within their working range [27] and, under normal conditions, are not stretched 
beyond the optimal working range. The surrounding extracellular matrix (ECM) not 
only serves to support musculature, but it also prevents the sarcomeres from being 
stretched beyond the optimal length for function. In fact, the extracellular matrix 
itself may modify the force-length curve by adding a passive force. Measurement of 
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active and passive forces can be used to test engineered 3D constructs for 
functionality and how closely the engineered muscle mimics native tissue. 
1.3. Considerations for Skeletal Muscle Tissue Engineering 
Three-dimensional engineered skeletal muscle tissues possess many of the 
important features of skeletal muscle in vivo, including many key functional proteins 
found in mature muscle, abundance of striations, contraction in response to 
electrical/neural stimuli and length-tension and force-frequency relationships similar 
to those of excised myofibers. However, there exist limitations of engineered in vitro 
muscle models that prevent complete recapitulation of native muscle – mainly that 
specific forces are substantially lower and fiber density and organization are not 
representative of native tissue. 
 Over the past decade, considerable advances have been made to address these 
challenges and produce three-dimensional engineered muscle bundles with higher 
myofiber density, organization, and increased functional force output.  Another 
challenge is regulation of myofiber type - ensuring that mature fibers are produced 
and that conditions are developed to selectively produce Type I, IIA and IIX 
myofibers.  Mimicking roles of innervation, either through co-culture with nerve 
cells or electrical stimulation and/or addition of neurotrophic factors, may be 
essential to producing mature human myofiber types [44, 45]. A large parameter 
space still needs to be explored with mechanical conditioning of engineered muscle. 
Finally, microRNAs provide a promising way to enhance differentiation and 
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function, and when expressed transiently by delivery via liposomes, could stimulate 
specific developmental steps.   
 Engineering challenges associated with culturing functional skeletal muscle in 
vitro include: (1) cell source and isolation from excised tissue, (2) selection of 
appropriate scaffold for maturation of cells into muscle, (3) skeletal myofiber type 
development, (4) generation of contractile forces, and (5) methods for stimulating 
construct maturation, including co-culture with other cell types and microRNA 
modulation of cells.  
 In order to utilize engineered muscle bundles for a relevant clinical drug and 
toxicity testing, human engineered skeletal muscle bundles need to be developed.  
Optimized culture conditions to efficiently expand human satellite cells and 
myoblasts and promote their fusion and maturation are needed.   
1.3.1. Satellite Cells 
To engineer skeletal muscle, the stages of cell development must be carefully 
controlled in order to produce organized and mature skeletal muscle. As satellite 
cells are removed from the native niche environment, they are activated to myoblasts 
capable of proliferation. Myoblast proliferation is promoted by high content of 
serum contained in the culture medium; the serum contains significant growth 
factors necessary for cell division, including IGF-1, TGF-β1, FGF-2. Common sera 
used include fetal calf serum and fetal bovine serum. Myoblast differentiation and 
fusion are promoted by switching to media containing low growth factor serum or 
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serum-free medium to inhibit further proliferation. In three-dimensional skeletal 
muscle cultures, it is important to produce an engineered construct with high 
density of fused myofibers in order to allow for important cell-cell interactions and 
enough power to exert strong contractile forces. This necessitates expanding 
myoblasts to an appropriate number corresponding to the size/volume of engineered 
muscle to ensure the density criterion is met.  
1.3.2. Scaffold 
Tissue engineering involves recreating the structure and function of native 
tissue. This goal has been approached many ways, including layering contracting 
sheets of myofibers to form a muscle bundle (myooid) [46], embedding skeletal 
myoblasts into hydrogels [47-50], and by migration of myoblasts into a polymer or 
acellular tissue supporting matrix [51].  
To engineer myooids, static culture of myoblasts and fibroblasts were grown 
on Sylgard-coated 35-mm dishes in a two-dimensional manner. At opposing sides of 
the dish, two anchor points were made using laminin-coated silk sutures. As the co-
culture of myoblasts and fibroblasts matured, the monolayer detached from the 
Sylgard surface and rolled into a cylindrical three-dimensional construct anchored 
by the suture points. [52] Two-week culture of myooids led to 30-60% of total cross 
sectional area occupied by myotubes and gradual loss of ECM. However, there was 
significant cellular disorganization: cross sections appeared markedly different from 
differentiated adult mammalian skeletal muscle, visible striations were rarely 
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evident in myooid constructs, and myotubes in myooids contained centrally located 
nuclei (a sign of muscle immaturity) rather than peripherally located nuclei [52]. 
Myoblast survival and formation of organized, aligned myotubes in culture 
requires the generation of tension by fixing the ends of engineered constructs and 
allowing passive contraction of the cells; co-culture conditions have utilized 
fibroblasts or smooth muscle cells to serve as the tension-generating entity [53]. 
Engineered myooid constructs did not apply tension to myoblasts until after 
differentiation had occurred, as differentiation was induced by change in culture 
medium approximately 2-3 weeks prior to monolayer detachment from the substrate 
[52]. Other methods for establishing a more mature myofiber phenotype include 
incorporating specific peptide sequences of extracellular matrix proteins or signaling 
molecules in the scaffold, application of electrical or mechanical stimulation, and 
suspension of cells within a 3D matrix.  
Many groups have chosen to seed myoblasts into a three-dimensional 
scaffold prior to differentiation so that tension of the 2 anchor points can direct cell 
alignment and fusion. Important considerations when choosing an appropriate 
scaffold and supporting matrix hydrogel include material biocompatibility, 
degradation over time, rigidity, and cell to scaffold ratio (cell seeding density). 
Biocompatibility of material is important to prevent cell toxicity within culture; 
additionally, it is a vital criterion for research aiming to develop implantable tissues 
[54]. Many hydrogel and ECM materials degrade over time, and it is important to be 
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able to tune the degradation rate to allow enough time for skeletal myoblasts to fuse 
and mature into robust muscle tissue and form connection with surrounding ECM 
proteins. Many have cited the importance of fibroblasts for secretion of ECM [55]. 
Differentiation medium supplemented with 1 mg/mL 6-aminocaproic acid (ACA) 
has been used to inhibit rapid fibrin gel degradation by serum in the culture 
medium; the concentration of ACA in media dictates the degradation rate of the 
fibrin gel [47]. The rigidity of a hydrogel can also influence myoblast fusion and 
differentiation.  Myoblast differentiation has been found to be enhanced on surfaces 
with elasticity of 8-12 kPa [56], which modulates integrin engagement with the 
cytoskeleton [57].   
 Engineered skeletal muscle bundles in hydrogels have been produced using 
fibrin, Matrigel, and collagen-based hydrogels [47-50, 58].  Collagen hydrogels are 
stiffer and tend to rupture more easily at high cell densities which limit the 
contractile forces that can be produced [46, 47].  Fibrin gels assemble into a network 
of branching fibers [59], enabling them to withstand higher contractile forces. 
Engineered muscle bundles made with collagen or fibrin hydrogels can survive for 
several weeks, whereas myooids prepared with primary myoblasts and fibroblasts 
and without a hydrogel or extracellular matrix can survive as long as 100 days [46].  
Myooids exhibit a similar force length-relationship to that found in vivo and show 
insulin-stimulated glucose uptake [60], but take over one month to produce [61]. 
Relatively mature three-dimensional engineered fibrin hydrogel muscle bundles can 
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be produced in 10-12 days and also produce a physiological force-length relationship 
[47]. 
1.3.3. Metabolism and Myofiber Types 
 Under resting conditions in vivo, skeletal muscle energy needs are met by fatty 
acid breakdown.  Muscle has limited permeability to glucose due to low levels of the 
primary glucose transporter, GLUT4, on the cell membrane. When plasma insulin 
levels rise, insulin binds to its receptor, activating a series of signaling molecules that 
cause GLUT4 to move from intracellular vesicles to the plasma membrane [62] 
enabling glucose to enter into myofibers. Glucose is then stored as glycogen to meet 
long-term energy needs and fatty acid metabolism is reduced.  While skeletal muscle 
accounts for little glucose uptake in the absence of insulin, skeletal muscle is 
responsible for about 75% of whole body insulin-stimulated glucose uptake. 
Moderate to heavy exercise can cause GLUT4 translocation to the cell membrane 
independent of insulin, thereby increasing glucose uptake [63]. 
 Skeletal muscle energy metabolism is regulated by the peroxisome proliferator-
activated receptor γ (PPARγ) coactivator-1α (PGC-1α), which interacts with a wide 
range of transcription factors involved in mitochondrial biogenesis, glucose and fatty 
acid metabolism as well as fiber type switching [64, 65]. Peroxisome proliferator-
activated receptors (PPARs) are a family of nuclear transcription factors that regulate 
the expression of genes important to myofiber development. In skeletal muscle, 
PPARδ is more abundant than PPARα or PPARγ [64] and is also more abundant in 
  
23 
type I [65] than Type II myofibers, while PPARα induces metabolic changes in 
muscle and regulates the expression of muscle-specific markers, including myocyte 
enhancer factor 2A (MEF2A) [66].  
 PGC-1α increases mitochondrial biogenesis and respiration rates and regulates 
the expression of many genes involved in metabolism [67]; PGC-1α directly co-
activates nuclear receptors (e.g. – thyroid hormone receptor, glucocorticoid 
receptors, estrogen receptors) and nonnuclear transcription factors (e.g. Mef-2 and 
the family of forkhead O-box (FOXO) transcription factors [68, 69]) to quickly and 
effectively manipulate cellular energy metabolism. As a potent co-activator, it 
regulates metabolic events indirectly. PGC-1α overexpression in skeletal muscle 
enhances the proportion of oxidative Type IIA and Type I myofibers [69, 70]. Lin et 
al. reported that PGC-1α is a principal factor regulating muscle fiber type 
determination [69].   
 Much of skeletal muscle tissue engineering has been achieved by using 
murine and rodent myoblast sources.  Although myosin heavy chain isoforms 
expressed by myotubes derived from rodent myoblasts reflect the distribution found 
in the muscle from which the cells were derived, cultured human myotubes express 
MYH1, MYH2 and MYH7 in ratios that differ from those found in the muscle of 
origin [14]. Limited studies with human myoblasts have shown that after seven 
days, embryonic (MYH3), perinatal (MYH8), Type I (MYH7), Type IIA (MYH2) and 
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Type IIX (MYH1) mRNA are expressed [71]. After three weeks, adult MHC I was the 
major isoform [71], suggesting maturation of myofibers in vitro. 
1.3.4. Contractile Forces 
Muscle is composed of multinucleated myofibers that are 100 µm or less in 
diameter and can span the muscle length. Each myofiber contains thousands of 
myofilaments consisting of repeating functional units (sarcomeres). Muscle 
contractile forces can be generated under conditions of constant force or tension 
(isotonic) or constant length (isometric). During isometric contraction the sarcomeres 
act in series with elastic elements in the muscle, and sarcomere contraction is 
balanced by extension of elastic elements. Typically, the twitch contraction times 
range from 10 ms to 40 ms in vivo [29]. Lewis and Chamberlain found that a 50:50 
mixture of fast and slow fibers in vitro had a time to peak force of about 19 ms [72]. 
In vitro, contraction of aneural myotubes can be induced by electrical stimulation or 
alteration of extracellular ion concentrations.  Contractile forces have been measured 
with myotubes attached to a cantilever [73], small engineered muscle bundles 
attached to elastic posts [74], and cell sheets cultured on deformable polymer sheets 
[75]. Forces as high as 1.68±0.32 mN for twitch and 2.84±0.5 mN for tetanus have 
been obtained for a fibrin-Matrigel hydrogel system seeded with neonatal rat 
myoblasts [47].  Corresponding specific forces (force/cross-sectional area) were 
5.5±0.6 kPa and 9.4±0.7 kPa, respectively [47].  By preparing fibrin hydrogels with 
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rodent primary myoblasts that were cast around posts of different sizes, the 
contractile force of the sheet increased due to increased myofiber alignment, 
increased numbers of nuclei per fiber and increased total volume occupied by 
myofibers [76]. Myoblasts seeded into fibrin gels led to contractile forces as high as 
36.3±4.2 kPa were produced [61].  Engineered muscle derived from primary cells 
produce higher specific forces than those derived from cell lines [46]. 
Specific forces produced by engineered rodent or human muscle are 10-100 
times less than values measured for individual myofibers in vivo. A number of 
factors may be responsible for the lower contractile forces in vitro: myofiber density 
and orientation, presence of fetal forms of myosin, and/or inadequate force 
transmission from myofibers to extracellular matrix. As noted above, increasing the 
alignment of the myoblasts and using higher initial cell densities may enhance the 
fusion of myofibers and increase the specific force [76]. The inadequate 
differentiation of myotubes is probably the major factor contributing to lower 
specific forces in vitro than in vivo.  The low specific force of individual myotubes 
estimated from studies with small bundles of rodent muscle cells (0.69±0.13 kPa) 
[74], individual myotubes on cantilevers (0.94 kPa) [73], and from three-dimensional 
aligned muscle bundles (0.80±0.15 kPa) [76] suggests that cultured myotubes are not 
fully reproducing the differentiated state found in vivo.  
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1.4. Methods to Increase Muscle Maturity and Force Production 
While engineered muscle bundles with mouse and rat cells spontaneously 
contract and produce significant contractile forces, the application of electrical 
stimulation, mechanical stimulation or innervation with cultured neurons may be 
needed to generate active contraction of three-dimensional engineered human 
muscle bundles [44, 51]. Studies have found that denervation reduces the 
contractility of muscles in vivo [77]. Conversely, contractile force is increased by the 
co-culture of muscle with nerve fibers to form neuromuscular junctions [78] or 
addition of a recombinant form of agrin, a proteoglycan found in neuromuscular 
junctions [79].  
1.4.1. Mechanical and Electrical Stimulation 
Mechanical and electrical stimulation have both been found to enhance 
differentiation of skeletal muscle in vitro through the mimicking of exercise; 
however, the mechanisms are very different. Skeletal muscle contraction is initiated 
by the depolarization of the membrane potential. In vitro, skeletal muscle fibers 
require the need for external stimulation for the generation of an action potential 
since muscle in vivo activation of contraction is cause by cues from the central 
nervous system via motor neurons [80]. Mechanical stimulation simply stretches 
engineered muscle at preset parameters of percent stretch and frequency, but does 
not elicit action potentials and engage the machinery for contraction. Electrical 
stimulation, though, does provide the required stimulus for membrane 
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depolarization and has been shown to promote the transition toward adult 
myofibers in engineered skeletal muscle [80].  
Cyclic mechanical stimulation of engineered three-dimensional human 
muscle bundles in collagen increases the construct elasticity and myofiber diameter 
[50]. After mechanical stimulation, human muscle bundles generate passive forces 
between 500-1000 μN/106 cells, 2-4 times greater than unstretched samples [50].  
Passive forces in collagen-based human muscle constructs without Matrigel or 
mechanical stimulation are much lower with a peak force of 43 μN/106 cells [81]. 
Mechanical preconditioning of acellular porcine bladder repopulated with human 
skeletal myoblasts and collagen improved tissue organization and fiber orientation 
[51]. Applying 17% stretch at 1 Hz on murine myoblasts [82] or 10% stretch at 0.5 Hz 
for 1 hour on bovine myoblasts inhibited differentiation and promoted proliferation, 
while 10% strain at 0.5 Hz for 1 hour alternated with 5 hours of relaxation enhanced 
expression of integrin 1D, which activates RhoA, thereby regulating myofiber 
formation, differentiation and nitric oxide release [83]. Human skeletal muscle 
constructs exhibited KCl induced contraction after three weeks of mechanical 
conditioning [51], although this must be interpreted cautiously since myofibroblasts 
also contract in response to KCl. After implantation in the mouse latissimus dorsi for 2 
or 3 weeks, mechanically conditioned engineered human muscle exhibited tetanus, 
although the specific forces were far below those in the native mouse muscles, and 
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the contribution of host vs. donor cells to generated force of explanted muscle 
constructs was not determined [51]. 
Low frequency electrical stimulation induced spontaneous contraction of 
human skeletal myofibers in two-dimensional cultures [84].  Like exercise, low 
frequency stimulation of human myofibers in vitro increased glucose uptake 
independent of insulin and increased mitochondrial content and PGC-1α gene 
expression [84]. Mechanical or electrical stimulation produces more mature 
sarcomeres [85] resulting in a greater percentage of myotubes in three-dimensional 
muscle bundles expressing adult forms of MHC than fetal forms [86].  Electrical 
stimulation also promotes GLUT4 transport to the cell membrane, but does not alter 
the levels of GLUT1 and GLUT4 [85]. GLUT4 activity has been associated with type I 
fibers that utilize oxidative metabolism compared to glycolysis [87]. 
1.4.2. MicroRNA’s 
MicroRNAs are short (~22nt), highly conserved, non-coding RNAs [49, 88, 
89] that act by negatively regulating gene expression, and are usually repressors of 
repressors [89]. Currently, their known functions include inhibiting protein 
translation by directly blocking translation or enhancing messenger RNA 
degradation [90]. MicroRNAs are initially transcribed in the cell nucleus as a long 
strand of primary microRNA, or pri-microRNA, that contains the mature microRNA 
as a hairpin. Inside the nucleus, Drosha (an RNase III endonuclease) cleaves the pri-
microRNA into an intermediate (~60-70nt) precursor microRNA, or pre-microRNA. 
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Exportin-5 (XPO5) transports the pre-microRNA from the nucleus and into the 
cytoplasm where further processing occurs: a second RNase III endonuclease called 
Dicer1 excises the pre-microRNA into a ~22nt microRNA duplex. One strand is 
degraded, leaving the mature single-stranded microRNA [90]. This mature 
microRNA is then incorporated into the RNA-induced silencing complex (RISC), a 
ribonucleoprotein complex. This enables the RISC to target specific portions of the 3’ 
untranslated region (UTR) of the target mRNA by base-pairing across the “seed 
sequence” – the 7-8nt sequence of the mature microRNA that dictates the 
microRNA:microRNA binding. This binding results in repression of protein 
translation [89]. 
The role of microRNAs is essential to many important cell processes, such as 
proliferation, differentiation, and apoptosis [89]. Three muscle-specific microRNAs 
are essential to the proliferation and differentiation of skeletal myoblasts: miR-1, 
miR-133a, and miR-206 [49, 88, 89, 91]. In the human and mouse genomes, miR-1 and 
miR-206 are located on different genetic loci, but are both known to promote 
myoblast differentiation, while miR-133a is located near miR-1, but promotes 
proliferation [89].  Since microRNAs are repressors of repressors, they effectively 
upregulate certain processes. For example, miR-133 represses serum response factor 
(SRF), which represses proliferation – therefore, miR-133a promotes myoblast 
proliferation (Figure 4). Since miR-1 and miR-133a are located on the same genetic 
locus, their expression is coupled. MiR-1 blocks histone deacetylase-4 (HDAC4), an 
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inhibitor of myocyte enhancer factor-2 (Mef-2).  Mef-2 is a family of transcription 
factors that encode for proteins to promote differentiation at various stages of 
development. The expression of Mef-2 is linked strongly to the onset of skeletal 
muscle differentiation. Mef-2C, a member of the Mef-2 family is particularly 
sensitive to mechanical stretch in skeletal muscle [92, 93]. This transcription factor is 
also implicated in a wide variety of muscle-specific developmental processes [94], 
including control of myoblast differentiation and function [95, 96], maintenance of 
myofiber integrity [94], and regulation of mitochondrial biogenesis [97, 98]. MiR-206 
negatively affects Pax7, discussed previously as the important factor for cell renewal 
and maintenance of “stemness.” The inhibition of Pax7 by miR-206 leads to the 
promotion of MyoD, another transcription factor important to the onset and 
succession of muscle differentiation. 
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Figure 4. MicroRNA Pathway for Proliferation and Differentiation of Skeletal Muscle. MiR-
133a represses serum response factor (SRF), which represses myoblast proliferation. MiR-1 
represses histone deacetylase 4 (HDAC4), which represses myoblast differentiation. MiR-206 
represses Pax7, which represses MyoD, an important transcription factor for myoblast 
differentiation. 
Our lab has shown that transfection of C2C12 myoblasts with miR-133a 
inhibitor successfully enhanced differentiation of myofibers in 3D muscle bundles 
[49]. Since miR-133a promotes proliferation, inhibiting it forced cells down the 
differentiation pathway and led to enhanced differentiation of in vitro muscle. 
Engineered muscle bundles seeded with anti-miR-133a C2C12 cells exhibited 20% 
higher forces than those transfected with a scrambled microRNA sequence [49]. 
Additionally, Mef-2C expression was used to assess extent of differentiation between 
anti-miR-133a and negative control (scrambled sequence) transfected cells. 
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Myoblasts transfected with anti-miR-133a exhibited heightened Mef-2C expression 
compared to the negative control as assessed by intensity of fluorescence stain [49]. 
Aside from affecting muscle maturation and differentiation, microRNAs also 
play important roles in muscle cell metabolism [99, 100] (Figure 5). MiR-696 plays a 
critical role in regulating myoblast response to mechanical stretch [101] and affecting 
the downstream metabolism co-activator PGC-1α. PGC-1α is a powerful 
transcriptional co-activator protein that binds to the activators of many transcription 
factors that influence in metabolism and energy expenditure [68, 101]. PGC-1α works 
by increasing mitochondrial biogenesis and respiration rates and the utilization of 
cues from the microenvironment, including oxidative stress or exercise, for energy 
production. This co-activator is recognized as a “master controller” of many genes 
involved in metabolic regulation [67]; PGC-1α directly co-activates a plethora of 
transcription factors, including nuclear receptors – thyroid hormone receptor, 
glucocorticoid receptors, estrogen receptors, etc. – and nonnuclear receptor 
transcription factors – Mef-2 and the family of forkhead O-box (FOXO) transcription 
factors [68]. PGC-1α affects various tissues, including adipose tissue, liver, cardiac 
muscle, and skeletal muscle [67]. Through these multiple pathways, PGC-1α is able 
to quickly and effectively manipulate cellular energy metabolism. 
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Figure 5. MicroRNA Pathway for Energy Metabolism in Skeletal Muscle. MiR-34a represses 
sirtuin 1 (SIRT1), which represses cellular senescence. MiR-696 represses PGC-1α, an 
important metabolism co-activator that has been shown to increase metabolic fitness and 
oxidative metabolism in skeletal muscle. 
PGC-1α is present in a wide variety of tissues, but it is highly expressed in 
tissues requiring high-energy oxidative capacity, like the heart and skeletal muscle 
[68, 102]. Transgenic animals with increased PGC-1α exhibit increased mitochondrial 
number and function compared to wild-type, while those with deletions of PGC-1α 
demonstrated abnormal glucose homeostasis, decreased endurance capacity and 
mitochondrial gene expression [68]. Due to the importance and overarching 
metabolic function of PGC-1α, even minor disturbances in the co-activator’s activity 
may lead to severe metabolic syndromes and/or low of whole-body homeostasis [68, 
103]. While the biology of PGC-1α and its regulation is still largely unknown, it is 
agreed that this co-activator is essential to maintaining balanced energy metabolism. 
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Recently, links between PGC-1α and myofiber composition have been 
reported [65, 69, 104, 105]; specifically, increased PGC-1α expression has been 
reported as a factor leading to the development of slow-twitch type I myofibers [69].  
1.5. Motivation and Significance 
In order to utilize engineered muscle bundles for a tissue engineering 
applications and relevant clinical drug and toxicity testing, human engineered 
skeletal muscle bundles must be developed.  Optimized culture conditions to 
efficiently expand human satellite cells and myoblasts and promote their fusion and 
maturation are needed.  Additionally, while the source of human muscle cells can be 
primary muscle biopsies, developing robust protocols for induction of satellite cells 
and myoblasts from human induced pluripotent stem cells will be needed to 
examine a range of physiological and pathological conditions.  
While considerable work has been done with murine skeletal myoblasts to 
study skeletal muscle in vitro, there is a dearth of knowledge about the 
differentiation and maturation of primary isolated human skeletal myoblasts in the 
same environment. This project aims to develop a three-dimensional human skeletal 
muscle construct that will demonstrate contraction under electrical stimulus. Such a 
construct would be instrumental to the pharmaceutical industry for pre-clinical 
testing of drugs, whether musculature-targeting or not [106]. Since skeletal muscle is 
the largest tissue organ system in the human body, it is important to study the effects 
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of any drug on its development and function. Treatments that may adversely affect 
the skeletal muscle could potentially be life altering. 
This project was conducted in conjunction with the Tissue Chip Award for 
Model Systems given by the National Institutes of Health (NIH) to develop 
microphysiological systems to test drugs in a pre-clinical setting. 
1.6. Hypothesis & Specific Aims 
This research aimed to evaluate primary human skeletal myoblast 
differentiation in vitro and the effect of microRNA modulation on the progression of 
differentiation and fiber type development. We hypothesized that joint inhibition of 
proliferation-promoting miR-133a and oxidative metabolism-repressing miR-696 
will lead to accelerated differentiation and directed myofiber type development of 
functional tissue-engineered 3D human skeletal muscle. The work presented here 
was approached by means of 3 specific aims: 
1. Specific Aim 1: Identify culture conditions for efficient HSkM growth and 
differentiation and establish a temporal profile of microRNA expression 
during differentiation. 
The goal of this aim was to identify proper culture conditions for the efficient 
differentiation of HSkM in vitro. Most research for skeletal muscle has been 
completed using the immortalized C2C12 mouse myoblast line due to 
accessibility and cost. However, it is important to study human tissue as 
there may be distinct differences. We hypothesized that HSkM would require 
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different culture conditions than those optimal for C2C12 culture (8% equine 
serum in differentiation medium on uncoated substrates). To test this 
hypothesis, immunofluorescence for sarcomeric α-actinin and microRNA 
expression was used to assess differentiation of muscle cultures. [92] 
2. Specific Aim 2: Assess the effects of miR-133a and miR-696 inhibition on 
gene and protein expression in HSkM cultured in 2D. 
The goal of this aim was to test the hypothesis that joint inhibition of miR-
133a and miR-696 would result in 2D human skeletal muscle cultures with 
accelerated differentiation and increased Type I muscle fibers compared to 
control and individual inhibition of each microRNA. To test this hypothesis, 
expression of genes and proteins important to the process of myogenesis and 
fiber type development were assessed. 
3. Specific Aim 3: Develop a 3D functional model for human skeletal muscle 
in vitro to assess effect of miR-133a and miR-696 inhibition on active 
contractile forces and ultrastructure. 
The goal of this aim was to develop a 3D human skeletal muscle model 
capable of active contraction. The second goal of this aim was to test the 
hypothesis that joint inhibition of miR-133a and miR-696 in this functional 3D 
human skeletal muscle model would result in active contraction significantly 
higher than control and individual inhibition by each microRNA. To test this 
hypothesis, isometric force testing was used to measure functionality of 
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engineered muscle bundles and compare forces between microRNA 
treatments. Additionally, immunofluorescence was used to visualize 
ultrastructural organization of bundles and identify myofiber type 
distribution as result of microRNA treatment. 
4. Specific Aim 4: Endothelialize 3D muscle bundle to model capillary-
muscle interface in vitro. 
The goal of this aim was to identify culture conditions to support a lamellar 
co-culture model in 3D of human cord blood-derived endothelial cells (hCB-
ECs) and HSkM capable of active contraction. To identify these conditions, 
immunofluorescence was used to visualize confluent layer of endothelium on 
fused human skeletal muscle and isometric force testing was used to test 
construct functionality. 
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CHAPTER 2. Optimization and Characterization of Primary Human 
Skeletal Myoblasts (HSkM) (Specific Aim 1) 
2.1. Introduction 
The use of murine models for the study of human diseases is a widely 
practiced phenomenon in biomedical research [107, 108]. This stems from the 
accessibility of mice and our shared organ systems and genetic material. Mice 
provide an easily genetically manipulated mammalian system and the rapid 
procreation necessary for efficient data collection. However, the question remains: 
how relevant are these results to human biology in phenotype and function [109]? 
Some recent studies have begun to study the similarities and differences between 
these two cell types; Harrison et al. found that in mouse and human skeletal muscle, 
myosin heavy chain IIB/X isoform (MyHC-IIB/X) genes have significantly different 
basal transcriptional activities despite highly conserved upstream regulatory regions 
[110]. Many groups have also delved into the characterization and use of human 
myoblasts in vitro; Stern-Straeter et al. measured the relative expression of various 
well-defined differentiation markers, including myogenic factor 5 (MYF5), 
myogenin, skeletal muscle α-actin1 (ACTA1), and adult myosin heavy chain (MYH1) 
[111]. This study saw a decrease of MYF5, an early differentiation marker, from day 
1-16 post-differentiation; there was a steady increase of expression in myogenin and 
ACTA1 post-differentiation; there was a rise and fall around day 12 post-
differentiation in MYH1 expression [111]. 
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Others have clearly demonstrated the importance of microRNA involvement 
in the successful proliferation and differentiation of human skeletal myoblasts to 
mature skeletal muscle; however, a detailed time course of microRNA dynamic 
expression during differentiation in human cells has not yet been shown. Koning et 
al. report significant downregulation in miR-106b, miR-25, miR-29c, and miR-320c 
levels between quiescent satellite cells and fused myotubes [112]; additionally, they 
showed miR-1 and miR-206 relative expression at four points throughout in vitro 
muscle growth: proliferation, confluency, differentiation, and muscle [113].  Chen et 
al. used a mouse model to show, both in vivo and in vitro, the expression of miR-351 
immediately after induced cardiotoxin (CTX) injury; in both cases, a peak and fall of 
miR-351 expression was seen post-CTX injury [114].  
Here, we attempted to fill this gap by measuring levels of miR-1, miR-133a, 
and miR-206 at various days post-differentiation. We began the study with a 
comparison of microRNA levels between isolated HSkM and immortalized C2C12 
cells. Next, brief characterization studies were conducted comparing the two as well: 
cell proliferation/growth rates, cell size/area, myoblast response to differentiation 
medium (DM), and rates of fusion and striation. Finally, we optimized the culture 
conditions for in vitro proliferation and differentiation of HSkM to use in future 
studies. This is the first study showing a detailed timeline of microRNA levels after 
the onset of differentiation. 
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2.2. Materials and Methods 
2.2.1. Primary Human Skeletal Myoblast Isolation 
Primary human skeletal myoblasts (HSkM) were isolated from biopsies of the 
vastus lateralis of healthy middle-aged volunteers (male and female) under 
conditions of informed consent and approval of the Duke Investigational Review 
Board. Biopsies were placed in growth medium for human skeletal myoblasts (hGM) 
containing low glucose (1 g/L D-Glucose) Dulbecco’s Modified Eagles’ Medium 
(DMEM; Gibco/Invitrogen), 8% heat-inactivated fetal bovine serum (HyClone), and 
SkGM Singlequots(Lonza/Clonetics) with insulin removed and kept on ice until 
ready for isolation. The muscle biopsy (30-50mg) was placed in Ca++ and Mg++-free 
HBSS (Gibco/Invitrogen) and minced into fine pieces. After removal of HBSS, 
minced tissue was placed in warmed solution containing 0.25% trypsin, 0.1% 
collagenase, 0.1% BSA, and 0.05% EDTA for 30 minutes. The action of the trypsin 
and collagenase were halted with addition of 10% fetal bovine serum in medium to 
tissue. Tissue was placed onto uncoated T25 flask to eliminate undesired cells (i.e. 
fibroblasts, nerve cells, blood cells) by adhesion to plastic. An adhesion time of 3 
hours was optimal for adhesion of other cell types but without significant adhesion 
of skeletal myoblasts. After 3 hours, tissue was transferred to collagen-coated T25 
flask (BD Biosciences) to allow migration of skeletal myoblasts from tissue. The hGM 
was changed every 5 days until the flask was 75% confluent, approximately 1-2 
weeks. Once 75% confluent, HSkM were split into dishes for expansion. After about 
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one week, when the cells were 85-90% confluent, cells were trypsinized and plated 
for studies or frozen. One 30-50mg biopsy yielded 15-20 million cells. 
Primary isolated HSkM were assessed for purity by staining for desmin, a 
muscle-specific intermediate filament protein that has been widely used in 
measuring primary skeletal myoblast purity [109, 115, 116]. Cultures were fixed with 
ice-cold 100% methanol and rinsed twice with PBS. Fixed samples were blocked in 
10% goat serum for 30 minutes at 37oC. The primary antibody against desmin 
(Sigma) was diluted 1:100 in 10% goat serum and incubated at 37oC for 30 minutes. 
After rinsing with PBS, samples were incubated at 37oC with secondary Alexa Fluor-
546 goat anti-mouse antibody (1:250, Invitrogen) for 30 minutes. Finally, Hoechst 
33342 nuclear stain (1:1000, Invitrogen) was added for 15 minutes at 37oC. Samples 
were thoroughly rinsed with PBS and viewed on a Nikon Eclipse TE2000-U 
fluorescent microscope. Images were analyzed using ImageJ software for percentage 
of desmin-positive cells per field of view. 
2.2.2. Cell Culture 
Primary HSkM cultures were expanded from 1,500 cells/cm2 in uncoated 
standard tissue culture plastic flasks at passages 3 to 6 (split 1:4 in flasks) at 37oC and 
5% CO2/95% air. Cells were fed every other day with hGM until confluent. 
Myoblasts were plated onto tissue culture plastic 6-well plates coated with either 100 
g/mL growth factor reduced Matrigel (GFR-MG, BD Biosciences) or left uncoated. 
To promote differentiation of confluent myoblasts to myotubes after 2-3 days, hGM 
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was changed to differentiation medium (DM), consisting of high glucose DMEM 
(Gibco/Invitrogen) supplemented with 2% or 8% equine serum (ES, HyClone) and 
0.1% gentamicin (Gibco/Invitrogen). 
Immortalized murine C2C12 myoblasts (ATCC), originally derived from C3H 
mouse leg muscle, were expanded and cultured on uncoated standard tissue culture 
plastic at passages 3 to 7 in conditions of 37oC and 5% CO2; each passage was split 
1:4. Cells were fed every other day with mGM consisting of high glucose (4.5 g/L D-
Glucose) DMEM, 8% calf serum (HyClone), 8% fetal bovine serum (HyClone), 0.5% 
chicken embryo extract (Accurate Chemicals), and 0.1% gentamicin. Similar to 
HSkM cultures, mGM was changed to DM to promote myoblast fusion upon 
confluency, about 2-3 days. 
2.2.3. Myoblast Size and Growth Rate 
Four hours post-plating, brightfield images were taken of HSkM and C2C12 
cultures. Areas of observation were marked on culture flasks and reexamined after 
28 and 48 hours. Cell growth rate was observed in the same manner as cell size; 
images were taken at 4, 12, 24, 36, 48, and 72 hours. Images were assessed using 
ImageJ software for cell size and cell number. 
2.2.4. Immunofluorescence 
Cellular proliferation was measured with the Click-iT EdU Imaging Kit 
(Invitrogen) following the manufacturer’s protocol. Briefly, cultures of myoblasts 
were incubated for 2 hours at 37oC with hGM or mGM containing 1mM EdU 
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solution. EdU (5-ethynyl-2’-deoxyuridine) is a nucleoside analog of thymidine and is 
incorporated into DNA during active DNA synthesis, and therefore, preferentially 
stains the nucleus of proliferating cells. Detection of EdU occurs through a click 
reaction: a copper-catalyzed covalent reaction between an azide and an alkyne [117]. 
The cells were fixed with ice-cold 100% methanol and rinsed with PBS. Fixed 
cultures were incubated for 30 minutes at room temperature with EdU reaction 
cocktail. The labeled cells were then incubated for 30 minutes at room temperature 
with Hoechst 33342. Cultures were rinsed with PBS and imaged using a Nikon 
Eclipse TE2000-U fluorescent microscope. EdU stained cells were counted with 
ImageJ software and quantified as fraction of total number of cells present in the 
field of view. Four fields of view were taken per well in a 6-well plate. 
To assess the timeline of differentiation for primary HSkM and C2C12 cells, 
samples were fixed every other day, starting from the day on which the media was 
changed from growth media to differentiation media at 80% confluence, denoted as 
Day 0, until Day 14 post-differentiation. Cultures were fixed with 100% ice-cold 
methanol and stained for sarcomeric α-actinin (1:800, Sigma) and nuclei (Hoechst 
33342, Invitrogen). At each time examined, the proportion of nuclei contained within 
α-actinin-positive fibers was calculated to find the rate of fusion during myoblast 
differentiation. 
To identify optimal level of serum for differentiation medium, HSkM were 
cultured in 2% and 8% equine serum-supplemented differentiation medium and on 
  
44 
100μg/mL GFR-MG coated surfaces and uncoated tissue-treated polystyrene surfaces 
in both normoxic (21% O2) and hypoxic (2% O2, physiologic) conditions. Samples 
were fixed at 10 days post-differentiation with 100% ice-cold methanol and stained 
for sarcomeric α-actinin and nuclei.  Briefly, fixed samples were blocked in 10% goat 
serum for 30 minutes at 37oC. The primary antibody against sarcomeric α-actinin 
(Sigma) was diluted 1:800 in 10% goat serum and incubated at 37oC for 30 minutes. 
After rinsing with PBS, samples were incubated at 37oC with secondary Alexa Fluor-
488 goat anti-mouse antibody (1:250, Invitrogen) for 30 minutes. Finally, Hoechst 
nuclear stain was added for 15 minutes at 37oC. Samples were thoroughly rinsed 
with PBS and viewed via Nikon Eclipse TE2000-U fluorescent microscope. At each 
time, the proportion of myofibers containing striations was calculated and compared 
to total number of fibers per field of view to assess development of striations and 
muscle maturation. 
2.2.5. MicroRNA/RNA Isolation and Quantitative Real-Time PCR 
Samples from static, stretched, and transfected studies were gathered at 
denoted days to track microRNA and RNA expression changes over time. 
MicroRNAs were isolated using the mirVANA microRNA Isolation Kit (Applied 
Biosystems). Total mRNA was isolated using the Aurum Total RNA Mini Kit (Bio-
Rad). 
To assess microRNA levels in mature human muscle tissue, fresh human 
muscle explants (from the vastus lateralis) were also used for microRNA isolation. 
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Tissue was minced in a glass petri dish using sterile forceps and scalpels. MicroRNA 
isolation was completed with the mirVANA microRNA Isolation Kit (Applied 
Biosystems). 
Quantitative RT-PCR (qRT-PCR) was used to assess microRNA and RNA 
expression from collected samples. MicroRNA/RNA concentration and quality were 
measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop, 
Wilmington, DE). For microRNA expression, cDNA was prepared using the 
MicroRNA Reverse Transcriptase kit (Applied Biosystems) and the MyiQ Single 
Color Real-Time PCR Detection System (Bio-Rad) per manufacturer instructions. 
Hairpin primers for microRNAs of interest were purchased (Applied Biosystems): 
hsa-miR-1, hsa-miR-133a, and hsa-miR-206. Small nucleolar RNA RNU6B was used 
as an endogenous control (Applied Biosystems). All primers were tested and 
approved by the manufacturer for use with mouse and human cell samples. TaqMan 
Universal PCR Master Mix (Applied Biosystems) and hairpin primers were added to 
the cDNA samples per manufacturer instructions and placed back into the MyiQ 
Single Color Real-Time PCR Detection System for PCR analysis. For RNA 
expression, cDNA was prepared using the iScript cDNA Synthesis Kit (Bio-Rad) 
following manufacturer instructions. Primers for Mef-2C and GAPDH (endogenous 
control) were custom ordered (IDT) for the following sequences: Mef-2C Forward 
ACTTCCTGGAGAAGCAGAAAGGCA, Mef-2C Reverse 
AACACGTTTCCTTCTTCAGCACGC, GAPDH Forward 
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TCAACAGCAACTCCCACTCTTCCA, GAPDH Reverse 
ACCCTGTTGCTGTAGCCGTATTCA. These primers have been previously used to 
measure GAPDH and Mef-2C mRNA levels [118, 119]. IQ SYBR Green Supermix 
(Bio-Rad) and primers were combined with cDNA and placed into the MyiQ Single 
Color Real-Time PCR Detection System for PCR analysis. The 2-∆∆CT method was 
used to assess the real-time mRNA and microRNA expression data. Total RNA from 
11-day-old mouse embryo was used as the calibrator (Clontech). 
PCR results were normalized to account for variability among the levels 
initially present in the different biological replicates. Data from all experiments, 
regardless of conditions, were averaged to obtain a “global average.” To identify the 
variability between experiments, data from each experiment were then averaged. To 
decrease inter-experiment variability while maintaining the relation between 
conditions within each experiment, a normalization factor was calculated by 
dividing the global average by the average of each experiment. New normalized 
values were calculated for each experiment by scaling each data point by the 
normalization factor of the experiment. This data was used to calculate statistical 
significance. 
2.2.6. Cyclic Mechanical Stretch 
Primary HSkM and C2C12 cells were cultured until 80% confluent. At this 
point, hGM and GM were shifted to 2% ES-DM and 8% ES-DM, respectively. This 
timepoint was denoted as Day 0. Mechanical stretching of myoblast cultures was 
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applied via the Flexcell FX-5000T Tension System (Flexcell International, Inc.) onto 
flexible silastic membranes; unstretched silastic membranes served as the control. 
Previous work on our lab with C2C12 optimized parameters for stretch studies to be 
10% stretch at 0.5Hz for 1 hour alternating with 5 hours of rest for differentiation 
[83].  
2.2.7. Statistical Analysis 
Data are presented as mean ± standard error (SEM) unless otherwise noted. 
ANOVA and Fisher’s PLSD post-hoc tests were performed using the STATVIEW 5.0 
statistical analysis package. A value of p < 0.05 was considered significant. HSkM 
isolated from separate individuals were considered distinct n’s whereas for C2C12 
cells, the value n represents separate cultures of the same cell line.  
2.3. Results 
2.3.1. Comparison of C2C12 and HSkM growth, size, and differentiation 
under conditions optimal for C2C12 myofiber maturation 
The purity of subconfluent primary HSkM myoblasts was assessed at 
passage 3. Using the percent of desmin-positive cells as a measure of purity, 90.4% ± 
4.2% (mean ± SEM, n=3) of subconfluent myoblasts were positive for desmin.  
When grown on uncoated tissue culture plastic in 8% serum, primary HSkM 
were significantly larger in cell size at 8, 28, and 48 hours post-plating than C2C12 
cells (n = 3, P4 all cells, Figure 6). Over 72 hours, both cell types exhibited the 
characteristic exponential growth; however, the primary HSkM had a lag phase 
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(typically 18-20 hours compared to none for C2C12) before reaching exponential 
growth (Figure 7). Using a linear fit to the log of the exponential growth phase, 
C2C12 doubling time was 19.7 ± 0.5 hours (R2 = 0.994, n = 3) and primary HSkM 
doubling time was 41.4 ± 3.3 hours (R2 = 0.912, n = 4).  
To assess proliferation at 0 and 24 hours in various culture media, an EdU 
cellular proliferation assay was used. Time zero (t = 0 hours) was designated when 
the cells reached 40% confluency; a sub-confluent time point was used to prevent a 
change in growth rate due to contact inhibition. Cell numbers were normalized to 
values at time zero for individual studies to allow for comparison between studies (n 
= 3, Figure 8). As assessed by ANOVA analysis of EdU levels on the different culture 
days, there was a significant drop in proliferation when DM was added at time zero 
for 24 hours compared to cultures kept in GM for 24 hours (p<0.05): C2C12 
proliferation dropped from 16.9 ± 3.8% in mGM to 7.3 ± 0.8% in DM, and HSkM  
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Figure 6. C2C12 vs. HSkM Cell Area. HSkM are larger than  
C2C12 at 8 (*p<0.03), 28 (**p<0.05), and 48 (***p<0.005) hours 
post-plating. Error bars are S
 
Figure 7. C2C12 vs. HSkM Growth Rates. Cell count values were  
normalized to counts on day 1 “percent growth.” C2C12 doubled  
in 19 hours and HSkM doubled in 35 hours. Error bars denote SEM. 
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Figure 8. Effect of DM on Cell Proliferation. Cultures were split into  
2 groups: cultures in GM and cultures shifted to DM at time zero.  
Time zero was determined to be 80% confluency. With repeated measured  
ANOVA analysis, the drop inproliferation at 24 hours post-differentiation  
was significant (*p<0.02). 
proliferation dropped from 18.8 ± 0.9% in hGM to 10.5 ± 3.3% in DM. HSkM EdU 
levels were similar to that of C2C12 under both conditions of GM and DM after 24 
hours. 
The extent of differentiation was first investigated by means of myotube 
formation and maturation to myofibers under conditions that were optimal for 
C2C12 differentiation (no protein coating, 8% serum in differentiation medium). 
Myoblasts fused and the resulting myofibers become striated as skeletal muscle 
matures [120]. The lag in development of striated HSkM relative to C2C12 is 
apparent by immunofluorescence for α-actinin, paralleling previous findings for 
growth rate (Fig. 9A-B) [121]. Using a linear fit, the rate of fusion was calculated over 
the linear portion of the data shown in Figure 9C. C2C12 fused at a rate of 11.13 ± 
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1.6% nuclei per field of view per day (R2 = 0.990) from Days 0-6, which was not 
different than the fusion rate of HSkM (6.92 ± 2.9% nuclei per field of view per day 
(R2 = 0.997)) from Days 0-10. HSkM had a significantly slower rate of developing 
striations compared to C2C12, an important indicator of muscle maturity: 3.25 ± 
0.78% vs. 8.65 ± 2.79% striations per field of view per day, respectively (Fig. 9D, 
ANCOVA p<0.05). As skeletal muscle differentiated, HSkM fibers decreased in 
diameter, while C2C12 fibers increased in diameter.   For Day 8 and earlier, the fiber 
diameters were similar. Then they diverged with diameter increasing for C2C12 and 
decreasing for HSkM; at Day 10, HSkM fiber widths were significantly thinner (54.0 
± 4.4μm, n = 3) than C2C12 (105.8 ± 14.5μm, n = 3)(p<0.05) (Fig. 9E). At Day 8, C2C12 
cultures showed prominent striations while the HSkM cultures took two weeks post-
differentiation (Day 14) to reach a comparable maturation point. Based on these 
results, subsequent studies for HSkM were conducted to Day 14 to allow for 
appropriate development and muscle maturation. 
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2.3.2. Culture Conditions for HSkM 
When HSkM myoblasts were cultured on an uncoated tissue culture 
polystyrene surface for 14 days after shifting to 8% equine serum, 
immunofluorescence for sarcomeric α-actinin showed a sparse distribution of short 
myofibers that lacked striations (Fig. 10A). Using MATLAB image analysis, the 
average sarcomeric α-actinin stained area was 29.7 ± 3.5% in each field of view (4 
fields of view/experiment, n=3). Staining for von Willebrand factor showed 3.1 ± 
0.8% positive staining for endothelial cells among the myoblast population. Unfused 
cells are a combination of unfused self-renewed satellite cells and other cells types 
that were not removed by the isolation process.  
In 2% serum on uncoated surfaces, myofibers appeared longer compared to 
those cultured in 8% serum. However, myoblasts cultured under these conditions 
also lacked striations (Fig. 10B) and only 23.9 ± 2.2% of total stained areas were 
positively stained for sarcomeric α-actinin. The culture of myoblasts on a surface 
treated with 100μg/mL GFR-MG, which has been shown to maintain differentiation 
capacity of muscle precursor cells in vitro [122], showed an increase of sarcomeric α-
actinin staining on Day 14 to 50.1 ± 5.2% of area. These myofibers also contained 
striations (Fig. 10C, arrow); however, there appeared to be scattered sarcomeric α-
actinin-stained aggregates as well (Fig. 10C, asterisk). HSkM grown on 100μg/mL 
GFR-MG and in 2% serum showed 43.4 ± 3.0% area positive for sarcomeric α-actinin 
with fewer stained aggregates and more striations (Fig. 10D, arrow); this result was 
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not statistically different than 50.1 ± 5.2% for 8% serum on GFR-MG. When cultured 
on surfaces coated with 100μg/mL GFR-MG in 2% serum, HSkM exhibited greater 
extent of fusion and striation after 14 days (84.0 ± 2.0% of α-actinin-positive area 
contained striations in 2% serum vs. 13.3 ± 7.7% striated in 8% serum, n=2). 
Therefore, 2% equine serum in DM on GFR-MG-coated surfaces appeared to best 
facilitate HSkM differentiation of other tested conditions.  
 
Figure 10. Effect of serum and Matrigel coating on formation of striated human muscle 
fibers 14 days after shifting to differentiation medium (DM) with the indicated level of 
serum.  Differentiation was characterized by immunofluorescence for sarcomeric α-actinin 
(green) and DAPI (blue). (A) Few fibers were seen under uncoated, 8% equine serum in DM 
conditions. (B) Few fibers were present in uncoated, 2% equine serum conditions; however, 
myofibers were longer compared to uncoated 2% equine serum conditions. (C) Fibers were 
more prevalent and robust in surfaces coated with 100 μg/ml GFR-MG in 8% equine serum 
DM. Some cell debris was also present (asterisk). Few striations were present (arrow). (D) 
Robust, striated fibers were seen for HSkM attached to GFR-MG-coated surfaces and 
differentiated in 2% equine serum-supplemented DM (arrow). All images taken at 20X 
magnification, scalebars are 50μm. [1] 
2.3.3. Effect of culture conditions on C2C12 and HSkM microRNA and MEF-
2C expression 
Based on the improved differentiation of HSkM on GFR-MG at low serum 
levels, we hypothesized that adding GFR-MG coating and decreasing media serum 
levels would significantly elevate the microRNA and Mef-2C gene expression of 
HSkM during differentiation in vitro. All microRNA expression was normalized to 
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the small nucleolar RNA RNU6B as endogenous control; Mef-2C gene levels were 
normalized to GAPDH as endogenous control. When cultured in 8% serum during 
differentiation on uncoated surfaces to reproduce typical culture conditions for 
C2C12, levels of miR-1, miR-133a, miR-206 and Mef-2C were at least 200% higher in 
C2C12 cells compared to HSkM on corresponding days (Fig. 11). C2C12 exhibited, 
on average, a 15-fold increase between miR-1 and miR-133a expression on Day 6 
compared to Day 0 post-differentiation for both genes.  In contrast, levels of these 
microRNAs in HSkM remained stable and very low compared to C2C12 cells (Fig. 
11A-B). MiR-206 reached a plateau of 800-1000 by Day 2 in C2C12 cells, and average 
of 2.5-times greater expression than HSkM on Day 0. However, in HSkM, miR-206 
showed a maximum expression above 350 on Day 4 and declined to less than 70 on 
Day 8 (Fig. 11C).  
MiR-1 represses histone deacetylase 4 (HDAC4), which is a repressor of Mef-
2C.  Therefore, increases in miR-1 levels promote skeletal muscle differentiation 
[123]. The levels of the Mef-2C gene in C2C12 increased 14.5-times between Day 0 
and Day 4, but remained consistently below 1 in HSkM (Fig. 11D). MiR-1 and Mef-
2C gene expression in C2C12 cells were over 40-times higher than in HSkM at all 
times. Overall, the lower levels of key muscle microRNAs and Mef-2C in HSkM 
were consistent with reduced levels of differentiation in HSkM relative to C212 cells. 
Relative to HSkM cultured on uncoated surfaces in 8% equine serum (Fig. 12, 
filled squares), HSkM plated onto GFR-MG surfaces in 8% serum (Fig. 12, gray 
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squares) produced average increases in the levels of miR-1, miR-133a, and miR-206 
of at least 14-times compared to uncoated surfaces in 8% serum. MiR-1 levels peaked 
at Day 6, with levels 26-times that of Day 0, followed by a plateau between 10-20 
from Days 6-14; similarly, miR-133a expression peaked at Day 4, with levels 29-times 
that of Day 0, followed by a plateau in expression around 40 from Days 6-14. MiR-
206 levels peaked at Day 4 with expression 28-times that of Day 0, then plateaued at 
400 from Day 6-14.  Mef-2C did not change much in 8% serum with the addition of 
GFR-MG coating: levels at Day 14 with and without GFR-MG averaged between 26-
27. Overall, GFR-MG presence increased Mef-2C expression an average of 67% that 
of uncoated HSkM in 8% equine serum-supplemented differentiation medium. 
While maintaining 100 μg/mL GFR-MG coating, differentiation medium was 
changed from 8% to 2% serum. With this change, microRNA levels in the HSkM 
cultures were compared to GFR-MG in 8% serum (Fig. 12, white squares). For all 
times, expression increased an average of over 220% between GFR-MG in 2% serum 
compared to GFR-MG in 8% serum for miR-1, miR-133a, and miR-206. Similar to the 
previous condition, microRNA expression also exhibited dynamic changes over the 
measured time of 2 weeks in GFR-MG and 2% serum. MiR-1 showed a 5-fold 
increase between expression at Day 0 and 6, followed by a drop of 35% at Day 14 
compared to Day 6. MiR-133a also peaked at Day 6, followed by a 24% drop in 
expression from Day 6 to Day 14. MiR-206 increased more than 6-times from Day 0 
to Day 10, followed by a 38% drop between Day 10 and 14. Mef-2C increased 6.5-
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times between Days 4 and 6, with a sharp 75% decline from Day 6 to 14. For all times 
studied, Mef-2C levels were an average of 4-fold higher when cultured on GFR-MG 
and 2% serum compared to the levels for GFR-MG in 8% serum.  
To assess whether the serum level also influenced the increased microRNA 
levels observed with HSkM cultured on GFR-MG, we measured miR-1, miR-133a, 
and miR-206 expression at Day 8 post-differentiation for HSkM cultured in 2% 
serum on uncoated tissue treated polystyrene.  This condition led to increases in 
expression for miR-1, miR-133a and miR-206 compared to the uncoated condition in 
8% serum: miR-1 increased 4.4-times, miR-133a increased 9.0-times, and miR-206 
increased 90.6-times. However, these cells showed markedly lower expression of all 
three microRNAs compared to conditions with HSkM cultured on GFR-MG and in 
2% serum. Due to the elevated levels of miR-1, miR-133a, miR-206, and Mef-2C, 
subsequent studies with HSkM were conducted using a 100 μg/mL GFR-MG-coated 
substrate and 2% serum DM. 
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Figure 11. Comparison of microRNA and Mef-2C mRNA levels in mouse C2C12 (reference) 
and HSkM cells.  Under optimal conditions to promote C2C12 differentiation (8% serum and 
no Matrigel coating of plastic surface), developing C2C12 myotubes had significantly higher 
expression of miR-1, -133a and 206. Dynamic expression of miR-1 (A), miR-133a (B) and miR-
206 (C) from day 0 to day 8 post-differentiation. C2C12 cultures exhibited significantly higher 
expression of MEF-2C gene at all timepoints than hSKM samples. All error bars denote SEM 
(n=4); *p<0.05 C2C12 compared to HSkM.[1] 
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Figure 12. Effect of culture conditions on expression of microRNAs. HSkM cultures were 
grown on plastic that was either uncoated or incubated with 100 µg/mL growth factor 
reduced-Matrigel (GFR-MG) in 2% or 8% equine serum. For all microRNAs, levels were higher 
under GFR-MG and 2% equine serum conditions (white squares) compared to uncoated, 8% 
equine serum conditions (black squares) at terminal day (n=3). *p<0.05 for uncoated, 8% equine 
serum compared to GFR-MG, 8% equine serum; ^p<0.05 for uncoated, 8% equine serum 
compared to GFR-MG, 2% equine serum; #p<0.05 for GFR-MG, 8% equine serum compared to 
GFR-MG, 2% equine serum. [1] 
2.3.4. Effect of stretch on HSkM differentiation 
We previously found that ±10% cyclic mechanical stretch at 0.5Hz for 1 hour 
followed by 5 hours of rest for 1 week significantly accelerated C2C12 differentiation 
[4] and hypothesized that this mechanical stimulation regimen would also enhance 
HSkM differentiation when applied for 2 weeks (to account for slower 
differentiation) to confluent monolayers. Cyclic sinusoidal stretch was applied 
continuously for 14 days after differentiation in both 8% and 2% serum. To facilitate 
stretch, C2C12 and HSkM were cultured on softer, flexible silastic membranes coated 
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with 100 μg/mL GFR-MG (for both static and stretched samples). The decreased 
substrate rigidity compared to tissue culture plastic can account for differences in 
microRNA expression of HSkM shown in Fig. 13 relative to Fig. 12. After 14 days of 
cyclic stretch, HSkM cultures in 8% serum showed an increase of 40% for miR-1 
expression and 128% for miR-133a expression (*p<0.05, n = 6) compared to HSkM 
grown statically on GFR-MG-coated membranes in 8% serum.  MiR-206 levels 
increased 20% after stretch in 8% serum (Fig. 13) compared to static control in 8% 
serum. In 2% serum, all microRNAs showed decreased expression after 14 days of 
cyclic stretch compared to static controls cultured in 2% serum: miR-1 decreased 
36%, miR-133a decreased 55% (*p<0.05, n = 3) and miR-206 decreased 53% (^p<0.01, n 
= 3).   
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Figure 13. Cyclic Stretch Affects microRNA Levels. Cyclic stretch was applied to HSkM 
monolayers for 14 days post-differentiation at ±10% strain and 0.5Hz for 1 hour alternating 
with 5 hours of rest. All studies were conducted on 100 µg/ml  GFR-MG-coated flexible 
membranes. (A) Under conditions of 8% serum, the levels of miR-1 increased significantly 
(*p<0.05, n=6) after 14 days of stretch. In 2% serum, 14 days of stretch saw a decreasing level of 
miR-1 compared to static controls. (B) MiR-133a increased significantly after 14 days of stretch 
in 8% serum (*p<0.05, n=6), but decreased in 2% serum (*p<0.05, n=3). (C) After 14 days of 
stretch, HSkM cultured in 8% serum rose in miR-206 expression; those cultured in 2% serum 
fell significantly in miR-206 level (^p<0.01). Error bars denote SEM. [1] 
2.3.5. Comparison of microRNA levels in fresh muscle explants and culture 
HSkM 
To assess the effect of culture on HSkM microRNA levels, microRNAs were 
isolated directly from mature skeletal muscle explants of the vastus lateralis from 
adult human subjects (Table 2) and compared with results obtained in vitro at Day 
14. Measured microRNA levels from fresh explants ranged from 3-times to over 500-
times greater than levels measured with no GFR-MG and 8% serum. With the 
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addition of a GFR-MG coating prior to culture with 8% serum during differentiation, 
microRNA levels in vitro increased drastically, but were still less than in explant 
tissue. Interestingly, miR-206 was most affected by the various culture conditions, 
with in vitro expression surpassing that of fresh explants by almost 6 times. In 
contrast, other measured microRNAs remained below levels in fresh explants. In 
GFR-MG and 2% serum conditions, microRNA levels further improved; however, 
the largest increase in expression occurred with the addition of GFR-MG coating 
(average 14-fold increase over uncoated) compared to a change in serum content 
(average 2.3-fold increase from 8% to 2% serum).  
Table 2. MicroRNA Levels in Explant, C2C12, and HSkM. [1] 
 
2.4. Discussion 
In this study, conditions were tested for improved differentiation of primary 
isolated HSkM myoblasts to form myofibers.  The use of 100 μg/mL GFR-MG coating 
and 2% equine serum-supplemented differentiation media promoted human 
myoblast fusion and striated fiber formation while elevating levels of myogenic 
genes miR-1, miR-133a, miR-206, and Mef-2C in human muscle cultured in vitro.  
Further, the addition of antisense miR-133a alone accelerated differentiation in 
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primary HSkM shown by the increased sarcomeric α-actinin protein expression by 
30%; previous studies have needed more than one microRNA to obtain a similar 
outcome in primary human cells [113].  
Murine myoblasts differentiate well under 8% [49], 2% [104], or 1% [120] 
serum, and even serum-free [124, 125] differentiation media conditions on uncoated 
surfaces. The decreased serum content in differentiation medium is sufficient to 
trigger a halt in myoblast proliferation and a shift to myoblast fusion and myofiber 
formation. Few similar studies have been conducted with human myoblasts; Stern-
Straeter et al. reported that gelatin-coated substrates induced higher rates of 
proliferation in primary isolated human myoblasts compared to non-coated 
polystyrene and used 2% horse serum in differentiation media [126]. Similar to 
Stern-Straeter et al., we showed the beneficial myogenic effect of decreased serum 
content and the addition of Matrigel coating to human skeletal myoblast culture and 
differentiation; however, the work presented here provides a more in-depth study of 
human myogenesis by way of microRNA and gene expression levels during HSkM 
differentiation in vitro. 
Mouse and human skeletal muscle cell types differ drastically in growth rate, 
cell size, formation of sarcomeres and substrates required for growth (Figures 6 and 
7). This may be due, in part, to the differences between a cell line and primary 
isolated cells, or due to differences in species. It has been consistently found that 
human cells proliferate and develop at a slower rate compared to murine cells in vivo 
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and in vitro [107].  The slower response of human myoblasts and myofibers may be 
due, in part, to the extended lifetime of humans. Human lives are, on average, 30-50 
times longer than mice – this translates to about 105 more cell divisions in our 
lifetime compared to mice [107].  If human myoblasts doubled at the same rate that 
murine myoblasts doubled, mathematically, there would be an expected increase in 
incidence of cancer and other late-onset illnesses. However, on average, 30% of 
rodents develop cancer at the end of their lifespan (typically 2-3 years), as well as 
30% of humans at 70-80 years [107]. The slowed proliferation and differentiation 
rates of human myoblasts compared to murine myoblasts can be partially attributed 
to the human body’s attempt to protect from rapid ageing, cancer, and other illness.  
Other groups had measured the expression levels of microRNAs during a 
few specific stages of human muscle development: proliferation, differentiation, and 
mature muscle [112, 113]; provided here is a more detailed time course of the 
changes in microRNA expression throughout the important process of muscle fusion 
and fiber formation – showing changes as large as 29-fold over a two week period of 
myoblast differentiation. Koning et al. report significant downregulation in miR-
106b, miR-25, miR-29c, and miR-320c levels between the quiescent human satellite 
cell stage and fused myotube stage [112]. Additionally, they showed miR-1 and miR-
206 relative expression at general points throughout in vitro muscle growth: 
proliferation, confluency, differentiation (5 days after inducing differentiation), and 
muscle (human biopsy tissue) [113]. The temporal trends of their miR-1 and miR-206 
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dynamic expression from confluency to differentiation are quite similar to our 
findings from Day 0-6 post-differentiation showing an increase in microRNA 
expression. However, they concluded that sole transfection with miR-1 or miR-206 
alone was not sufficient to trigger myotube formation [113], an important step in the 
process of differentiation; we showed here that transfection solely with antisense 
miR-133a was able to achieve myotube formation. 
The results presented in these studies are the first to show the effect of 
various culture conditions on the expression of myogenic microRNAs during 
differentiation. Culture conditions clearly have a significant effect on muscle growth, 
as miR-1, miR-133a, miR-206, and Mef-2C levels increased drastically with the 
introduction of protein coating and decrease in media serum content. Satellite cells 
are extremely sensitive to their surrounding environment [127]; we found that the 
presence of GFR-MG-coated substrate improved the differentiation of these cells by 
elevating levels of myogenic microRNAs and transcription factors. Lawson and 
Purslow [125] show significant mouse and rat muscle cell responses to both serum 
content in media and substrate extracellular matrix coating [125]. Rat L6 cells only 
formed myotubes in serum-containing media and exhibited higher creatine 
phosphokinase (CPK) activity when cultured in 2% serum media. In C2C12 cells, 
however, CPK activity was dependent on both the substrate coating and media 
serum content [125].  
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We found that microRNA levels in human myoblasts cyclically stretched 
respond differently depending on media serum content (Fig. 5). Since microRNA’s 
work in concert to guide myoblast development, there may exist compensatory 
increases in differentiation signals elsewhere pushing the myoblast towards 
differentiation. Additionally, cells with such environmental sensitivity may, indeed, 
respond to stimuli conversely than expected when exposed to different conditions. 
Carson and Booth [128] have shown that α-actin gene expression in primary chicken 
myoblasts was dependent on serum availability and static mechanical stretch; 
cultures underwent 8-20% static stretch in either 10% or 0.5% equine serum 
conditions. They did not find any difference in α-actin mRNA level for stretched and 
static samples in 10% serum; however, the levels decreased by 26% for samples 
stretched in 0.5% serum [128]. Thus far, the effects of serum content on cyclically 
stretched primary human myoblasts had not been reported. We showed increased 
microRNA levels after 14 days of cyclic stretch in 8% serum, while stretch in 2% 
serum led to significant microRNA decreases.  
We chose to study microRNAs for their potent effects on myogenesis [129], 
endogenous presence, and localization to the cytoplasm. The endogenous nature of 
microRNAs provides an available platform in which to affect myogenesis without 
the need to introduce foreign bodies, and the localization of microRNA’s to the 
cytoplasm allows for easier access and manipulation than nucleic acids that 
predominantly reside within the cell nucleus. MicroRNA’s exert their effects through 
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dynamic changes in expression over time, compared to transcription factors that 
function similar to on/off switches. Since microRNA’s can be effectively delivered to 
the cellular cytoplasm via liposomes and have been shown to exert effects transiently 
[49], the potential of microRNA’s to be used as therapy for individuals with 
muscular dystrophy or sarcopenia is large. In comparison to constitutive expression, 
the ability to deliver gene therapy non-virally and transiently is attractive due to 
lower cell cytotoxicity. However, knowledge of the microRNA expression in normal, 
healthy muscle tissue is necessary prior to understanding how best to treat disorders 
caused by their imbalances.  
Prolonged increases or decreases in miR-133a expression have been 
implicated in energy deficit, muscular dystrophy, skeletal muscle hypertrophy, and 
heart failure [129-133]. This study showed,  however, that transient miR-133a 
inhibition in primary isolated HSkM positively affects the differentiation rate of 
HSkM in vitro, consistent with past findings using C2C12 cells [49]. Transient 
transfection was utilized as microRNA’s demonstrated long retention within HSkM 
(t1/2 = 92.2 hours). Overexpression of miR-1 and miR-206 in murine and human 
cultures [49, 113] led to increased differentiation; however, it was found that both 
microRNA’s must be overexpressed in order to trigger myotube formation in vitro 
[88, 134]. Here, the inhibition of miR-133a alone successfully triggered formation of 
myotubes and increased sarcomeric α-actinin staining (a measure of differentiation) 
by 30%. 
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The delivery and application of transient myogenic microRNA’s may be a 
viable way to enhance the growth and differentiation of engineered skeletal muscle 
in vitro for basic and translational research. The research presented here shows the 
importance of culture conditions and the potential of microRNA modulation for 
affecting human myogenesis in vitro. 
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CHAPTER 3: Joint Inhibition of miR-133a and miR-696 for Accelerated 
Type I Human Myofiber Differentiation In Vitro (Specific Aims 2 & 3) 
3.1. Introduction 
Engineered functional three-dimensional human skeletal muscle in vitro can 
be used as implantable tissues for diseases and injuries of muscle and serve as a 
platform for the pre-clinical testing of drugs [71, 135]. The fabrication and growth of 
three-dimensional tissue-engineered skeletal muscle constructs depends on muscle 
progenitor cell type, biomaterial scaffold, treatment, and geometry. Engineered 
three-dimensional human muscle constructs form myofibers in vitro [51] and human 
myofibers spontaneously contract  in two-dimensional  cultures after co-culture with 
human motoneurons [44] or after cyclic electrical stimulation for eight hours [136].   
To date, contractile activity of three-dimensional engineered human muscle 
constructs has not been reported.  In contrast, functional three-dimensional skeletal 
muscle constructs using mouse or rat myoblasts produce active contraction without 
the need for external or supplemental stimuli [49, 137, 138]. Rhim et al. reported 
statically cultured C2C12 cells in a collagen hydrogel to exert 0.33 ± 0.12 mN of force 
after 6-8 days of static culture [49]. Engineered 3D muscle cultured with primary rat 
myoblasts have found even higher forces, above 0.8 mN in peak tetanic force after 10 
days of differentiation [79, 137] and even as high as 1.68±0.32 mN for twitch and 
2.84±0.5 mN for tetanus for a fibrin-Matrigel hydrogel system seeded with neonatal 
rat myoblasts [47]. The addition of various stimuli (stretch, proteoglycans, gene 
therapy, etc.) could further aide in elevation of active contractile forces [49, 79].  
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Possible reasons for the lack of active force generation by human muscle in 
vitro may be the seeding density of myoblasts into 3D scaffolds or immaturity of 
engineered skeletal muscle [139]. In comparing seeding densities of 1 x 105, 2 x 105, 
and 4 x 105 muscle-derived cells (MDCs) onto fibrin gels, Martin et al. found that 
seeding 4 x 105 human myoblasts in 200 μL exhibit the greatest myoblast fusion 
index and number of myotubes per microscope field [71].  
Muscle maturation can also be promoted by transient regulation of the level 
of microRNAs. MicroRNAs are short (20-22nt), noncoding RNA strands that act 
through post-transcriptional regulation of genes [90, 140]. Several microRNAs are 
extremely important in the regulation of muscle proliferation and differentiation and 
their overexpression or inhibition can have profound effects on myogenesis [49, 141]. 
MiR-1 and miR-206 promote myoblast differentiation, and miR-133a promotes 
proliferation. Koning et al. demonstrated increased myoblast differentiation when 
miR-1 and miR-206 were transiently overexpressed in primary human skeletal 
myoblasts [141]. We previously showed that inhibiting miR-133a alone in C2C12 
murine myoblasts and primary human skeletal myoblasts significantly accelerate 
differentiation [49]. Aoi et al. identified stretch-sensitive miR-696, which regulates 
the expression of an important and potent metabolism co-activator, PGC-1α. Aoi et 
al. demonstrated heightened levels of PGC-1α protein levels in anti-miR-696 C2C12 
samples 24 hours after transfection. [101] Heightened expression of PGC-1α, which 
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is encoded by the gene [142], has been linked to increased oxidative energy 
metabolism and type I (slow twitch) myofiber formation [65, 104, 142].  
We recently reported that in 2D cultures transient inhibition of miR-133a 
alone accelerated myogenesis in primary human myoblasts [1], similar to what we 
observed with mouse myofibers [49]. In the current study, we tested the hypothesis 
that jointly inhibiting miR-133a and miR-696 simultaneously will lead to accelerated 
differentiation of 2D and 3D human skeletal muscle bundles with increased type I 
myofiber expression compared to negative control transfected with vehicle. 2D 
cultured muscle allowed for the study of proteins and gene expression without the 
interference of hydrogel protein. 3D engineered muscle was used to demonstrate 
contractile forces production after electrical stimulation and to observe detailed 
ultrastructure and morphology in a more native-like environment containing tension 
and fiber alignment.  
3.2. Materials and Methods 
3.2.1. Primary HSkM Isolation 
Primary human skeletal myoblasts (HSkM) were isolated as presented 
previously [1]. Briefly, biopsies from the vastus lateralis of healthy, middle-aged 
volunteers were placed in growth medium (GM) containing low glucose (1g/L D-
Glucose) Dulbecco’s Modified Eagles’ Medium (DMEM, Gibo/Invitrogen), 8% heat-
inactivated fetal bovine serum (FBS, HyClone), and SkGM Singlequots with insulin 
removed (Lonza/Clonetics). The biopsy (30-50mg) was placed in Ca and Mg-free 
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HBSS (Gibco/Invitrogen) and minced into fine pieces. HBSS was removed and 
replaced with 37oC cocktail containing 0.25% trypsin, 0.1% collagenase, 0.1% BSA, 
and 0.05% EDTA for 30 minutes with occasional agitation. Proteolytic activity was 
halted with the addition of FBS in medium. Minced and partially digested tissue was 
then placed onto an uncoated T25 culture flask for 3 hours to eliminate fibroblasts by 
adhesion to plastic. Tissue was then transferred to a collagen-coated T25 flask (BD 
Biosciences) to allow for migration of skeletal myoblasts from tissue to surface. GM 
was changed every 5 days until flask reached 75% confluency, a process which took 
approximately 1-2 weeks. HSkM were then passaged into collagen-coated dishes for 
expansion and frozen or plated for studies. One 30-50mg biopsy yielded 15-20 
million cells.  Four isolations of HSkM from separate individuals were used for these 
studies with average purity of 88.0 ± 6.1% as assessed by desmin staining of 4 donors 
after thawing frozen cultures. 
3.2.2. Cell Culture 
Primary HSkM cultures were expanded from 1,500 cells/cm2 in uncoated 
standard tissue plastic flasks at passages 3 to 6 in conditions of 37oC and 5% CO2. 
GM was changed every other day until 85-90% confluent in approximately one 
week. Myoblasts were then trypsinized and plated onto tissue culture plastic 6-well 
plates coated with 100μg/ml growth factor reduced Matrigel (GFR-MG, BC 
Biosciences). To promote differentiation of myoblasts to myotubes  when near 
confluence, GM was changed to differentiation medium (DM) consisting of high 
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glucose DMEM (Gibco/Invitrogen) supplemented with 2% equine serum (HyClone) 
and 0.1% gentamicin (Gibco/Invitrogen). 
3.2.3. MicroRNA Transient Transfection 
Single-stranded antisense microRNA molecules specific for the miR-133a 
(UUUGGUCCCCUUCAACCAGCUG, Applied Biosystems) and miR-696 
(GCGUGUGCUUGCUGUGGG, Applied Biosystems) sequence were used with 
siPORT NeoFX Transfection Agent (Ambion). Anti-miR Negative Control #1 
(Applied Biosystems), a single-stranded random microRNA sequence, was used as 
transfected control. 
Transient microRNA transfection was achieved as previously described [1]. 
Briefly, siPORT NeoFX Agent was diluted with OptiMEM I (Gibco) and mixed with 
50nM of single-stranded anti-miR (anti-miR-133a, anti-miR-696, anti-miR-negative 
control). The transfection mixtures were allowed to incubate in tissue culture flasks 
at 37oC for 10 minutes to allow for formation of liposomes. Then, HSkM cells and 
GM were added. Cells were transfected at 37oC and 5% CO2 for 18 hours, after which 
cells were rinsed, trypsinized, and plated for studies. Day 0 was denoted at 80% 
confluency, in which GM was exchanged for DM.  
To assess the transfection efficiency and half-life of the anti-miR, Cy3 and 
FAM dye-labeled anti-miR Negative Control #1 (Applied Biosystems) were used as 
described above. The transfected HSkM containing Cy3 or FAM labels were viewed 
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under fluorescence and quantified as the proportion of total cells in the field view 
was recorded. 
3.2.4. Mold Preparation and Sterilization 
Molds for Human Bioartificial Muscle (HBAM) bundles were prepared from 
polydimethylsiloxane (PDMS, Dow Corning Corporation) cast onto a negative mold. 
Molds for 165μl and 45μl bundles were prepared.  
Molds were sterilized by 60 minutes of sonication in 70% ethanol. Next, they 
were placed into 6-well plates and allowed to dry in the biological hood under UV 
light for at least 2 hours. To prevent adhesion of hydrogel to mold, PDMS was 
soaked in 2% pluronics solution for 20-60minutes at 37C.  
Stainless steel minutien pins and small pieces of Velcro were soaked in 70% 
ethanol for at least 1 hour and allowed to air dry in the biological hood. After 
aspiration of pluronics solution from PDMS molds, Velcro was pinned into the 
molds in preparation for muscle bundle application. 
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Figure 14. Preparation of PDMS Molds for Engineered 3D human skeletal muscle bundle 
construction. (A) PDMS was placed onto Negative Mold made of Teflon and allowed to cure. 
Once cured, PDMS was removed from Teflon negative. (B) Top view of PDMS mold and (C) 
Side view of PDMS mold. 
3.2.5. Engineered 3D Human Muscle Bundle Construction 
Three-dimensional human skeletal muscle bundles were constructed using 
sterilized 45μl PDMS molds. Hydrogels were comprised of 20% Matrigel (BD 
Biosciences), 4mg/ml final concentration of fibrinogen (Sigma), 50U/ml thrombin 
(Sigma), and transfected HSkM (passage 5-7) at a final density of 5, 10 or 15 x 106 
cells/ml. The solution was allowed to gel at 37C and 5% CO2 for 1 hour before 
addition of GM. At 48 hours post-seeding, all gels had compacted and appeared 
opaque. At this time, GM was exchanged for DM (Day 0); DM was exchanged every 
48 hours for the 2-week culture period. 
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3.2.6. Immunofluorescence 
To assess for the presence of striations, as an indicator of muscle maturity, 
and type I and II myofibers, samples were fixed at 14 days post-differentiation with 
100% ice-cold methanol for 5 minutes and then rinsed 3 times with PBS. They were 
then blocked in 3% BSA in 0.05% TBST/PBS overnight with gentle rocking. Primary 
antibodies for mouse sarcomeric α-actinin (1:800, Sigma), slow myosin heavy chain 
(1:300, AbCam, reacts only with human adult type I skeletal muscle fibers), and fast 
myosin heavy chain (1:300, AbCam, reacts with human and mouse type IIA, IIX/B 
skeletal muscle fibers) were diluted in 3% BSA in 0.05% TBST/PBS and incubated 
overnight with gentle rocking. Samples were then rinsed with PBS and incubated 
with secondary antibody (Alexa Fluor, 1:250, Invitrogen) and Hoechst stain (1:1000, 
Invitrogen) for 45 minutes at room temperature with gentle rocking. Samples were 
thoroughly rinsed with PBS and viewed with a Zeiss 510 inverted confocal 
microscope. Confocal images were taken at varying depths throughout the muscle 
bundles. Resulting images were assessed with ImageJ software for fiber diameter, 
percent of nuclei in fibers (fusion index), and myofiber type. For fiber diameter 
measurements, 4 measurements were taken per field of view, and 3 fields of view 
were taken for each condition. Images were also assesses with ImageJ for pixels 
stained for sarcomeric α-actinin by installing the “Color Pixel Counter” plugin. The 
plugin was used to quantify pixels stained, then divided by total pixels per field of 
  
77 
view to calculate area fraction of myofibers. This area fraction was used to quantify 
area containing fibers, then used to calculate specific force per fiber area. 
3.2.7. Quantitative Real-Time PCR of Mef-2C and PPARGC1A 
For 2D experiments at days 6 and 14 after onset of differentiation and from 
3D at day 14 after onset of differentiation, total mRNA was isolated from samples 
using the Aurum Total RNA Mini Kit (Bio-Rad). RNA concentration and quality 
were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop). For 
RNA expression, cDNA was prepared using the iScript cDNA Synthesis Kit (Bio-
Rad) following manufacturer’s instructions. Primers for Mef-2C, PPARGC1A, and 
GAPDH (endogenous control) were custom ordered (IDT) for the following 
sequences: Mef-2C Forward ACTTCCTGGAGAAGCAGAAAGGCA, Mef-2C 
Reverse AACACGTTTCCTTCTTCAGCACGC, PPARGC1A Forward 
TGTGCAACTCTCTGGAACTG, PPARGC1A Reverse 
TGAGGACTTGCTGAGTGGTG, GAPDH Forward 
TCAACAGCAACTCCCACTCTTCCA, GAPDH Reverse 
ACCCTGTTGCTGTAGCCGTATTCA.  
3.2.8. Western Blot 
Western blots were performed to determine the presence of sarcomeric α-
actinin and mitochondria in 2D cultures. At Day 14, cells were harvested with a cell 
scraper and lysed using CellLytic-M (Sigma) and Protease Inhibitor Cocktail (Sigma). 
Protein concentration was assessed using the BCA Protein Assay Kit (Pierce). 15 μg 
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of protein was loaded into each lane on a 12% Ready Gel Tris-HCl Precast Gel (Bio-
Rad) for SDS-polyacrylamide gel electrophoresis. Following, all protein was 
transferred from the gel onto a nitrocellulose membrane with 0.45 μm pore size 
(Invitrogen). The membrane was blocked for 30 minutes in 5% nonfat milk in Tris-
Buffered Saline with 0.1% Tween 20 (TBST) with gentle rocking at room 
temperature. Primary antibodies for mouse sarcomeric α-actinin (1:2500, clone EA-
53, Sigma), mouse anti-human 60 kDa glycosylated mitochondrial protein (1:2500, 
MTC02, AbCam), mouse PGC-1α (1:2000, Calbiochem) and mouse β-actin (1:1000, 
Santa Cruz Biotechnology) were diluted in TBST solution containing 3% BSA and 
incubated with the membrane overnight at 4oC with gentle rocking. All antibodies 
reacted with the human antigens, as specified per manufacturer’s protocols. After 
rinsing the membrane to remove unbound antibody, the membrane was incubated 
with goat anti-mouse HRP secondary (1:2500, Invitrogen) in TBST containing 3% 
BSA for 30 minutes at room temperature with gentle rocking. Residual antibody was 
washed and immunoreactive bands were detected by luminography using 
Supersignal chemiluminescent substrate (Pierce). Band density was determined by 
densitometry after scanning onto autoradiographic films (Kodak) and evaluated by 
ImageJ software. Protein expression is reported as normalized intensity of the band 
of interest to the band of the reference protein (β-actin). 
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3.2.9. Measurement of Contractile Force 
At Day 14 post-differentiation, muscle bundles were removed from PDMS 
molds and pinned into a custom chamber and immersed in 37oC DM. Bundles were 
pinned to a fixed tissue anchor at one end and a PDMS holder suspended by the 
force transducer (custom-made by Dr. Robert Dennis, University of North Carolina, 
Chapel Hill, NC, USA) at the other end. Positioning of the force transducer was 
controlled by a motorized linear actuator (Thorlabs). A pair of parallel platinum foil 
electrodes applied the electrical stimuli to suspended bundles to elicit isometric 
muscle contractions. (Figure 15) 
 
Figure 15: Schmatic of isometric force testing setup. Muscle bundles were pinned into 
reservoir with media at 37C. Bundles were pinned at the left to a PDMS anchor point and on 
the right to a force transducer. Platinum foil electrodes were used to stimulate bundles with 
100V at various frequencies for 2 msec.  
Using the motorized linear actuator, the initial length of the engineered 
muscle bundle was set to the length of culture (8 mm). Force output was recorded 
for electrical stimuli at 1, 5, 10, 20, and 40Hz and 100V. Measurements were repeated 
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for 5% increments up to 120% of initial construct length. Force traces were recorded 
into LabVIEW and exported to Microsoft Excel files.  
For analysis, Microsoft Excel files were loaded into a custom made MATLAB 
program and peak forces found for each frequency and length condition. Photos 
taken at 100% length prior to force testing were assessed in ImageJ for muscle bundle 
cross-sectional area; specific forces were calculated by dividing force output (mN) by 
cross-sectional area (mm2).  
The MATLAB code used for analysis is attached in Appendix C. 
3.2.10. Statistical Analysis 
Data are presented as mean ± standard error (SEM) unless otherwise noted. 
ANOVA and Fisher’s PLSD post-hoc tests were performed using STATVIEW 5.0 
statistical analysis package. HSkM isolated from separate individuals were 
considered distinct n values. A value of p<0.05 was considered significant. 
3.3. Results 
3.3.1. Transient Transfection Efficiency and Lifetime of MicroRNA’s 
The transfection efficiency of HSkMs receiving Cy3- 1 and FAM-labeled negative 
control anti-miRs was 90.6±2.3% (Figure 16) and the transfection efficiency with one 
microRNA was 94.4±2.9%. These efficiencies were not significantly different.  Using 
a polynomial fit, single microRNA transfection had a half-life of 105.2 ± 0.7 hours (% 
transfected = -5E-5(hours)2 + 0.0008(hours) + 0.9416, R2 = 0.9923, n = 3) and joint 
microRNA transfection had a half-life of 104.1 ± 0.6 hours (% transfected = -3E-
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5(hours)2 – 0.0014(hours) + 0.9235, R2 = 0.9623, n = 3). The half-lives of single and joint 
microRNA transfection were not significantly different. 
 
Figure 16: Transfection efficiency and lifetime of exogenous microRNA. Single transfection 
with one fluorescently-tagged microRNA shows 94.4 ± 2.9% initial efficiency after 18 hours of 
incubation of HSkM with microRNA and half-life of 102.3 ± 0.7 hours (white squares). Joint 
transfection with two microRNA’s shows 90.6 ± 2.3% initial efficiency after 18 hours of 
incubation of HSkM with microRNA’s and half-life of 97.7 ± 0.6 hours (black squares).  
 Mathematically, the efficiency of joint transfection is equal to the square of 
single transfection efficiency. This was calculated to be 89.1% efficiency (marked in 
Figure 16 with “X”), slightly lower than 94.4% efficiency with one microRNA. The 
measured efficiency was, in fact, very close to this value: 89.1% calculated efficiency 
vs. 90.6% measured efficiency.  
3.3.2. MiR-133a and MiR-696 Inhibition in 2D Cultures Accelerates 
Myogenesis and Affects PGC-1α 
HSkM differentiation was examined after plating on GFR-MG and shifting to 
DM for 14 days, duration previously found to produce prominent striations 
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demonstrating tissue maturity [143]. Western blot analysis of sarcomeric α-actinin 
expression at day 14 post-differentiation showed significant differences between 
joint inhibition samples and negative control (Fig. 17A and 17B, *p<0.05, n=4). Joint 
inhibition samples presented over 55% more sarcomeric α-actinin protein 
normalized to reference β-actin as compared to negative control. Based on the 
expression of a 60 kDa non-glycosylated protein component of mitochondria, there 
was no significant difference in mitochondrial presence at 14 days post-
differentiation between tested microRNA inhibition treatments. Consistent with our 
prior results in mouse and human myotubes [1, 49], inhibiting miR-133a promotes 
myotube maturation. These results of sarcomeric α-actinin presence indicate an 
interaction between miR-133a and miR-696 in the development of skeletal muscle 
tissue, as individual effects were not significant but joint effects were significant. 
Further, there may a possible additional role of miR-133a on downstream 
transcription factors that affect the oxidative metabolism pathway. 
Since miR-696 negatively regulates expression of PGC-1α protein [101], 
Western blots were performed for PGC-1α, which should increase with the 
inhibition of miR-696. Relative to negative control anti-miR-133a, anti-miR-696, and 
joint inhibition conditions all showed significantly increased protein expression of 
PGC-1α (Figure 17C).  Treatment of myoblasts with anti-miR-133a caused over 65% 
increase in  PGC-1α expression, anti-miR-696 showed over 80% increase in 
expression, and joint inhibition showed over 70% increase in expression over 
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negative control PGC-1α expression (Fig. 17D, *p<0.05, #p<0.005, n=3). While 
treatment of myoblasts with either anti-miR-133a or anti-miR-696 did not affect the 
levels of PPARGC1A gene relative to negative control, joint inhibition of anti-miR-
133a or anti-miR-696 caused PPARGC1A levels to increase over 2-times the levels 
found in negative control samples (p<0.05, n=3, Figure 18), suggesting an interaction 
between anti-miRs that affects not only the protein, but also the gene that encodes 
PGC-1α. 
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Figure 17: Sarcomeric α-actinin and mitochondria presence in 2D cultures. (A) Western blot 
for sarcomeric α-actinin (SAA) and mitochondrial protein showed significant increase in SAA 
with joint inhibition of miR-133a and miR-696 compared to negative control. There was no 
difference in mitochondrial protein expression between transfection conditions. β-actin was 
used as reference for normalization of protein expression. (B) Densitometry of SAA and MT 
normalized to β-actin showed significantly higher SAA in joint inhibition compared to negative 
control (n=4, *p<0.05) and no change for MT. (C) Western blot for PGC-1α with β-actin as 
reference protein. (D) Densitometry of PGC-1α protein normalized to β-actin and negative 
control showed significant increases in expression for anti-miR-133a, Anti-miR-696. and Joint 
Inhibition, compared to negative control. (*p<0.05, #p<0.005, n=3) 
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Figure 18: Expression of PPARGC1A gene at Day 14 post-differentiation. Joint transfection 
samples showed significantly increased expression of PPARGC1A gene compared to negative 
control. Results were normalized to housekeeping gene GAPDH (*p<0.05, n=3). Error bars 
denote SEM. 
 
Due to the observed increases in PGC-1α expression with anti-miR 
transfection, immunofluorescence for slow and fast myosin heavy chain, 
corresponding to Type I and Type II fibers, respectively, was used to visualize the 
distribution of fibers within 2D human skeletal muscle culture 14 days post-
differentiation to see downstream effects of this elevated metabolism co-activator. 
There was no apparent difference between the staining of slow and fast myosin in 
both proportion of fibers stained as well as intensity of staining at day 14 post-
differentiation (Figure 19). Proportion of fibers positive for fast myosin heavy 
averaged 91.9 ± 2.9%, and proportion of fibers positive for slow myosin heavy 
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averaged 86.9 ± 3.9% between all conditions, including negative control. Most 
human skeletal muscle fibers co-expressed both slow and fast myosin protein 
isoforms, consistent with previously reported in vitro [144-146] and in vivo [18, 29] 
findings. Edom et al. found similar distribution of culture human skeletal myofibers 
isolated from the masseter: 94.4% of fibers expressed fast myosin heavy chain and 
95% expressed slow myosin heavy chain after 4 days of differentiation [146]. 
Similarly, studies using satellite cells isolated from human quadriceps found 95.2% 
positive for fast myosin heavy chain and 91% positive for slow myosin heavy chain 
after 4 days of differentiation [146]. There was no significant difference between 
myofiber density and nuclei in fibers between all conditions. 
  
87 
 
3.3.3. Functional Three-Dimensional Human Skeletal Muscle Bundles 
Results with human myotubes in 2D culture suggest that miR-133a and miR-
696 inhibition of myogenesis should affect skeletal muscle function. We hypothesized 
that a 3D tissue engineered human skeletal muscle bundle seeded with anti-miR-
treated HSkM and cultured in a fibrin-based hydrogel under static conditions could 
exert active contraction forces under isometric force testing. Since the seeding 
density of skeletal myoblasts into a 3D scaffold or hydrogel affects maturation of 
muscle and generation of force [71, 147, 148], we examined seeding densities from 5 
x 106 HSkM myoblasts/mL 15 x 106 HSkM/mL.  While a seeding density of 5 x 106 
Figure 19: Fiber Type in 2D 
Engineered Human Skeletal Muscle. 
Immunofluroescence for fast (red) 
and slow (green) myofibers did not 
show any difference in intensity or 
proportion of image stained. 
Scalebars at 50 μm. 
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C2C12/mL was sufficient to produce contractile forces after electrical stimulation in a 
collagen-based gel [48], HSkM muscle bundles with 5 x 106 cells/mL repeatedly did 
not elicit forces when subjected to electrical stimulation at various frequencies 
(Figure 19A). Consistent with this result, confocal imaging of immunostained 
bundles showed negligible myoblast fusion and little organization (Figure 20). 
 
Figure 20: Engineered human skeletal muscle bundles with  5 x 106 cell/mL. Constructs 
seeded with 5 x 106 HSkM/mL consistently showed little fusion and organization. Sarcomeric 
α-actinin shown in red and nuclei shown in green. 
Bundles seeded with 10 x 106 HSkM/mL exhibited fusion and striations of 
myofibers when subjected to immunofluorescence (Figure 21). Furthermore, these 
muscle bundles produced contractile forces after electrical stimulation (Fig. 22A-B). 
Muscle bundles containing 15 x 106 HSkM/mL generated 33.2% and 15.8% greater 
SAA Sytox Green (nuclei) 
  
89 
forces compared to 10 x 106  HSkM/mL bundles at 10 and 20 Hz frequencies, 
respectively (Fig. 22B, *p<0.05, n = 3). Furthermore, engineered human muscle 
exhibited the characteristic force-length relationship of native muscle: magnitude of 
force output increased with percent length of engineered constructs (Fig. 22C). We 
observed little decline in force after the peak, which may be attributed to the low 
level of force generated in our engineered constructs. Subsequent studies were 
conducted with 15 x 106 HSkM/mL in fibrin/Matrigel bundle system. Thus, there 
appears to be a threshold of HSkM seeding density into fibrin-based muscle 
constructs that allows for functional force output by engineered muscle. 
 
Figure 21: Human skeletal muscle bundle ultrastructure in 3D cultures seeded with 10 x 106 
cells/mL. Immunofluorescence for sarcomeric α-actinin (SAA, green) and Hoechst (blue) show 
myofibers aligned to the direction of tension with striations (arrows). Image taken at 40X 
magnification. 
SAA DAPI 
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Figure 22: HSkM 
seeding density for 
muscle bundles. 
Bundles were seeded 
with 5 x 106 HSkM/mL, 
10 x 106 HSkM/mL, and 
15 x 106 HSkM/mL and 
cultured statically for 2 
weeks. (A) Bundles 
seeded at 5 x 106 
HSkM/mL did not 
return forces. Bundles 
seeded with 10 x 106 
HSkM/mL and 15 
HSkM/mL did exhibit 
force output at 10 Hz 
and 100V, with forces at 
15 x 106 HSkM/mL 
significantly higher 
than those at 10 x 106 
HSkM/mL (n=3, 
p<0.05). (B) Functional 
force testing showed 
significantly higher 
specific force output at 
both 10 Hz and 20 Hz 
for constructs seeded 
with 15 x 106 
HSkM/mL. All 
frequencies measured 
showed increased 
specific forces with 15 x 
106 HSkM/mL seeding 
density. (C) Engineered 
human skeletal muscle 
construct exhibit 
characteristic force-
length curves, with 
increasing length 
leading to slight 
increases in force 
output. All error bars 
denote SEM. (*p<0.05, 
n=3) 
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To assess the maturation of engineered skeletal muscle, bundles were fixed 
and stained for sarcomeric α-actinin, acetylcholine receptors, and nuclei. Constructs 
showed high density of aligned myofibers containing striations (Fig. 23A-C, 
striations denoted by arrows). Myofibers were aligned with the direction of tension, 
which was generated through attachment to Velcro anchor points at each end of the 
PDMS mold.  Functional force output in innervated tissue necessitates the presence 
of machinery for the propagation of an action potential, notably acetylcholine 
receptors (AChR) [149, 150]. Although the engineered muscle is not innervated, the 
formation of AChR in vitro is a sign of muscle proper development and maturity. In 
native tissue, AChR are clustered in mature muscle fibers in the postsynaptic 
membrane at the neuromuscular junction [151]; here, the presence of these receptors 
in vitro indicates myofiber maturity within the engineered bundles. 
Immunofluorescence for acetylcholine receptors showed their presence at the 
periphery of myofibers within the engineered muscle; however, they appeared to 
occur infrequently (Fig. 23B-C, arrows).  
3.3.4. Effect of MicroRNA-133a and/or -696 Inhibitors upon 3D Human 
Skeletal Muscle Bundles 
Compaction of hydrogels is a cell-mediated process [152, 153], resulting from 
tension produced by cells aligned along the longitudinal axis of the construct [153, 
154]. The extent of fibrin gel compaction depended upon the microRNA treatment 
administered to HSkM prior to bundle seeding. Anti-miR-133a constructs were 22.4 
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± 6.1% thinner than the negative control (Fig. 24A, p<0.05, n=3). Joint inhibition led to 
36.8 ± 3.4% thinner constructs compared to negative control (p<0.005, n=3). 
Interestingly, myofiber diameters did not differ between various microRNA 
conditions. While adding the anti-miR did reduce the diameter of the 3D constructs, 
myofibers within engineered muscle constructs did not differ in diameter based 
upon microRNA treatment. Constructs made with HSkM that received the negative 
control contained myofibers were 14.3 ± 3.7 μm in diameter, anti-miR-133a 
constructs contained myofibers with a diameter of 16.0 ± 3.4 μm, anti-miR-696 
constructs contained myofibers with a diameter of 13.7 ± 4.4 μm, and joint inhibition 
constructs contained myofibers with a diameter of 13.9 ± 3.3 μm. Myofiber diameters 
between all microRNA treatments were not different; however these diameters were 
lower than those reported in 2D most likely due to the spreading of myofibers on the 
substrate in 2D compared to suspension of fibers in the hydrogel in 3D.   
To further assess ultrastructure of the bundles, the fusion within the bundles 
was quantified by counting proportion of nuclei within sarcomeric α-actinin-stained 
myofibers. The average percent of nuclei in fibers (fusion index) for negative control 
bundles was 61.9 ± 3.5% nuclei in fibers. There was no significant difference between 
the negative control and anti-miR treatments, as all conditions fell in the range of 60-
70% nuclei in fibers (n=3). Fiber density was significantly higher in anti-miR-133a 
constructs compared to negative control constructs (p<0.05, n = 4, Figure 24B).  
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Figure 24: Bundle diameters and fiber density. (A) Engineered muscle bundles were measured for 
diameter at 2 weeks post-seeding. Negative control bundles were significantly thicker than Anti-miR-
133a (n=3, *p<0.05) and Joint inhibition bundles (n=3, #p<0.005). Joint inhibition bundles were 
significantly thinner than Negative Control and Anti-miR-696 bundles (n=3, *p<0.05). (B) Sarcomeric α-
actinin-stained human skeletal muscle bundles were analyzed by ImageJ for density of fibers per area. 
Anti-miR-133a bundles exhibited the highest density of fibers compared to negative control (*p<0.05, 
n=4). All other conditions were not statistically different in fiber density. 
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After 2 weeks of culture, isometric force testing of twitch forces was 
conducted over the range of various length elongations: 100-120% in increments of 
5%. This allowed us to study the force-elongation relationship of the engineered 
muscle bundles and verify that it is behaving similarly to native tissue. Additionally, 
measurements of passive force were taken to assess the contribution of ECM to the 
overall force production and determine whether the anti-miR treatments affected 
fibroblast function which might explain the different levels of compaction. Increased 
passive force generation has been correlated with increased ECM presence in both 
native and 3D engineered tissues [47, 155-158]. Active force amplitudes exhibited the 
characteristic force-elongation relationship in which forces increase around the 
optimal length elongation and decrease at shorter and longer lengths (Figure 25). 
Joint inhibition bundles exhibited significantly higher active forces per elongation for 
twitch and tetanus than negative control (p<0.0001, n=4), anti-miR-133a (p=0.0004, 
n=4), and anti-miR-696 (p=0.0002, n=4). The magnitudes of active force amplitude 
changes, however, were not large, which may be due to the low forces generated by 
tissue-engineered skeletal muscle compared to native muscle.  
Passive forces exhibit a characteristic force-length relationship that is 
exponential with increasing length elongation [159]. Our range of length elongation 
led to an approximately linear relation with force output due to shorter deformations 
of the tissue. Figure 28 shows the measured passive forces for microRNA-treated 
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muscle bundles.  ANCOVA analysis of linear regression slopes did not show any 
significant difference between rates of passive force amplitude change with 
increasing construct elongation, indicating that there is likely no significant 
difference in ECM content between microRNA treatments. Additionally, the 
increased forces produced by joint inhibition engineered muscle bundles are likely 
not due to presence of ECM, but the differentiated muscle itself. 
 
 
  Figure 25: Active and passive forces generated by engineered human skeletal muscle. 
Both active and passive forces measured exhibited characteristic force-elongation 
relationship. Active forces were maximal within optimal length elongation. Passive forces 
linearly increased with increasing force elongation. Error bars denote SEM. 
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Muscle bundles derived from myoblasts that were transfected with both anti-
miR-133a and anti-miR-696  exhibited increases in twitch and tetanic forces 
compared to other conditions: over 130% compared to negative control (p<0.005 
twitch, p<0.0001 tetanus, both n=4, Figure 26), over 65% compared to anti-miR-133a 
(p<0.005 twitch, p<0.0001 tetanus, both n=4), and over 120% compared to anti-miR-
696 bundles (p<0.005 twitch, p<0.0001 tetanus, both n=4).  Bundles with anti-miR-
133a HSkM showed over 35% increase in tetanic force relative to the negative control 
(p<0.05, n=4). These bundles also gave over 40% higher active tetanic forces 
compared to anti-miR-696 bundles (p<0.05, n=4). Magnitudes of twitch force and 
tetanus force (20 and 40 Hz) were used to calculate tetanus-to-twitch ratio (TtR). All 
TtR fell in the range of 2.0-2.5, and there was no significant difference in TtR between 
all tested bundle conditions. 
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Figure 26. Isometric force testing of muscle bundles. Functional force output was measured after 
excitation with 100V electrical impulses at various frequencies. Twitch forces were recorded at 1 Hz and 
tetanic forces between 10-40 Hz frequencies. Anti-miR-133a bundles gave significantly higher tetanic 
forces compared to negative control (*p<0.05, n=4) and anti-miR-696 (*p<0.05, n=4). Joint inhibition 
demonstrated significantly higher twitch and tetanic forces compared to all other transfection 
conditions (*p<0.05, #p<0.005, &p<0.0001, n=4). Error bars denote SEM.  
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Area fraction of fibers was quantified by ImageJ to estimate proportion of 
area containing fibers and proportion of area of ECM of images taken are varying 
depths throughout the bundle. There was no significant difference between area 
fraction of fibers for conditions tested: negative control contained 58.4 ± 8.3% of the 
total area occupied by fibers, anti-miR-133a contained 68.2 ± 7.4% of the total area 
occupied by fibers, anti-miR-696 contained 63.9 ± 7.0% of the total area occupied by 
fibers, and joint inhibition contained 61.5 ± 8.2% of the total area occupied by fibers 
(n=4 for all). While force per fiber area is most accurately calculated utilizing 
measurements from transverse cross-sections of the muscle bundle, the area fraction 
quantified here may provide an informative estimate. Using the calculated area 
fraction of fibers and specific force results per bundle presented above, we calculated 
the force produced by fiber area for each microRNA treatment condition. This 
analysis was important as it accounts for variables of extracellular matrix area and 
discrepancies in muscle fiber density between microRNA treatments. Calculating 
force per cross-sectional area allows for better comparison with published work. 
Although we did not measure cross-sectional area occupied by fibers, area fractions 
are equivalent to volume fraction for thin sections of tissues. Therefore, the area 
fraction in the longitudinal direction is a good approximation to the area fraction of 
fibers in the cross-section. 
From this analysis, we found that while anti-miR-133a bundles produced 
significantly higher tetanus specific forces than negative control and anti-miR-696 
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bundles, the myofiber density of anti-miR-133a bundles was higher than other 
conditions. This led to equal twitch force per fiber cross-sectional area produced by 
individual fibers between negative control, anti-miR-133a, and anti-miR-696 (Figure 
27). Additionally, tetanus force per fiber cross-sectional area amplitudes for negative 
control, anti-miR-133a, and anti-miR-696 individual fibers were equal as well. Joint 
inhibition conditions saw significant increases in specific force amplitudes per fiber 
area over all other conditions. Twitch and tetanus force amplitudes per fiber area 
saw over 2-times increase in magnitude between joint inhibition and all other 
conditions (*p<0.05 compared to negative control, #p<0.05 compared to anti-miR-
133a, ^p<0.05 compared to anti-miR-696, n=4 for all). Therefore, the increase in anti-
miR-133a bundle tetanus forces may be partially attributed to the increased fiber 
density within the engineered constructs. These forces per fiber saw a range of 1.4-
1.8-times increase in specific force compared to specific force per bundle, due to the 
area fraction containing myofibers. The low specific force of individual myofibers 
estimated from studies with small bundles suggests that engineered muscles are 
failing to reproduce the differentiated state found in vivo. Individual myofibers from 
engineered small bundles of rodent muscle have been reported to exert 0.69 ± 0.13 
mN/mm2 [160], individual myotubes on cantilevers exerted 0.94 mN/mm2 [161], and 
3D aligned muscle bundles exerted  0.80 ± 0.15 mN/mm2 [162]. Our studies found 
specific forces from human muscle to fall within this range:  0.61 ± 0.02 mN/mm2 at 
tetanus in the joint inhibition condition.  
  
101 
  
Figure 27: Specific force per muscle fiber area. Twitch and tetanus specific forces normalized 
to fiber area showed significantly higher forces in joint inhibition conditions compared to all 
other conditions. The forces reported here are comparable to those reported in literature for 
engineered muscle [160-162]. *p<0.05 compared to negative control, #p<0.05 compared to anti-
miR-133a, ^p<0.05 compared to anti-miR-696, n=4 for all 
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We next examined whether microRNA treatments on human muscle bundle 
contraction affected contraction kinetics by measuring time to peak twitch (TPT), 
half relaxation time (½RT), and time to tetanus (TT). No difference was observed 
between TPT and TT kinetics: TPT ranged from 160-190 msec for all conditions, and 
TT ranged from 1100-1125 msec for all conditions. However, ½RT demonstrated a 
larger range, from 260-320 msec. In fact, negative control bundles took 10.4% longer 
to reach half relaxation compared to anti-miR-696 treated constructs (p<0.05), Anti-
miR-133a treated bundles took 17.6% longer to reach half relaxation than anti-miR-
696 treated bundles (p<0.0005), and anti-miR-696 bundles reached half relaxation 
13.9% faster than bundles treated with both anti-miR-133a and anti-miR-696  (p<0.01) 
(Figure 28). 
 
Figure 28. Half Relaxation Time. Measurements of half relaxation time showed significantly 
decreased time for miR-696 inhibition bundles compared to all other conditions: Negative 
Control, miR-133a Inhibition, and Joint Inhibition. *p<0.05, #p<0.01, ^p<0.0005, all n=3.  
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Studies of microRNA transfection in 2D showed a change in gene expression 
of PPARGC1A. In 3D, real-time qPCR was also used to assess the presence of slow 
and fast myosin heavy chain within engineered 3D human skeletal muscle tissues at 
day 14 post-differentiation. Following 2D results which showed increased 
PPARGC1A gene expression levels at day 14 for the joint inhibition condition, it was 
expected that joint transfection in 3D would lead to increased slow myosin heavy 
chain gene expression. Instead, heightened expression of slow myosin heavy chain 
was measured for anti-miR-133a (over 2-times compared to negative control, p<0.05, 
n=3) and anti-miR-696 (almost 3-times compared to negative control, p<0.005, n=3) 
bundles only, with slow myosin heavy chain gene levels falling significantly in joint 
inhibition samples (Figure 29A). Slow myosin heavy chain gene levels fell over 60% 
between anti-miR-133a bundles and joint inhibition bundles (p<0.05, n=3) and over 
70% between anti-miR-696 bundles and joint inhibition samples (p<0.005, n=3). Fast 
myosin heavy chain showed over 2-times higher expression in anti-miR-696 
conditions compared to negative control (p<0.05, n=3, Figure 29B) and over 3-times 
higher expression in joint inhibition conditions compared to negative control (p<0.05, 
n=3). Ratios of slow:fast myosin heavy chain gene expression fell over 80% between 
anti-miR-133a bundles and joint inhibition bundles (p<0.05, n=3, Figure 29C) and 
over 75% between anti-miR-696 bundles and joint inhibition bundles (p<0.05, n=3).  
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Figure 29: Myosin 
heavy chain 
presence. (A-B) 
Total RNA isolated 
from engineered 
human skeletal 
muscle bundles 
treated with various 
miR inhibitors was 
used for real-time 
qPCR for slow and 
fast myosin heavy 
chain. (A) Slow 
myosin heavy chain 
showed significantly 
higher ratios for 
anti-miR-696, 
compared to 
negative control and 
joint inhibition 
conditions (*p<0.05, 
n=3). Error bars 
denote SEM. (B) Fast 
myosin heavy chain 
showed significantly 
higher expression in 
anti-miR-696 and 
joint inhibition 
conditions, 
compared to 
negative control 
(*p<0.05l, n=3). Error 
bars denote SEM. 
(C) Ratios of 
slow:fast myosin 
showed significantly 
higher ratios for 
anti-miR-133a and 
anti-miR-696, 
compared to joint 
inhibition (*p<0.05, 
n=3). Error bars 
denote SEM. 
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While immunofluorescence for slow and fast myosin heavy chain did not 
show a difference in percent of fiber stained (92-97% slow and 90-100% fast), 
assessment of stain intensity did support PCR findings. Slow myosin heavy chain 
stain intensity showed highest values for anti-miR-133a over negative control and 
joint inhibition conditions (p<0.05, n=3, Fig. 30A). Anti-miR-696 bundles showed 
over 60% higher slow myosin staining intensity compared to negative control 
(p<0.05, n=3). Immunofluorescence for fast myosin heavy chain (Type II myofibers) 
showed over 65% increase in stain intensity for joint inhibition compared to negative 
control, over 55% increase in stain intensity compared to anti-miR-133a, and over 
40% increase in stain intensity compared to anti-miR-696 (p<0.05 for all, n=3, Figure 
30B). Figure 30C show representative immunofluorescence images for slow and fast 
myosin heavy chain staining. These findings indicate that proportion of Type II 
fibers may be higher when miR-133a and miR-696 are simultaneously inhibited, 
compared to negative control and each anti-miR individually.  
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Figure 30: Immunofluorescence for slow and fast fibers. (A-B) Immunofluorescence for slow 
and fast myosin heavy chain was analyzed for pixel intensity. Images for slow myosin showed 
increased intensity in anti-miR-133a samples (*p<0.05, n=3). Images for fast myosin showed 
increase intensity for joint inhibition (*p<0.05, #p<0.005, n=3). Error bars denote SEM. (C) 
Engineered human skeletal muscle bundles treated with various miR inhibitors were stained for 
slow (green) and fast (red) myosin heavy chain. Anti-miR-133a and Anti-miR-696 showed 
highest proportion of fibers and intensity of stain positive for slow myosin heavy chain 
antibody. Joint inhibition showed the least slow myosin heavy chain staining and most intense 
fast myosin heavy chain compared to all other conditions. All other conditions stained similarly 
for fast myosin. All scalebars are 50 μm.  
A. 
B. 
C. 
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Mef-2C is an important transcription factor involved in the activation of 
PGC-1α and the further development of oxidative metabolism as well as the onset of 
myogenesis. Mef-2C gene expression levels were measured in engineered muscle 
bundles to assess any correlation of the transcription factor with the distribution of 
muscle fiber type. Mef-2C levels were over 20-times higher in anti-miR-133a 
condition compared to joint inhibition (p<0.05, n=3, Figure 31).  
 
Figure 31: Mef-2C expression of engineered human skeletal muscle. After 2 weeks of culture, 
Mef-2C gene expression was measured by qPCR. Expression was normalized to GAPDH and 
reference total mouse embryo RNA. Joint inhibition constructs exhibited significantly lower 
expression of Mef-2C compared to anti-miR-133a constructs after 2 weeks. (*p<0.05, n=3 for all) 
3.4. Discussion 
In this study, we successfully induced contraction of engineered three-
dimensional muscle bundles by increasing the cell density and promoted 
differentiation by inhibition of miR-133a and miR-696.  While inhibition of miR-133a 
and miR-696 separately promoted differentiation, when these two microRNAs were 
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inhibited simultaneously, 2D engineered human skeletal muscle in vitro showed over 
55% increase in presence of sarcomeric α-actinin protein and over 70% increase in 
PGC-1α protein 14 days after onset of differentiation compared to negative control. 
In 3D engineered human skeletal muscle, joint inhibition of miR-133a and miR-696 
led to 153% higher peak specific forces when subjected to electrical stimuli.  
We used microRNAs for the modulation of human skeletal muscle 
myogenesis and metabolism due to their potent effects on myogenesis [129], 
endogenous presence, and localization to the cytoplasm [1]. The endogenous 
presence of microRNAs allows for their modulation without the need of introducing 
viral vectors, and the localization of microRNAs to the cytoplasm allowed for easier 
access and manipulation of nucleic acids that reside primarily within the cell nucleus 
[1]. MicroRNAs can be effectively delivered to the cytoplasm using liposomal 
transfection, which holds great potential as therapy for individuals with muscular 
dystrophy or sarcopenia. The ability to deliver gene therapy nonvirally and 
transiently, as opposed to constitutively, is advantageous due to lower cell 
cytotoxicity [163]. While microRNA transfection is transient in nature, our studies 
found that the half-lives of single and joint microRNA inhibition are over 4 days, 
enough time for anti-miRs to exert their effects on myofiber development. 
While our cultures are predominantly composed of human skeletal 
myoblasts, there still exists some infiltration of fibroblasts. In fact, fibroblasts have 
been shown to help stabilize engineered muscle tissue and produce important ECM 
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[55]. Thus, it is important to consider the effects of anti-miR transfections on not only 
skeletal myoblasts, but on fibroblasts as well. Duisters et al. reported that levels of 
miR-133 were 15-fold higher in rat cardiac myocytes compared to rat fibroblasts 
[164]; therefore, inhibition of miR-133a would most likely leave the fibroblasts 
unaffected due to the low endogenous levels of this microRNA. Furthermore, there 
exists no literature quantifying the levels of miR-696 in fibroblasts – likely owing to 
the low endogenous levels as well. 
These results are the first to show active contractile forces in response to 
electrical stimulation of static 3D tissue-engineered human skeletal muscle. Our 
fibrin-based muscle bundles are not subjected to mechanical conditioning or 
electrical stimulation during the culture period – rather, myogenesis occurs over the 
course of 2 weeks in a controlled, static environment. Similar to the results of 
Mudera et al. [147], we did find a drastic difference in specific force output when 
constructs were seeded at different cell densities. Mudera et al. found that 30 x 106 
primary isolated human skeletal myoblasts seeded into a 5 mL compliant collagen 
gel construct produced the highest passive force contraction: 1372 ± 313 μN 
compared to 622 ± 254 μN for 20 x 106 cells and 926 ± 249 μN for 40 x 106 cells.  Our 
results showed a significant elevation of active force amplitude with the increase 
from 10 x 106 to 15 x 106 HSkM/mL; however results presented by Mudera et al. 
indicate the existence of an optimal range of densities at which force production is 
greatest. Above this range, the force production may be impaired due to 
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overcrowding of cells, leading to cell death [165, 166], diffusion limitations of 
nutrients and oxygen [167, 168], and inability to adequately form muscle fibers.  
In 2D culture, joint inhibition of miR-133a and miR-696 significantly 
increased PPARGC1A gene expression, which encodes metabolism co-activator 
PGC-1α [169], whereas inhibition of either miR-133a or miR-696 did not affect 
PPARGC1A levels. It is important to remember, however, that the mechanism of 
microRNA involves silencing of specific mRNA seed sequences for protein 
translation. Since the transcription of these genes are not affected, the levels of 
mRNAs may likely remain unchanged [170], similar results of unchanged 
PPARGC1A expression were shown by Aoi et al. for miR-696 overexpression and 
inhibition [101]. This may be the reason for the unchanged gene expression in 
individual miR-133a and miR-696 inhibition. MicroRNAs control the translation of 
thousands of target mRNAs, and each mRNA is targeted by multiple microRNAs 
[170]. Inhibition of miR-133a and miR-696 both upregulate Mef-2: miR-133a 
inhibition affects Mef-2-dependent myogenesis and miR-696 inhibition affects Mef-2-
mediated PGC-1α activation and promotion of oxidative metabolism. Simultaneous 
inhibition of these two microRNAs may overexpress Mef-2 to an extent that negative 
feedback loops (necessary for maintaining homeostasis) may be used to retain 
normal cell function. In this case, negative feedback of Mef-2 influenced by miR-133a 
and miR-696 inhibition may lead to a decrease in Mef-2, slowing myogenesis and 
development of oxidative metabolism. This, in turn, would negatively affect PGC-
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1α, a potent metabolism co-activator that is under careful control by many different 
pathways, leading to increased transcription of PPARGC1A to increase PGC-1α 
expression.  
Measurement of PGC-1α protein found an increase in presence for all cases, 
compared to negative control after 14 days of differentiation in 2D culture. Our 
findings for miR-696 inhibition complement those of Aoi et al., who reported an 
increase in PGC-1α protein expression 24 hours after miR-696 transfected with miR-
696 inhibitor after 24 hours, compared to negative control [101]. We also saw an 
increase in PGC-1α protein for miR-133a inhibition due to the activation of the PGC-
1α promoter by Mef-2. Our PGC-1α protein findings show that this elevation is 
retained for a much longer time period than the initial 24 hours and, therefore, may 
have a major impact on skeletal myofiber development. Additionally, joint inhibition 
led to significantly higher levels of sarcomeric α-actinin protein compared to 
negative control levels after 14 days in 2D culture. An increase in sarcomeric α-
actinin expression indicates increased levels of organization and muscle maturity 
within engineered tissues.  
Placing cells into a 3D environment containing a native, tissue-like 
extracellular matrix allows for the testing of more detailed responses and key factors 
controlling behavior in response to various biological stimuli, including oxygen 
depletion [171], microRNA inhibition, and drug toxicity testing. The ultrastructure of 
skeletal muscle cultured in 2D and 3D geometries may differ quite drastically: the 
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generation of tension in 3D allows for the orientation and alignment of myofibers 
while 2D cultures usually lack necessary stimuli to elicit this level of organization. 
Interactions between skeletal myoblasts and their surrounding extracellular matrix 
proteins are also essential to the development of mature skeletal muscle [172]. 
Specifically, Thorsteinsdóttir et al. reported the importance of the “extracellular 
matrix dimension” as a contributing factor to skeletal myogenesis.  Therefore, the 
maturation of engineered skeletal muscle in a 2D conformation may not be at same 
degree of engineered tissue cultured in a 3D ECM-rich geometry.  
Isometric force testing of transfected bundles after 2 weeks of differentiation 
showed at least 65% higher twitch and tetanic forces by joint inhibition engineered 
muscle bundles compared to all other tested conditions. This phenomenon may be 
explained by the muscle fiber type distribution within each microRNA treatment 
condition. Our results of miR-133a inhibition matched those reported by Liu et al in 
an in vivo mouse model: miR-133a inhibition led to an increase in Type I fibers [173]. 
Additionally, our results for miR-696 inhibition were expected, as an increase in 
PGC-1α has been shown to increase Type I fiber as well [69, 142]. However, we 
hypothesized that the joint inhibition of miR-133a and miR-696 would lead to 
increased proportion of Type I fibers within the engineered 3D human tissue, but we 
found that Type II fibers were actually more prominent by immunofluorescence and 
qPCR for slow and fast myosin heavy chain. Herein may lay the reason that joint 
inhibition 3D muscle constructs exhibited far higher twitch and tetanus forces 
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compared to negative control and inhibition of each microRNA individually:  a 
highly aligned, dense, and striated type II myofiber-rich muscle tissue is capable of 
higher and faster active contractile forces compared to type I myofiber-rich tissue of 
the same maturation due to the nature of glycolytic metabolism. 
The mechanism for fiber type switch to favor Type II in joint inhibition cases, 
compared to each anti-miR individually, remains to be elucidated. However, the role 
of the transcription factor Mef-2 may play an important factor, as mentioned above. 
The Mef-2 transcriptional activator is stimulated by calcineurin and other calcium-
regulated signaling molecules [174]. Mef-2 binding sites have been found to be 
necessary for fiber type-specific activities of myoglobin and troponin I slow 
promoters – specifically, Mef-2 binding is required for the function of slow fiber-
specific enhancers [174]. Furthermore, inactivation of Mef-2 has been reported to 
lead to loss of slow fiber formation [97]. Myostatin, a secreted growth factor of 
skeletal muscle, has also been reported to affect fiber type development. Hennebry et 
al. reported that lack of myostatin resulted in an increase in fast twitch fiber 
formation and that this growth factor positively regulates Mef-2C levels in skeletal 
muscle [175]. They showed that skeletal muscle containing a deficiency in myostatin 
also contained low levels of Mef-2. Rachagani et al. reported altered expression of 
miR-1, miR-133, and miR-206 in myostatin knockout mice, implicating that there 
may be an interaction between miR-133 and myostatin as well [176]. However, the 
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mechanism of interaction remains to be elucidated between myostatin, microRNAs, 
and fiber type [177].     
Anti-miR-133a and anti-miR-696 individually both lead to enhanced 
differentiation and development of oxidative metabolism and Type I myofibers, by 
repression of serum response factor (SRF) and upregulation of Mef-
2/myogenin/MyoD transcription factors, respectively (Fig. 32). Similarly, Horie et al. 
found that miR-133 overexpression in cardiomyocytes led to a downregulation ot 
Mef-2C expression [178]. Haberland et al. have found that Mef-2 activity is closely 
regulated by HDAC9, a member of the class II histone deacetylase family of enzymes 
[179]. As Mef-2 expression increases, HDAC9 activity increases as well, serving as a 
negative feedback loop to control overexpression of Mef-2 in skeletal muscle. 
HDAC9 associates with the MADS (MCM1, Agamous, Deficiens, serum response 
factor) domain of Mef-2 and prevents activation of Mef-2 target genes. HDAC9 was 
found to be directly controlled by Mef-2 both in vitro and in vivo. [179, 180] Figure 32 
shows that the joint inhibition of miR-133a and miR-696 leads to upregulation of 
Mef-2 to a higher extent than cases of each anti-miR alone, which may trigger the 
negative feedback of HDAC9. Measurement of Mef-2C levels in engineered human 
skeletal muscle bundles found that joint inhibition conditions resulted in depressed 
gene levels at 2 weeks post-differentiation, evidence that downregulation of Mef-2 
by HDAC9 may indeed cause the switch in fiber type to predominantly Type II 
myofibers.  
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Therefore, it is clear that while microRNAs may have huge potential as 
therapy for enhancing growth and differentiation of engineered human skeletal 
muscle, there is still much to be learned about their interactions and targets. The 
research presented here shows the importance of understanding these interactions in 
order to effectively and specifically modulate various biological processes. 
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CHAPTER 4. Endothelialization of Human Skeletal Muscle Bundles 
(Specific Aim 4) 
4.1. Introduction 
Over 40% of the human body is comprised of skeletal muscle, therefore, it is 
necessary to study the effects of any drug introduced into the body, regardless of the 
targeted tissue. Developing a direct co-culture model of the human skeletal muscle-
endothelial cell interface is important for studying the effects of other cell types on 
the differentiation of skeletal muscle in the body. As no tissue exists in a vacuum 
biologically, it is important to understand the interactions between cell types and 
model a more native-like environment for subsequent study of human skeletal 
muscle tissue.  
In this chapter, we explored the interactions between human cord blood-
derived endothelial cells (ECs) and human skeletal muscle in vitro. A co-culture 
model using these two cell types would provide insight into the effects of endothelial 
cells on the organization and functionality of skeletal muscle  - an important 
interaction to study as capillaries (lined with ECs) run throughout muscle tissue in 
vivo. Three dimensional co-culture systems have been approached using many 
different cells types and have utilized a variety of cell seeding techniques, including 
mixed and lamellar conformations [181]. Ye et al. described a co-culture system of 
human skeletal myoblasts and human endothelial cells separated by a permeable 
membrane used to test the transport of drugs across endothelium and to the 
differentiated skeletal muscle [182]. They found that perfusion with doxorubicin led 
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to transport across the endothelium and resulted in cytotoxic effects on 
differentiated human skeletal muscles, indicating suitability of the co-culture model 
for testing trans-membrane transport [182]. In developing a replicable EC and HSkM 
3D co-culture system, we decided to pursue a direct lamellar co-culture to allow for 
skeletal muscle fusion to myofibers, important cell-cell junctions to form between 
ECs, and direct contact between the two cell types to facilitate interactions. 
Physiologically, a lamellar co-culture could model the skeletal muscle-capillary 
interface at a micro-scale.  
An important consideration when developing a successful co-culture system 
is an appropriate culture medium capable of supporting both cell types.  Developing 
conditions to co-culture ECs and HSkM in vitro is particularly difficult, however, due 
to the nutrients required to develop mature, confluent cell coverage for both cell 
types. Countless studies have reported successful co-culture of two or more different 
cell type in vitro, including ECs and smooth muscle cells (SMCs) [183], ECs and 
hepatocytes [184], skeletal muscle and adipocytes [185], and skeletal muscle and 
motoneurons [44]. Studies of co-culture systems using skeletal muscle and 
endothelial cells have been reported as well, but none using only primary isolated 
human cell types. Levenberg et al. developed a 3D co-culture system consisting of 
mouse myoblasts and human embryonic stem cell-derived endothelial cells or 
human umbilical vein endothelial cells (HUVECs) seeded into biodegradable porous 
polymer scaffolds [186]. They found that skeletal muscle differentiation and 
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endothelial lumens developed better in DMEM containing 10% FBS, 10% calf serum 
(CS), and HEPES compared to endothelial cell media (EBM-2 with 2% FBS and 
endothelial growth factor supplements). [186] As mentioned previously, the 
formation of cell-cell junctions are important for EC cell culture. Studies seeding 
porcine ECs onto a layer of porcine SMCs have noted the importance of seeding at 
confluent densities – the resulting co-culture of ECs on SMCs expressed PECAM, a 
marker of EC-EC cell junctions, by immunofluorescence. [183, 187, 188] 
We hypothesized that identification of appropriate media conditions would 
allow for a 3D human skeletal muscle bundle – EC co-culture capable of producing 
functional force output similar in magnitude to monoculture tissue-engineered 
human skeletal muscle constructs. 
4.2. Materials and Methods 
4.2.1. Endothelial Progenitor Cell Isolation and Culture 
Human cord blood-endothelial cells (ECs) were isolated from blood as 
described previously by Ingram et al. [189]. Umbilical cord blood was obtained from 
the Carolina Cord Blood Bank for isolation of ECs. The Institutional Review Board of 
Duke University approved the protocol for the collection and use of human blood 
used in this study. 
Blood was diluted 1:1 with HBSS (Invitrogen), placed into Histopaque 1077 
(Sigma), and centrifuged for 30 minutes. Mononuclear cells contained in the buffy 
coat were collected and washed 3 times with 10% complete EBM-2 EC media (10% 
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FBS, endothelial basal medium EBM-2, supplemented with EGM-2 SingleQuots, 1% 
antibiotic/antimycotic solution). Cells were then plated onto 35-mm diameter dishes 
coated with rat tail collagen type I (BD Biosciences) in 10% complete EBM-2 media. 
Media was exchanged every 24 hours for 1 week to remove nonadherent cells. 
Colonies of cells were trypsinized, and 200 cells were plated into a collagen-coated 
T25 flask as passage 1 (P1). 
ECs were cultured using 10% complete EBM-2 media to confluency, then 
split 1:10 using 0.025% trypsin (Lonza) for each passage. Cells were used between 
P6-P8 for co-culture studies. 
4.2.2. Human Skeletal Muscle and Endothelial Progenitor Cell Co-Culture in 
2D 
HSkMs were seeded into 6-well plates at a density of 16,000 cells/cm2 in GM. 
Once HSkM reached 80% confluency, media was shifted to DM and kept in DM for 
4-5 days before being seeded with ECs. ECs were seeded at 125,000 cells/cm2 based 
on previous 2D co-culture optimization studies (performed by Lydia Ran). Co-
culture media was added upon seeding of ECs onto skeletal muscle; media tested 
included: 1:3 DM:EBM-2 and 3.3% FBS in DMEM based on previous monoculture 
and indirect co-culture studies performed by Lydia Ran. 3.3% FBS in DMEM was 
chosen for its reported use for culture of tissue-engineered blood vessels (TEBV) 
[190].  DM was used as control for 2D co-culture studies.  
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4.2.3. Human Skeletal Muscle and Endothelial Progenitor Cell Co-Culture in 
3D 
Human skeletal muscle bundles were constructed and cultured as previously 
described. For control HSkM-only bundles, DM (2% equine serum in DMEM) was 
used for the entire 2-week post-differentiation culture period. For co-culture 
bundles, DM was aspirated after 10-12 days post-differentiation and 45 μL of an EC 
cell solution at a density of 1x106 cells/mL was pipetted on top of the muscle bundle. 
The compaction of the bundle away from the PDMS mold allowed room for the EC 
cell solution. The ECs were allowed to attach to the surface of the muscle bundle for 
1 hour at 37C, after which co-culture media was added back on top of the construct. 
Muscle bundles were co-cultured with ECs for 48 or 96 hours, up to day 14 post-
differentiation.  
The co-culture media conditions tested included 1:3 DM:EBM-2 with 2% 
equine serum and 3.3% FBS in DMEM. 1:3 DM:EBM-2 with 2% equine serum was 
chosen based on 2D co-culture. All muscle bundles were tested for functional force 
output and immunofluorescence for skeletal muscle morphology and EC coverage. 
4.2.4. Isometric Force Testing 
Force testing was conducted as previously described in Section 3.2.9. Briefly, 
at Day 14 post-differentiation, bundles were removed from PDMS molds and pinned 
into a custom chamber and immersed in 37oC DM. Bundles were pinned to a fixed 
tissue anchor at one end and a PDMS holder suspended by the force transducer 
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(custom-made by Dr. Robert Dennis, University of North Carolina, Chapel Hill, NC, 
USA) at the other end. Positioning of the force transducer was controlled by a 
motorized linear actuator (Thorlabs). A pair of parallel platinum foil electrodes 
applied the electrical stimuli to suspended bundles to elicit isometric muscle 
contractions. 
Using the motorized linear actuator, the initial length of the engineered 
muscle bundle was set to the length of culture (8 mm). Twitch measurements at 1 Hz 
and 100V were repeated for 5% increments up to 120% of initial construct length. 
The maximum twitch force was recorded and this percent length used for further 
isometric force testing at 5, 10, 20, and 40Hz. Force traces were recorded into 
LabVIEW and exported to Microsoft Excel files.  
For analysis, Microsoft Excel files were loaded into a custom MATLAB 
program and peak forces found for each frequency and length condition. Photos 
taken at 100% length prior to force testing were assessed in ImageJ for muscle bundle 
cross-sectional area; specific forces were calculated by dividing force output (mN) by 
cross-sectional area (mm2).  
4.2.5 Immunofluorescence 
Co-culture 3D muscle bundles were fixed using ice-cold methanol for 5 
minutes. Constructs were then rinsed 3 times with DPBS without Ca and Mg. Next, 
bundles were blocked in 10% goat serum in DPBS overnight with gentle tilting at 
room temperature. The next day, the primary antibodies were added and allowed to 
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bind overnight with gentle tilting at room temperature. Antibodies used included: 
mouse anti-CD31 (PECAM-1, 1:300 dilution, Life Technologies) and rabbit anti-alpha 
sarcomeric actin antibody (1:300 dilution, Thermo Scientific). The primary antibody 
was rinsed 3 times with DPBS for 5 minutes each with gentle tilting at room 
temperature. Next, the secondary antibodies were added: Alexa Fluor 488 goat anti-
mouse (1:250, Invitrogen) and Alexa Fluor 546 goat anti-rabbit (1:250, Invitrogen). 
Nuclei were stained with Hoescht 33342 (1:1000, Invitrogen). Secondary antibodies 
were diluted in DPBS and added to the cultures for 45 minutes, protected from light 
with gently tilting at room temperature. Finally, the secondary antibody solution 
was rinsed 3 times with DPBS for 5 minutes each with gently tilting at room 
temperature and images via Zeiss 510 inverted confocal microscope. 
4.2.6. Statistical Analysis 
Data are presented as mean ± standard error (SEM) unless otherwise noted. 
ANOVA and Fisher’s PLSD post-hoc tests were performed using STATVIEW 5.0 
statistical analysis package. HSkM and ECs isolated from separate individuals were 
considered distinct n values. A value of p<0.05 was considered significant. 
4.3. Results 
4.3.1. Endothelial Cell Coverage of Fused Skeletal Muscle in 2D Studies 
Initial studies were conducted in a 2D conformation onto 6-well plates to 
quickly and more efficiently assess proper culture conditions, as these studies 
  
125 
required fewer cells. Immunofluorescence for PECAM and sarcomeric α-actinin 
showed formation of an EC layer on top of fused muscle. (Figure 33) 
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Of the conditions tested, 1:3 DM:EBM-2 appeared to have the best EC 
coverage on fused skeletal muscle, although these findings were not significant 
(Figure 34). All conditions tested showed equal fused skeletal muscle coverage.  
 
 
 
Figure 34: Percent Coverage of EC and HSkM. (A) Quantification of area covered by PECAM-stained 
ECs showed >60% coverage for all cases. 3.3% FBS in DMEM appeared to have least PECAM-coverage. 
(B) Quantification of area covered by sarcomeric α-actinin-stained skeletal muscle fibers showed equal 
coverage by all conditions. All error bars denote SEM (n=2). 
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 4.3.2. Identification of Co-culture Media for Retention of HSkM Bundle 
Functionality  
Based on the results in 2D, the culture conditions tested in 3D models were: 
DM (control), 1:3 DM:EBM-2 (due to high EB coverage and equivalent skeletal 
muscle coverage to control in DM), and 3.3% FBS in high-glucose DMEM (since this 
media has been used in literature to successfully culture tissue-engineered blood 
vessels [190]). High-glucose DMEM contains 25mM glucose, as noted by the 
manufacturer. Additionally, DMEM is the base media used for skeletal muscle 
culture; therefore, it may be instrumental in retention of muscle functionality in vitro. 
Two potential co-culture media were first tested on HSkM-only bundles to observe 
any effects on functional force output as well as protein expression and formation of 
myofibers. DM was used as control and 1:3 DM:EBM-2 and 3.3% FBS in DMEM were 
tested for use as co-culture media. After 1 week of differentiation in DM and 1 
additional week of culture in one of the three tested media conditions, force testing 
showed over 70% decrease in twitch force (*p<0.05, n=3) and over 60% decrease in 
tetanic forces (*p<0.05, n=3) from muscle bundles cultured in 1:3 DM:EBM-2 media 
compared to DM and 3.3% FBS in DMEM conditions (Fig. 35). 3.3% FBS in DMEM 
did not change twitch or tetanic force compared to DM. Bundles in 3.3% FBS in 
DMEM also exhibited over 3.5-times higher twitch (*p<0.05, n=3) and almost 3-times 
higher tetanus forces (^p<0.01, n=3) compared to 1:3 DM:EBM-2 media.  
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Figure 35: Testing co-culture media in muscle-only engineered constructs. Muscle bundles 
were tested in potential co-culture media to assess retention of functionality. 2% equine serum 
in DM was used as control. Bundles cultured for 1 week in 1:3 DM:EBM2 media saw 
significantly decreased twitch and tetanus forces compared to control forces. However, 
bundles tested in 3.3% FBS in DMEM exhibited comparable forces to the control condition. 
(*p<0.05, ^p<0.01, n=3 for all) 
  
Sarcomeric α-actin immunofluorescence of HSkM-only bundles in DM, 1:3 
DM:EBM-2, and 3.3% FBS in DMEM showed elongated myofibers and the clear 
presence of striations in all conditions (Fig 36). Bundles cultured in DM (Fig. 36A) 
and 3.3% FBS in DMEM (Fig. 36C) expressed most intense staining of sarcomeric α-
actinin compared to 1:3 DM:EBM-2 (exposure time held constant).  
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Figure 36: Ultrastructure of muscle-only bundles in tested co-culture media. Engineered 
human skeletal muscle was cultured in (A) control DM media, (B) 1:3 DM:EBM-2 media, and 
(3) 3.3% FBS in DMEM. Myofibers were stained for sarcomeric α-actinin (green) and DAPI 
(blue). Bundles cultured in DM and 3.3% FBS in DMEM exhibited the more intense sarcomeric 
α-actinin staining compared to those cultured in 1:3 DM:EBM-2 media. All condition exhibited 
alignment and development of striations. 
4.3.3. Co-culture Bundle Functionality is Retained in 3.3% FBS in DMEM 
From initial studies with 1:3 DM:EBM-2 and 3.3% FBS in DMEM media, it 
was clear that the latter was beneficial to the formation of mature, functional 
myofibers. Therefore, twitch and tetanus forces were measured for control (no ECs) 
muscle bundles and co-culture muscle bundles in 3.3% FBS in DMEM. (Fig. 37) 
Results showed an over 4-times increase in twitch force of co-culture bundles with 
ECs for 48 hours compared to control in DM (p<0.01, n=3) and over 2.5-times 
compared to control in 3.3% FBS in DMEM (p<0.05, n=3).  Tetanus force amplitudes 
rose significantly over these conditions as well: 48 hour co-culture saw over 3-times 
tetanus forces compared to control in DM (p<0.005, n=3) and over 2.5-times 
compared to control in 3.3% FBS in DMEM (p<0.01, n=3). Twitch and tetanus force 
amplitudes fell in 96 hour co-culture bundles compared to 48 hour bundles; 
however, this result was not significant.  
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Figure 37: Twitch and tetanus force amplitude for co-culture bundles. The addition of ECs 
for 48 hours led to an increase in twitch and tetanus specific force amplitudes compared to all 
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control conditions. Co-culture of cells for 48 hours led to higher forces than longer cultures of 
96 hours. (*p<0.05, ^p<0.01, #p<0.005, †p<0.001, n=3 for all) 
To see whether a discrepancy in muscle fiber density within the engineered 
constructs was the cause of increased forces, fibers stained positively for sarcomeric 
α-actinin were quantified per area in each field of view taken from confocal 
microscopy. We found that the fiber density within control in DM was 97.4 ± 3.4 
fibers/mm2, and the densities for 48 and 96 hour co-culture were 71.7 ± 16.4 and 75.1 
± 13.6 fibers/mm2, respectively. These findings were not significantly different. Fibers 
were slightly thicker in co-culture bundles compared to control: 10.9 ± 0.7 μm for 
control bundles, 13.2 ± 1.2 μm for co-culture for 48 hours, and 13.8 ± 0.3 μm for co-
culture for 96 hours. Fiber diameters were thinner than previously reported values of 
~50 μm [1] likely due to the difference in geometry: HSkM were previously plated in 
a 2D conformation, with considerable cell spreading on the surface of the substrate 
whereas HSkM contained in a 3D fibrin gel do not spread since they are suspended 
within the construct.  
4.3.4. Endothelial Cell Coverage of Muscle Bundle in 3.3% FBS in DMEM 
Confocal microscopy for PECAM (an indicator of the formation of important 
cell-cell junctions essential to EC health and functionality) was used to visualize the 
spreading and coverage of ECs on the surface of the construct. Co-culture of ECs 
with HSkM in 3.3% FBS in DMEM for 48 hours yielded 21.8 ± 10.4% PECAM-stained 
area, compared to 9.8 ± 2.6% in 96 hour co-culture bundles (n=2). Co-culture with 
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ECs for 48 hours led to over 30% more coverage of engineered muscle with ECs 
compared to co-culture for 96 hours. (Fig. 38) 
For both 48 and 96 hour cases, though, there did not appear to be infiltration 
of ECs into the muscle bundle. Orthogonal views of confocal Z-stacks show PECAM 
on the bundle surface (green), but not within the interior of the construct (red). This 
is important for retention of construct functionality, as EC networks throughout the 
muscle may interrupt fiber formation and decrease the magnitude of bundle 
contraction (Fig. 39). This could be due to the difficulty of forming cell-cell junctions 
within the inside of the fused muscle bundle due to space constraints and oxygen 
and nutrient diffusion limitations. 
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Figure 38: Endothelial cell coverage on engineered muscle bundles. Control and co-culture bundles 
seeded for 48 and 96 hours with ECs were stained with sarcomeric α-actinin, PECAM, and DAPI. (A) 
Control bundles showed highly aligned and striated muscle fibers. (B) Co-culture bundles cultured for 
96 hours in 1:3 DM:EBM2 media showed high EC coverage and PECAM staining. (C-D) Co-culture 
bundles showed PECAM staining on the surface of muscle bundles, but not over 50% coverage. There 
appeared to be more PECAM staining (spread ECs) on the surface of co-culture bundles for 48 hours 
compared to those for 96 hours.  
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Figure 39: Orthogonal views of co-culture bundles. Z-stacks of co-culture bundles were taken and 
orthogonal views reconstructed to visualize localization of PECAM and sarcomeric α-actinin staining. 
Co-culture bundles for (A) 48 hours and (B) 96 hours were visualized. In both cases, PECAM staining 
was localized to the surface of the bundle, with muscle fibers underneath.  
A. 
B. 
PECAM SAA DAPI 
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4.4. Discussion 
In this study, we identified conditions for the co-culture of functional human 
skeletal muscle with human cord blood-derived endothelial cells in a 3D engineered 
model. Two co-culture media conditions were tested, 1:3 DM:EBM-2 and 3.3% FBS in 
DMEM, and compared to skeletal muscle DM to assess retention of engineered 
muscle functionality and EC spreading and coverage on muscle. 3.3% FBS in DMEM 
resulted in retention of active contractile force magnitude in muscle-only engineered 
constructs, and increased force magnitude at least 2-times after addition of ECs to 
the muscle for 48 or 96 hours. Co-culture engineered human muscle with ECs 
exhibited the greatest twitch and tetanus forces and EC coverage when cultured in 
3.3% FBS for 48 hours – an over 6.5-fold increase in twitch force and over 3.5-fold 
increase in tetanic force compared to control muscle bundles in DM. These studies 
serve as proof of principle for developing a human only skeletal muscle and 
endothelial cell 3D co-culture model.  
Many factors influence the choice of media used for co-culture, including 
metabolic differences between cells types and growth factors necessary for proper 
cell growth and maintenance of proper cell and tissue function [191, 192]. Many 
growth factors have been implicated in the culture of healthy skeletal muscle from 
myoblasts, including vitronectin, basic fibroblast growth factor (bFGF), 
cardiotrophin-1 (CT1), glial cell line-derived neurotrophic factor (GDNF), brain-
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derived neurotrophic factor (BDNF), and neurotrophin 3 and 4 (NT3, NT4) [193]. 
Growth factors important for endothelial cell growth include human epidermal 
growth factor (hEGF), hydrocortisone, vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), insulin-like growth factor-1 (IGF-1), and heparin [194, 
195]. After the identification of proper growth factors, it is then imperative to test 
culture health and growth in potential co-culture media as certain morphologies or 
functions may be desired. In this study, the identification of a proper co-culture 
media for human skeletal muscle and human CB-ECs necessitated recapitulating a 
lamellar morphology between cell types and the retention of skeletal muscle 
functionality, as demonstrated by active contractile forces. Additionally, the hCB-
ECs layered on top of human skeletal muscle must be spread and express the 
important junctional marker PECAM.  
Van der Schaft et al. described a co-culture system of vascularized 3D muscle 
constructs composed of murine embryonic heart-derived endothelial cells and 
C2C12 murine myoblasts. [196] They achieved aligned, vascularized murine skeletal 
muscle constructs cultured in muscle differentiation media: high-glucose DMEM 
supplemented with L-glutamine, 20 mM HEPES buffer, 0.4% Ultroser G (a serum 
replacement), 0.1 mM nonessential amino acids, penicillin, and streptomycin. 
Vascularized muscle constructs were assessed for myofiber and endothelial cell 
directionality, construct stiffness, and role of VEGF in vascular orientation within 
engineered muscle. [196] However, there was no verification of retention of muscle 
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construct contractile force, a key factor for engineering of muscle tissue. In this 
study, we found that identifying proper culture media is extremely important to 
retaining or enhancing the functionality of tissue-engineered skeletal muscle.  
It was unexpected that the addition of ECs in a lamellar fashion to fused 
human skeletal muscle in vitro would increase the twitch and tetanus force 
amplitudes significantly. We hypothesized that introduction of ECs into the culture 
could lead to infiltration of ECs into the interior of the bundle and interrupt 
myofiber formation and hinder active force generation – this phenomenon has been 
observed in mixed skeletal muscle-EC co-cultures. However, this was not observed, 
as isometric forces increased significantly for 48 hour co-culture and PECAM 
staining was localized to the surface of the tissue engineered bundle for both co-
culture conditions. Tissue engineered skeletal muscle has been shown to differentiate 
more quickly in the presence of nitric oxide [4, 197-200]. Additionally, endothelial 
cell production of nitric oxide increases dramatically when cells are exposed to high 
glucose conditions [201]. Since the basal media for co-culture was high glucose-
DMEM (with 3.3% FBS), it is plausible that the glucose contained within the media 
led to increased nitric oxide production from ECs, resulting in accelerated muscle 
maturity. Additionally, metabolic byproducts of active muscle have been shown to 
dilate surrounding blood vessels, resulting in increased endothelial nitric oxide 
production [202]. Retention of ECs on the surface of the muscle may be important to 
the levels of nitric oxide produced, as the isometric forces dropped after 96 hours of 
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co-culture, which had over 30% less retention of ECs as compared to 48 hour co-
culture.  
The co-culture results presented here provide proof of principle that a 
functional 3D model of the human skeletal muscle-capillary interface can be 
developed in vitro. Further studies are needed to understand the increase in 
functional force output with the addition of ECs to culture. This may be due to 
endothelial cells in co-culture with HSkM producing higher amounts of nitric oxide, 
leading to an increase in differentiation. Zhang et al. showed that addition of nitric 
oxide donor L-arginine onto stretched C2C12 myoblasts  resulted in an increase in 
accumulation of focal contact proteins talin and vinculin , leading to an increase in 
apparent elastic modulus of muscle cells and increased muscle differentiation [4]. 
Studies to measure the nitric oxide production of muscle-only bundles and co-
culture bundles would help elucidate whether there is a difference in nitric oxide 
levels between conditions. Additionally, nitric oxide donor and inhibitor studies 
could be performed to test the functionality of engineered skeletal muscle (without 
added ECs) in response to nitric oxide levels. Following the studies of Zhang et al., L-
arginine could be used as the nitric oxide donor and Nω-nitro-L-arginine methyl ester 
(L-NAME) could be used as the inhibitor [4].  
Such models that replicate key elements of in vivo physiology are necessary 
for development of human drugs [203, 204]. Due to the large percentage of human 
body mass given to skeletal muscle, this tissue is both a potential target for drug 
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delivery and a site of drug toxicity [135]. Being able to model the transport and 
delivery of drugs across human endothelium to functional engineered human 
skeletal muscle will be extremely useful in helping streamline the therapeutic 
development process.  
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CHAPTER 5. Dissertation Summary & Future Work 
5.1. Dissertation Summary 
Overall, the results within this dissertation provide the novel results that (1) 
engineered human skeletal muscle can generate active contraction when cultured in 
static conditions at 10 x 106 cells/mL or more, (2) inhibition of miR-133a and miR-696 
simultaneously significantly accelerate human myogenesis in vitro and increase 
development of Type II fast myofibers, and (3) direct lamellar co-culture of ECs on 
engineered muscle bundles are feasible and can be maintained in culture for at least 
4 days. These results suggest that there may be a connection between the pathways 
for miR-133a and miR-696, as inhibition of miR-696 typically increases metabolism 
co-activator PGC-1α expression and leads to preferential development of Type I 
slow myofibers. These results also demonstrate the importance of microRNAs in the 
process of human muscle myogenesis and the potential they hold for 
musculoskeletal therapies. 
The global hypothesis that motivated this research was that joint inhibition of 
miR-133a and miR-696 would accelerate and direct human skeletal muscle 
myogenesis in vitro. The proposed research tested the following hypotheses: (1) 
HSkM require different culture conditions than those optimal for C2C12 culture, (2) 
joint inhibition of miR-133a and miR-696 would result in 2D human skeletal muscle 
cultures with accelerated differentiation and increased Type I muscle fibers 
compared to control and individual inhibition of each microRNA, (3) joint inhibition 
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would result in functional 3D human skeletal muscle capable of active contractions 
significantly higher than control and individual inhibition by each microRNA, and 
(4) HSkM and EC lamellar co-culture can exert active contraction when maintained 
in the proper co-culture media. 
Chapter 2 showed that culture conditions optimized for C2C12 murine 
myoblast culture are not optimal for efficient HSkM culture due to low microRNA 
levels and few striated fibers. To promote human skeletal muscle differentiation it 
was necessary to coat substrates with 100 μg/mL growth factor reduced Matrigel and 
reduce the serum content from 8% to 2%. This change in culture conditions elevated 
levels of myogenic microRNAs and Mef-2C and increased the presence of striations 
increased after 14 days of differentiation compared to C2C12 culture conditions. 
Further evidence that serum content in differentiation medium is highly influential 
of HSkM gene expression was found in the opposing responses of microRNA levels 
to cyclic stretch at ±10% and 0.5 Hz for 1 hour alternating with 5 hours of rest for 2 
weeks. However, when microRNA expression was compared between HSkM 
culture conditions and human explant tissue, there still existed a large gap between 
in vivo and in vitro tissue. Native tissue is dynamic as it is exposed to many biological 
stimuli that aide in the differentiation process. Cultured tissue, in contrast, tends to 
exist in a static state as the stimuli are minimal and unchanging.  As well, the 3D 
microenvironment provides the necessary interactions with ECM and cells to 
achieve a much more differentiated state than that which is achieved in vitro. 
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However, there exist other methods of promoting differentiation of cultured HSkM 
in vitro. We focused on microRNA inhibition to accelerate differentiation in vitro due 
to their endogenous presence and demonstrated potent effects on skeletal muscle 
myogenesis. As we had observed with C2C12 cells, inhibition of miR-133a in HSkM 
accelerated HSkM differentiation in 2-week cultures, as shown by increased 
sarcomeric α-actinin protein expression and accelerated striation development by 
immunofluorescence. Thus, the results in Chapter 2 confirm the hypothesis that 
HSkM require culture conditions different from C2C12 for efficient differentiation in 
vitro. Inhibition of miR-133a served as proof of principle for the studies presented in 
Chapter 3. 
Results from Chapter 3 showed that joint inhibition of miR-133a and miR-696 
in HSkM accelerated and directed myogenesis. In 2D, joint inhibition led to 
significantly increased PPARGC1A gene expression and the corresponding 
increased expression of PGC-1α compared to negative control, while individual 
inhibition of microRNAs did not. Joint inhibition also led to increased expression of 
sarcomeric α-actinin. These 2D studies served as proof of principle for studies of 
joint inhibition in a 3D functional human skeletal muscle model. This work is the 
first to show that when seeded at 15 x 106 HSkM/mL into a 45 μL fibrin hydrogel and 
allowed to differentiate for two weeks, engineered muscle exhibited spontaneous 
contractions as well as active contraction in response to electrical stimuli. Muscle 
seeded with HSkM transfected with miR-133a and miR-696 inhibitors exerted twitch 
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and tetanus forces higher than all other conditions studied. Anti-miR-133a 
engineered muscle gave tetanus forces higher than negative control and anti-miR-
696 bundles. Thus, the increase in force magnitude seen for joint inhibition samples 
may be due to the distribution of muscle fiber type. PCR and immunofluorescence 
for slow myosin heavy chain showed low gene expression and low staining 
intensity, respectively, in joint inhibition constructs. However, immunofluorescence 
for fast myosin heavy chain showed an increase in presence for fast myosin heavy 
chain protein in joint inhibition conditions compared to all other conditions. 
Therefore, there may be a higher proportion of fast:slow myofibers in joint inhibition 
bundles, leading the force production to favor the higher magnitude forces 
characteristic of Type II myofibers. The results in Chapter 3 confirmed the 
hypothesis that joint inhibition of miR-133a and miR-696 inhibitors would accelerate 
differentiation in 2D and 3D conformation; however, joint inhibition led to increased 
Type II fiber presence in 3D rather than Type I – possibly as a result of Mef-2 
negative feedback loops. 
Results from Chapter 4 identified a 3.3% FBS in DMEM as common media to 
co-culture HSkM and ECs and retain active contraction of engineered skeletal 
muscle interface. Use of 3.3% FBS in DMEM has also been reported for co-culture of 
SMCs and ECs [183] as well as tissue-engineered blood vessels seeded with human 
aortic ECs or primary coronary artery disease ECs [188]. Isometric force testing of 
muscle-only constructs in control DM, 1:3 DM:EMB-2, and 3.3% FBS in DMEM 
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found that 1:3 DM:EBM-2 led to significant depression of forces and 3.3% FBS in 
DMEM saw retention of forces compared to control. 3.3% FBS in DMEM was then 
tested in co-culture bundles containing ECs seeded onto fused 3D skeletal muscle 
constructs for 2-4 days. Isometric force testing found co-culture for 48 hours led to 
over 2.5-times increase in twitch and tetanus force amplitudes compared to all 
control cases (DM, 1:3 DM:EBM-2, 3.3% FBS in DMEM). Force amplitudes of bundles 
co-cultured with ECs for 96 hours appeared elevated compared to controls as well; 
however, these findings were not significant. EC retention on the surface of the 
engineered muscle bundle was over 30% higher at 48 hours compared to 96 hours of 
co-culture. Therefore, there appears to be a strong correlation between presence of 
ECs and increasing twitch and tetanus force amplitudes, however, further work is 
needed to obtain higher EC coverage. This may be achieved by using low glucose 
DMEM rather than high glucose DMEM, since the latter has been implicated to 
activate EC inflammation [205]. Overall, the results from Chapter 4 confirm the 
hypothesis that HSkM and ECs can be co-cultured in appropriate media to retain 
functionality of the engineered skeletal muscle. In fact, we found a significant 
increase in force production for short co-culture times (48 hours). 
5.2. Strengths & Weaknesses of Work 
As with any research project, there exist strengths and weaknesses to the 
study, both in approach and application. Here, we discuss both with respect to the 
studies performed in each specific aim of this dissertation. 
  
146 
The culture conditions identified in Chapter 2 provide significant elevation to 
microRNAs and presence of striations without the introduction of drastic changes to 
the culture procedure, which is beneficial overall. The conditions studied were by no 
means exhaustive and further enhancement of differentiation could be obtained by 
addition of other microRNAs or further modification of culture conditions. For 
example, optimization of growth factors added to the media or modulation of 
microRNAs can regulate fiber type (such as miR-696).  
Perhaps the most important finding of Chapter 3, though, is the ability to 
tissue engineer human skeletal muscle in vitro capable of active contractile forces. 
This has not been previously demonstrated in the literature, so developing a human 
model of contractile skeletal muscle is a large step forward for the field of 
musculoskeletal tissue engineering. We demonstrated that seeding density plays an 
important factor in the generation and magnitude of forces produced; however, full 
optimization of HSkM seeding density into the fibrin hydrogels was not conducted. 
It is possible that even higher seeding densities could produce significantly higher 
forces as well. 
Other important aspects of the work shown in Chapter 3 are consistency of 
anti-miR studies using human myoblasts with previously published work, including 
PGC-1α protein presence after miR-696 inhibition in C2C12 cells by Aoi et al. [101] 
and muscle bundle forces after miR-133a inhibition in C2C12 cells by Rhim et al. [49], 
and the extension of these results further by introducing longer culture times of anti-
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miR-696-transfected HSkM before PGC-1α protein measurement as well as the 
addition of anti-miR-696 conditions to anti-miR-133a conditions for force 
measurement. Therefore, our studies built upon the published literature and found 
important information, including long-lasting effects of anti-miR-696 on PGC-1α 
protein presence and the effect of both microRNAs on human muscle force 
production.  
In Chapter 3, isometric force testing of joint inhibition muscle bundles found 
significantly elevated specific forces and increased fast myofiber phenotype, 
compared to all other conditions. This result was surprising due to previous findings 
that miR-696 inhibition leads to increased slow myofiber formation in C2C12 cells. 
The results suggest that inhibition of miR-133a and miR-696 simultaneously must 
have some shared regulation within their pathways affecting fiber type 
development. Since this was a tissue engineering study and not a detailed 
mechanistic study the Mef-2C gene expression data provide limited insight into the 
mechanism. Since samples were only taken at one timepoint, it is not known 
whether Mef-2C expression decreases (due to negative feedback) after an initial 
overexpression, or whether expression is depressed from the onset of differentiation. 
Measuring class II histone deacteylases (HDAC4, HDAC5, HDAC9) that negatively 
affect Mef-2C [206] would also help provide insight into the mechanism behind Mef-
2C expression and the resulting fiber type development. Mef-2C expression and 
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class II histone deacetylase information would all be instrumental in understanding 
the role of miR-133a and miR-696 inhibition on slow and fast fiber development. 
 Chapter 4 identified culture media capable of maintaining human skeletal 
muscle active function with the co-culture of human endothelial cells on the surface. 
Thus far, there have been no reports of skeletal muscle and endothelial cell co-
culture capable of active contraction. Additionally, there has not been development 
of a human-only co-culture system as well. Therefore, our protocol is quite novel. 
Strengths of this study include the ability to obtain PECAM-expressing endothelial 
cells on the surface of the fused human muscle and the generation of high specific 
forces. The identification of a common culture media is quite important to the 
ultimate identification of a common media capable of sustaining multiple cell types. 
While the results presented in Chapter 4 are exciting, further work is needed identify 
suitable co-culture media, optimal seeding conditions for a confluent layer of 
endothelial cells, and the reason for higher specific force amplitudes. Similar to the 
results in Chapter 2, our testing of possible co-culture media was not exhaustive, and 
thus, the media identified is not necessarily optimal. In fact, the media used may not 
be favorable since it contained high glucose (25 mM), which has been shown to 
activate the inflammatory response of endothelial cells, disrupt cell-cell connections, 
and enhance passive force contraction [207]. Additionally, while we did see PECAM-
staining, indicating endothelial cell junction formation, the layer of endothelial cells 
was not confluent on the surface of the fused human skeletal muscle. Further 
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evaluation of seeding conditions (duration, density, etc.) is necessary to find ways to 
increase cell retention and spreading. Finally, the reason behind the increase in 
specific force output is known, as we did not study the mechanism. However, this is 
important to understanding the interactions between skeletal muscle and endothelial 
cells and the effects on muscle functionality. 
5.3. Implications for Tissue Engineering 
 Overall, the results presented in this dissertation showed that that 
modulation of microRNAs can robustly affect engineered skeletal muscle 
differentiation and functional force output. Others have reported this as well [49, 92, 
113], but this is the first demonstration with muscle with the addition of multiple 
microRNAs. Results presented in Chapter 3 demonstrate that engineering of 
functional human skeletal muscle bundles cultured in static conditions is possible. 
The ability to engineer functional human skeletal muscle in vitro after static 
conditions is novel and has important functional implications to the study of skeletal 
muscle myogenesis and the treatment of musculoskeletal disease. Tissue-engineered 
human skeletal muscle has great potential to be used as implantable tissue to replace 
injured native tissue or as models to study diseases and treatments. Our results 
demonstrate the ability to accelerate differentiation and direct fiber type in vitro, and 
these techniques are great tools that can be used to grow mature human skeletal 
muscle for implantation purposes. Our demonstration of regulating fiber type in a 
static culture provides room for additional stimuli to provide environmental cues to 
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further encourage development of specific fiber phenotypes. Additionally, this 
method of primary myoblast isolation from human explant tissue lends itself well to 
establishing a method of engineering autologous muscle constructs that could be 
transplanted back into the individual to replace lost or injured tissues, especially in 
elderly patients whose regenerative potential is lessened by age. Those with diseased 
tissue, however, cannot provide healthy skeletal myoblasts for isolation, and instead 
must rely on therapies to help treat their musculature. In this scenario, our model 
could be used to model various disease states and test drugs and therapies prior to 
use in human subjects [208]. Furthermore, our work with delivering microRNA 
therapies to muscle have shown their effects and great potential to be used as 
therapies targeting various pathways, including differentiation, fiber type, and 
metabolism. Our findings that multiple microRNA transfection does not diminish 
the transfection efficiency allows for great flexibility when designing microRNA 
treatments to target several desired pathways. As more microRNAs are discovered 
that affect myogenesis, the more possibilities there are for genetically designing 
engineered muscle, including miR-208b and miR-499 for increased type I myosin 
heavy chain protein expression [209], miR-181 for enhanced muscle differentiation 
[210], and miR-24 for regulating myogenesis by TGF-β, myogenenin, and Mef-2 
[211]. 
The findings presented in Chapter 4 show the feasibility of human skeletal 
muscle with human cord blood-derived endothelial cells. The identification of co-
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culture media that can support both human skeletal muscle and human endothelial 
cells is the first step towards the engineering of vascularized human skeletal muscle 
in vitro. With the identification of EC seeding time and density to increase EC 
coverage, this method could be utilized to model the important skeletal muscle-
endothelial cell interface. Such a model is important to the study of drug delivery to 
skeletal muscle and the accumulation and toxicity of drugs within the muscle. As 
stated previously, skeletal muscle comprises over 40% of the human body, so the 
effects of all drugs must be considered – even if the skeletal muscle is not the 
targeted tissue [212]. Drugs must pass through the skeletal muscle, and inevitably, 
there will be accumulation within the muscle tissue. This could possibly lead to 
tissue toxicity and other unpredicted effects. A model of the skeletal muscle-
endothelial cell interface will allow for the study of drug diffusion across the 
endothelial cell layer into the skeletal muscle and the effects of drug accumulation 
on muscle organization and functionality. This model could prove very useful for 
preclinical testing of drugs. 
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APPENDIX A. Antibodies 
Antibody Manufacturer Species Catalog No. 
Sarcomeric α-actinin Sigma Mouse A7811 
Desmin Sigma Mouse D1033 
Collagen IV AbCam Rabbit ab6586 
PECAM/CD31 Life Technologies Mouse 370700 
Sarcomeric α-actin Thermo Scientific Rabbit PA5-21396 
Slow Myosin Heavy Chain AbCam Mouse ab11083 
Fast Myosin Heavy Chain AbCam Rabbit ab91506 
PGC-1α Calbiochem Mouse ST1203 
β-actin Santa Cruz Biotechnology Mouse sc-47778 
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APPENDIX B. Primer Sequences for Quantitative Real Time RT-PCR 
Gene of 
Interest 
Forward Reverse 
MHC I GCCGAGTCCCAGGTCAACAAG TGAGCAGATCAAGATGTGGCAAAG 
MHC IIA TTGCTGAGTCCCAGGTGAACA TTTGTGCCTGTCTTCAGTCATTCC 
MHC IIX CTGAGGGTGAAGAGCAGGGAGGT TTTTCACATTTTGTGCATTTCTTTGG 
GAPDH TCAACAGCAACTCCCACTCTTCCA ACCCTGTTGCTGTAGCCGTATTCA 
PPARGC
1A 
TGTGCAACTCTCTGGAACTG TGAGGACTTGCTGAGTGGTG 
MEF-2C ACTTCCTGGAGAAGCAGAAAGGCA AACACGTTTCCTTCTTCAGCACGC 
 
  
  
155 
APPENDIX C. MATLAB Code for Force Measurements 
%% HBAM FORCE TESTING DATA ANALYSIS %% 
%% Written by C.S.Cheng, August 2012 %% 
%% George A. Truskey Lab %% 
  
clear all 
p=input('Enter the percent length:  '); 
length=p*ones(1,5); 
hz=[1,5,10,20,40]; 
for k=1:5 
      
    % Import force data from excel 
    [filename, pathname, filterindex]=uigetfile('*.xls'); 
    filelocation=strcat(pathname,filename); %concatenate strings 
    [num, txt, raw]=xlsread(filelocation,'a15:a2014'); 
  
    % Calculate Offset and Adjust data 
    offset(k)=mean(num(25:30)); 
    data(k,1:2000)=num-offset(k); 
  
    % Find Peak Force Output (mN) 
    if hz(k)<4 
        Peak(k)=max(data(k,100:2000)); 
    elseif 4<hz(k)<9 
        Peak(k)=max(data(k,950:2000)); 
    else 
        Peak(k)=max(data(k,1500:2000)); 
    end 
end 
  
% Plot Force Output data (adjusted for offset) 
t=(1:2000); % msec 
figure(1) 
for m=1:5 
    subplot(2,3,m) 
    plot(t,data(m,1:2000)) 
    title(sprintf('%g. %d%%Length, %dHz, Peak Force = 
%gmN',m,length(m),hz(m),Peak(m))) 
    xlabel('msec') 
    ylabel('mN') 
end 
subplot(2,3,6) 
plot(hz,Peak,'o--') 
title('Peak Forces') 
ylabel('mN') 
xlabel('Frequency (Hz)') 
axis([0 max(hz) 0 max(Peak)+0.5]) 
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APPENDIX D. HSkM Culture Media Recipes 
Growth Media (GM): 
Component Vendor Product Number 
DMEM, low glucose Gibco 11885 
8% fetal bovine serum (FBS) Hyclone SH30071.03 
SkGM Singlequots (insulin removed) Lonza CC-4139 
 
Differentiation (Shift) Media (DM/SM): 
Component Vendor Product Number 
DMEM, high glucose Gibco 11995 
2% Equine (Horse) Serum (HS) Hyclone SH30074.03 
0.1% Gentamicin (1X) Gibco 15750-060 
 
Aliquots (all sterile, stored at -20oC, except Gentamicin, which is stored at room 
temperature) 
45-50ml FBS; 550μl Gentamicin; 10.2ml HS 
 
For GM: 
To a 500ml bottle of LG-DMEM, add 45-50ml FBS, and all components of SkGM 
Singlequots except insulin in sterile fashion. If sterility is compromised, sterile filter 
with 0.2μm bottle top filter. 
 
For SM: 
To a 500ml bottle of HG-DMEM, add 10.2ml HS and 550μl Gentamicin in sterile 
fashion (either by carefully pouring or by pipetting in). If sterility is compromised, 
sterile filter with 0.2μm bottle top filter. 
 
Protocol: 
1. Before thaw, warm up growth media. 
2. Thaw the cryovial containing the cell solution quickly at 37C with agitation 
3. Transfer the contents of the vial to a 15ml conical containing 9ml of warm 
growth media 
4. Pellet the cells for 5min at 1000rpm 
5. Aspirate the media and add fresh media to resuspend the cells 
6. Transfer cell solution evenly between uncoated tissue culture flasks. Label 
flasks with date, patient ID, passage number, and initials. 
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7. Cells should start growing and reach 30% confluency in 3 days. Feed the 
plates every other day until they reach about 80-85% confluency. Note that 
they grow much slower than other cell lines 
8. To plate cells for experiments, first coat substrate with 100ug/mL growth 
factor reduced Matrigel (BD # 356231) diluted in HG-DMEM for 2 hours, then 
rinse 2X with cold HG-DMEM. Add warmed GM and seed HSkM. Note: to 
trypsinize, rinse 1-2 times with sterile DPBS-/- before adding 0.05% 
trypsin/EDTA (Gibco 25300-054) 
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APPENDIX E. Matrigel Coating Protocol 
Updated by CC on Jan2010 
 
Materials: 
 Phenol-free growth-factor-reduced (GFR) Matrigel (BD Biosciences) 
 HG-DMEM (11995, Gibco) 
 6-well plates 
 DPBS +/+ (14040, Gibco) 
 Growth Media 
 
Protocol: 
1. Place phenol-free Matrigel on ice and place in sterile hood 
2. Thaw Matrigel on ice (thaw out entire aliquot and mix by tipping tube!) Keep 
on ice to prevent solidification! 
3. Using concentration given on chemical sheet, dilute stock Matrigel to 
100μg/ml using cold HG-DMEM; make enough for 2ml per well. 
4. Incubate for 2 hours at 37oC 
5. After incubation, rinse 2X with cold DMEM 
6. Plate cells onto Matrigel-coated well 
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APPENDIX F. HSkM Isolation Protocol 
Updated on 9.5.2012 by C.Cheng 
Contributions from Dorothy Slentz, Yasser El-Abd 
Dr. Kraus and Dr. Truskey, Duke University 
 
Stage 1: Isolation 
Day before isolation 
1. Make sure that the forceps, scalpel, glass petri dish to be used are packaged 
sterile or autoclaved. 
2. Check for stock of trypsin cocktail, HBS (HBSS), growth media, and both 
collagen and non-coated T25 flasks. 
Day of Isolation (Day Zero) 
1. Obtain the muscle biopsy in a conical or vial of ice-cold DMEM.  
2. Place muscle under laminar flow hood. Collect required sterile supplies: glass 
petri dish, scalpel, pair of forceps. 
3. Aspirate excess media, leaving only 2-5ml of liquid to keep muscle moist. 
4. Using forceps, carefully move tissue onto glass petri dish. Clean it from any 
fat, connective tissue, blood clots, etc.  
5. Add 0.5ml HBS (Ca and Mg free) and begin mincing muscle tissue using 
scalpel and forceps. Dissect away fat, connective tissue, and blood clots 
missed in first cleaning. 
6. Once the tissue has been cut into fine pieces (less than 1-2mm in width), add 
about 4.5ml HBS to petri dish. 
7. Using 5ml pipette, transfer minced muscle tissue into 50ml conical and bring 
total volume up to 20ml (do this through 5ml aliquots, rinsing petri dish with 
each wash). *Note: keep muscle in tip of pipette to avoid muscle getting stuck 
to side of pipette. 
8. Centrifuge muscle at 550xg for 10min 
9. Aspirate supernatant and resuspend in 20ml HBS. Recentrifuge at 550xg for 
10min. This will rid cells of any Ca/Mg that was present in the growth media 
(necessary for trypsin to work). 
10. Aspirate supernatant, resuspend pellet in 5ml warmed trypsin cocktail (see 
recipe, attached). Place tube to incubate in 37C shaker water bath for 30min. 
Swirl tube periodically by hand during incubation. Note: do not refreeze any 
leftover trypsin cocktail, as effects on the solution of multiple thaws are not 
known. 
11. Once the 30min incubation is done, add 15ml warmed growth media (see 
recipe, attached). Centrifuge tissue at 550xg for 10min. 
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12. Aspirate trypsin and resuspend tissue in 3.2ml growth media. Note: you 
want volume to be low 
13. Preplate cells onto uncoated T25 flask for 3 hours at 37C. This will allow time 
for cells other than undifferentiated skeletal myoblasts to adhere to T25 flask. 
14. After preplate is complete, carefully transfer media and unattached cells 
(including tissue) to collagen-coated T25 flask. Make sure to gently flush 
down the muscle stuck on the sides of the preplated T25. 
15. Place flask in 37C incubator. 
Day 3 
1. Add 3ml warmed growth medium to T25 flask. Make sure that the flask is 
lying down and add the growth media slowly, to disturb the myoblasts as 
little as possible. 
Day 8 
2. Change media in T25 flask. Keep the total volume at 6ml. Try to take up as 
much of the old liquid as possible without drawing up any tissue in the 
process. 
3. Continue to change the media every 5 days, as the human cells tend to grow 
fairly slow. Culture should reach about 60-75% confluency around 4-5weeks.  
Stage 2: Expansion 
At this point, you should have a single collagen-coated T25 flask in which the 
original muscle sample was grown. The confluency of the cells should be 
approximately 60-75%, yielding roughly 106 cells total. 
1. Aspirate the old media and wash twice with 1X PBS (add about 2ml) 
2. Add 2ml of 0.05% trypsin (this is not the trypsin cocktail used in the 
isolation!). Keep track of passage number. Rock the plate back and forth to 
immerse the cells in the trypsin. View underneath the microscope 
periodically to see that the cells have detached. 
3. When the cells have detached, add 7ml of growth media to the T25 flask. This 
will stop the trypsinizing process. Transfer the solution to a new 15ml conical 
tube. 
4. Mix the cell suspension and take out a small aliquot to count the cells. 
Determine the concentration and the total number of cells. 
5. Pellet the cells for 5min at 1000rpm in the centrifuge 
6. While the cells are in the centrifuge, prepare 3 100mm collagen-coated petri 
dishes with 8ml warmed growth media added to each plate. 
7. After the centrifuge, aspirate the media solution in the tube and add 6ml of 
the growth media to resuspend the cells. Split the cell solution evenly among 
the 3 petri dishes. 
8. Mix gently by moving the plates side to side. The cells should start sitting 
down within 1-2 hours. 
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9. Check the cells every day; change media every other day. Cells should reach 
about 90% confluency within 1 week. 
Stage 3: Storage 
At this point, you should have 3 petri dishes that have reached 90% confluency 
1. Aspirate the old media. Wash 2X with 7-8ml of 1X sterile PBS. 
2. Add 2ml of trypsin to each plate. Warm up and tap to loosen the cells. 
3. Add 8ml of growth media to stop the trypsinizing process. Wash down the 
petri dish with the growth media to make sure all of the cells are collected. 
Transfer the entire solution to a 50ml conical. 
4. Count the cells using the hemacytometer. Should have at least 6E6 cells total. 
5. Centrifuge the 50ml conical containing the cell solution at 100rpm for 5min.  
6. Aspirate the trypsin/media solution. Make freezing solution: 10% DMSO in 
growth media. Resuspend cells so that there are 0.5E6 cells/ml 
7. Aliquot 1ml of cell solution to cryovial. Label with patient ID, date, passage 
number, and initials. Place in Frosty and keep in -20C for 24 hours. Then 
transfer to -80 freezer. 
Stage 4: Thawing/expanding cells 
At this point, the cells should be stored in the -80C freezer. Their concentration 
should be 0.5E6 cells/vial. 
9. Before thaw, warm up growth media. 
10. Thaw the cryovial containing the cell solution quickly at 37C with agitation 
11. Transfer the contents of the vial to a 15ml conical containing 9ml of warm 
growth media 
12. Pellet the cells for 5min at 100rpm 
13. Aspirate the media and add fresh media to resuspend the cells 
14. Transfer cell solution evenly between uncoated tissue culture flasks. Label 
flasks with date, patient ID, passage number, and initials. 
15. Cells should start growing and reach 30% confluency in 3 days. Feed the 
plates every other day until they reach about 80-85% confluency. Note that 
they grow much slower than other cell lines 
Trypsin Cocktail Recipe 
Final Concentration  For 50ml 
0.25% trypsin   5ml 10X trypsin (2.5) (Invitrogen 15090-046) 
0.1% collagenase  0.05g collagenase (Invitrogen 17104-109) 
0.1% BSA   5ml 1% BSA (Sigma A-7888) 
0.05% EDTA   1.25ml 2% EDTA (Sigma E-6511) 
    Sterile water to 50ml 
 
Weight out collagenase into 50ml conical 
In the tissue culture hood add EDTA, BSA, trypsin 
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Add water in the hood 
Filter (0.2μm) sterilize and aliquot 5ml/15ml tube 
Store at -20C 
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Materials 
Company Product Cat Number Application 
Invitrogen (Gibco) Hanks’ Balanced Salt 
Solution (HBSS)(1X)(liquid 
100ml) 
14170-120 Isolation 
 Trypsin/EDTA (0.05%) 1X 
liquid 100ml 
25300-054 Splitting after isolation 
 Trypsin 2.5% (10X) 100ml 15090-046 Trypsin cocktail 
 Type IV collagenase (1g) 17104-019 Trypsin cocktail 
 DMEM low glucose 11885 Growth media 
 DMEM high glucose 11995 Differentiation media 
Hyclone Fetal Bovine Serum 500ml SH30071.03HI Growth media 
 Horse Serum heat inactivated SH30074.04HI Differentiation media 
Sigma EDTA E-6511 Trypsin cocktail 
 BSA A-7888 Trypsin cocktail 
 DMSO D-2650 Freezing media 
Lonza SkGM Singlequots CC-4139 Growth media 
VWR Biocoat collagen I coated 
dishes (by BD) 
62405-425 (100mm 
dish) 62405-025 (T25) 
Isolation  
 No. 10 scalpel blades (pk 10) BD371110 isolation 
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APPENDIX G. HSkM Muscle Bundle Protocol 
C.Cheng, 5/2013 
Materials: 
Sterile forceps   ice+bucket   12-well culture plate 
45μl PDMS molds  2% pluoronics solution minutien pins 
Velcro (cut into small pieces) 70% ethanol   100ml media bottle 
Sonicator   0.05% trypsin/EDTA  sterile PBS-/- 
10ml syringe+needle  Syringe filter   Growth media 
Fibrinogen (Sigma F8630) Thrombin (T9649, 50U/ml) Matrigel (BD, 356231) 
 
Methods: 
 
Sterilization of PDMS molds 
1. Rinse molds with DI water (soak for 15 minutes) 
2. Using sterilze forceps, transfer all molds to 100ml glass media bottle 
containing 70% ethanol. Make sure all molds are submerged in the ethanol. 
Sonicate for 60 minutes. 
3. Place molds in 12 well plate to dry (about 1 hour). Unused molds can be kept 
in the ethanol until needed. 
4. In the meantime, place pins and Velcro in 70% ethanol to soak for 1 hour. 
5. Once molds are dry, UV for at least 30 minutes. Place pins and Velcro in a 
petri dish and UV along with molds. 
6. After UV, place 2% pluronics solution in each mold and place in incubator 
(anywhere from 20-60min). Do not place pins and Velcro in pluronics! Pins 
and Velcro should remain in petri dish in hood to continue drying. 
7. Aspirate pluronics solution and check that no liquid remains. Pin Velcro into 
molds and set aside. 
Seeding HBAM (Human Bioartificial Muscle) 
1. Gather the following materials: ice, sterile forceps/tweezers, thrombin, 
Matrigel, growth media (GM). Place thrombin, Matrigel, and GM on ice.  
2. Make fibrinogen fresh each time: weigh out 15mg and dissolve in 1ml sterile 
PBS-/-. Use syringe filter to sterilize. Label and place on ice with other 
reagents. 
3. Warm 0.05% trypsin/EDTA and GM. Rinse hSKM with sterilze PBS-/- and 
add trypsin/EDTA. Make sure cells are detached after 3 min, if not wait 
another 2 minutes. Stop action of trypsin with warm GM. Transfer cell 
solution to 50ml conical and count cells using hemacytometer. Calculate 
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volume to centrifuge in order to seed 15E6 cells/mL. Spin cells at 1000rpm for 
5 min. 
4. After spin, aspirate all supernatant, leaving only cell pellet. Resuspend in 
cold GM. Add Matrigel and fibrinogen. Finally, add thrombin and quickly 
pipet 45μl into each mold. (Note: thrombin starts the fibrin gel formation, so 
work quickly!) Make sure the mixture is pipetted around and into the Velcro 
for anchoring! 
5. Place 12-well plate into incubator to gel for 1 hour. During this time, make 
GM supplemented with 1.5mg/ml aminocaproic acid (ACA) – syringe filter 
for sterility.  
6. After 1 hour, gently add GM+ACA on top of molds and gels, making sure to 
keep molds from floating to top. 
7. After 48 hours, change media to 2%SM+ACA (again, 1.5mg/ml ACA but now 
dissolved into 2% shift media) 
8. Culture for 2 weeks, exchanging 2%SM+ACA every other day. Then, treat 
with drugs and/or measure forces. 
 2 HBAMs (1 mold) 4 HBAMs (2 
molds) 
6 HBAMs (3 
molds) 
Matrigel 20 μl 38 μl 56 μl 
15mg/ml 
Fibrinogen 
26.7 μl 50.7 μl 74.7 μl 
50U/ml Thrombin 3.9 μl 7.5 μl 11 μl 
Cell solution (in 
GM) 
49.4 μl 93.9 μl 138.3 μl 
Total (45ul/HBAM) 100 μl 190 μl 280 μl 
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APPENDIX H. Immunostaining Protocol 
1. Aspirate media from all wells and rinse once with DPBS-/- (does not need to 
be sterile). Aspirate all DPBS. 
2. Add ice-cold methanol (3mL/well) to wells to fix cells. Let sit at RT for 2-3 
minutes. You may see white residue in the well (this is ok). Aspirate 
methanol and rinse twice with DPBS-/-. 
3. Store cultures in DPBS-/- in fridge until ready to stain.  
4. Aspirate DPBS-/- from wells and block for at least 1 hour with 10% goat 
serum on rocker at RT (up to overnight is fine). 
5. Aspirate goat serum and add primary antibody solution (diluted in 10% goat 
serum, see Table below). Incubate for at least 4 hours (up to overnight) on 
rocker at RT. 
6. Aspirate primary antibody solution and rinse 3X with DPBS-/- (5 min/wash, 
on rocker). 
7. Make secondary antibody solution (Alexa Fluor, 1:250 dilution in DPBS-/-) 
and incubate for 45 minutes, protected from light (foil) on rocker at RT. 
8. Wash 3X with DPBS-/- (5min/wash on rocker). Add 3 mL DPBS-/- to each 
well and image. 
Antibody Species Dilution Vendor/Cat# 
Sarcomeric alpha-actinin (SAA) Mouse 1:800 Sigma, A7811 
Collagen IV Rabbit 1:500 AbCam, ab6586 
Laminin Rabbit 1:500 AbCam, ab11575 
Fast myosin heavy chain Rabbit 1:500 AbCam, ab91506 
Slow myosin heavy chain Mouse 1:500 AbCam, ab11083 
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APPENDIX I. HSkM miR Transfection Protocol 
Updated by C.Cheng 12/2009, taken from CRIII Lab Notebook p. 8C 
Updated by C.Cheng 3/2014 
 
Materials 
 T75 flasks 
 GM 
 Opti-MEMI Reduced Serum Media 1X (Life Technologies 31985-070) 
 siPORT NeoFX Transfection Agent (Life Technologies AM4511) 
 Negative Control #1 (NC#1; Life Tech AM17010) 
 Anti-miR  
Anti-miR-133a: Life Technologies AM17000 ID AM10413 
Anti-miR-696: Life Technologies AM17000 ID AM11434) 
 
Methods 
1. Bring up HSkMs into T75 flasks.  Grow to 75-80% confluence. 
2. Warm up Growth Media (GM) 
3. Prepare transfection solutions: NTC, NC, A133a, A696, Joint (A133a+A696) 
 
NTC: non-transfected control 4.9ml Opti-MEM 
NC: negative control 
(tranfected with scrambled 
miR sequence) 
98.28 μl siPORT + 2.36ml Opti-MEM 
196.56 μl NC#1 + 2.26ml Opti-MEM 
A133a: transfected sample 98.28 μl siPORT + 2.36ml Opti-MEM 
196.56 μl anti-miR-133a + 2.26ml Opti-
MEM 
A696: transfected sample 98.28 μl siPORT + 2.36ml Opti-MEM 
196.56 μl anti-miR-696 + 2.26ml Opti-MEM 
Joint: transfected sample 98.28 μl siPORT + 2.36ml Opti-MEM 
196.56 μl anti-miR-133a + 196.56 μl anti-
miR-696 + 2.26ml Opti-MEM 
 
4. Place each transfection solution into a different T75 flask and spread evenly 
on the bottom of the flask. Let sit for at least 10 minute to equilibrate to RT. 
5. Passage cells at 75-80% confluence. Resuspend cells in warm GM and place 
1E6 cells/flask into flasks with tranfection solutions. Make sure to clearly 
label each flask to avoid confusion! 
6. Add warm GM to each T75 (for a total of 19.7ml of GM and 4.9ml 
transfection solution in each T75) 
7. Place in incubator and allow transfection to sit for 18 hours (do not exceed!) 
8. After 18 hours, trypsinize and count cells for studies. 
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APPENDIX J. miR Isolation Protocol 
Updated on 11.21.2011 by C.Cheng 
Life Technologies mirVANA microRNA Isolation Kit (Cat# AM1560) 
 
Setup/Prep 
1. RNasZap benchtop, pipettors, and tip of Pasteur pipette 
2. Get bucket of ice from autoclave room 
3. Gather two 1.5-2.0 RNase/DNase-free tubes per sample/condition and two 
tubes from mirVANA miR isolation kit box (one filter per 2 tubes) 
4. Label tubes with conditions, hSKM ID#, SD#, and date 
5. Get box of miR isolation solutions from fridge, place Lysis Buffer and miR 
homogenate additive on ice. Let Wash Solutions #1 and #2/3 equilibrate to 
RT. Aliquot 110 μl/condition of Elution Solution and place on heating block 
(on HIGH with dial turned to KO – should be around 95oC). 
6. Gather plate(s) from incubator and place on ice. 
Cell Lysis Procedure 
1. Aspirate media, rinse 1X with 1000 μl DPBS and aspirate. Add 500 μl DPBS 
to each well and use cell scraper to collect sample. Be sure to use new scraper 
and pipette tip for each condition! 
2. Centrifuge samples at 10k rpm for 5 minutes. While spinning, discard plates 
and scraper wrappers. After pelleting cells, aspirate DPBS 
3. Resuspend each cell pellet in 300 μl Cell Lysis Buffer; vortex each tube for 1 
min (the lysis buffer tends to drip, so make sure tubes are open and ready!) 
4. Add 30 μl miR homogenate additive to each tube. Vortex for 15sec. Incubate 
on ice for 10min. 
5. Return Cell Lysis Buffer, miR homogenate additive, and Elution Solution to 
the fridge. Keep Wash Solutions out to reach RT. 
Organic Extraction: all steps to be done in fume hood! 
1. Before the 10-min incubation is complete, gather pipettors (P200 and P1000) 
and tubes and take to fume hood.  
2. Double-glove with nitrile gloves and wear lab coat! 
3. Get metal canister from top shelf of large fridge. Be very careful 
carrying/handling this chemical! It is toxic! Take to fume hood and carefully 
remove bottle from canister and open lid.  
4. Make sure all tubes are open and pipette 300 μl from the bottom phase of the 
chemical into each tube. You may use the same pipette tip if you do not touch 
any tubes! (Try to be quick and very careful! The chemical tends to drip) 
5. Close bottle and all tubes *carefully*, place bottle back into canister and 
promptly return to fridge. 
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6. Vortex each tube 1 min in the fume hood. Minimize exposure by closing 
doors as much as possible. 
7. Use centrifuge in fume hood to spin for 5min at 10k rpm. 
8. After spin, carefully remove each tube and pipette out upper phase and 
transfer into new tube (about 300-320 μl). Discard lower phase into waste 
bottle and used tubes into biohazard in fume hood. 
9. Add 430ul 100% Ethanol to each tube, pipette to mix and transfer 700 μl to 
filter. Spin for 15sec at 10k rpm 
10. Pipette waste into waste bottle, add 700 μl Wash Solution #1 to each filter. 
Spin for 15sec at 10k rpm 
11. Discard waste into waste bottle, add 500 μl Wash Solution #2/3.Spin for 15sec 
at 10k rpm.  
12. Repeat Step #11 above 
13. Dry spin for 1min at 10k rpm. During spin, get warmed Elution Solution, 
turn off heat block. 
14. Transfer each filter to correspondingly labeled clean tube, pipette 100 μl 
warm Elution Solution and spin for 15sec at 10k rpm. 
15. Discard filters and store in -80C until RT-PCR. 
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APPENDIX K. TAQMAN qRT-PCR for miR Expression 
C.Cheng, created 7.19.2010; Updated 11.01.2010 
 
Materials Needed 
 miR samples isolated previously (frozen in -80oC freezer) 
 RNase/DNase-free water 
 20, 200, 1000 μl barrier tips 
 Appropriate primers for RT and Real Time PCR reactions 
 Endogenous control 
 Reference RNA (isolated or bought) 
 TaqMan MicroRNA Reverse Transcription Kit (ABI: 4366596, 4366597) 
 TaqMan Universal PCR Master Mix, No AmpErase UNG (ABI: 4324018) 
 DNase/RNase-free tubes (0.2ml, 2.0ml) with caps 
 96-well optical plate for PCR 
 
miR Purity 
1. After miR isolation, aliquot samples and take to NanoDrop ND-1000 (outside 
CIEMAS 2208B) to measure purity and concentration 
2. Log in, open program 
3. Choose RNA Assay and Blank once 
4. Place 1ul of sample carefully on NanoDrop and click Measure 
5. Record 260/280 and RNA concentration 
6. Calculate amount of nuclease-free water to add to dilute to 1-10ng of total 
RNA per 15 μl reaction 
 
Reverse Transcription (RT) Reaction 
1. Calculate number of reactions to perform. 
2. Prepare RT Master Mix (MM) by scaling volumes to desired number of RT 
reactions. Account for 10% pipetting loss; mix by pipetting up and down. 
 
Color Tube Reagent/Component Volume for 1 
reaction 
Volume for N 
reactions 
Yellow 10X RT Buffer 1.5 μl (1.5ul)(N)(1.1) 
Blue dNTP mix 0.15 μl (0.15ul)(N)(1.1) 
White RNase Inhibitor 0.19 μl (0.19ul)(N)(1.1) 
Purple Multiscribe RT 
enzyme 
1.00 μl (1.00ul)(N)(1.1) 
-- Nuclease-free water 4.16 μl (4.16ul)(N)(1.1) 
TOTAL for 1 
RT reaction 
 7.0 μl (7.0ul)(N)(1.1) 
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3. Add 5ul of total RNA (for final concentration of 1-10ng/reaction) to RT MM. 
Mix gently by pipetting up and down. 
4. Thaw primers on ice and centrifuge briefly. Label tubes. 
5. Place 12 μl of RNA + MM mix into each labeled tube. 
6. Add 3 μl of RT primer to appropriate tubes for a final volume of 15 μl. Mix 
by pipetting. Seal with caps. 
7. Centrifuge, place plate on ice for at least 5 minutes. Load thermal cycler. 
8. Set thermal cycler at reaction volume of 15 μl and start run listed below: 
 
STEP TIME TEMP 
Hold 30 min 16oC 
Hold 30 min 42oC 
Hold 5 min 85oC 
Hold ∞ 4oC 
 
qPCR Amplification 
1. Use clean 1.5ml microcentrifuge tubes for each sample (Nuclease-free!) 
2. To each tube add the following volumes for triplicates: 
 
Component Single Reaction Triplicate Reaction 
TaqMan RNA Assay (20X) – primer 1.00 μl 3.60 μl 
Product from RT reaction 1.33 μl 4.80 μl 
TaqMan Universal PCR Master Mix II (2X) 10.00 μl 36.00 μl 
Nucelase-free water 7.67 μl 27.61 μl 
TOTAL Volume 20.00 μl 72.01 μl 
 
3. Cap tube and invert to mix. Centrifuge. 
4. Transfer 20 μl of qPCR reaction mix to 3 corresponding wells on a 96-well 
optical plate. Place optical plate on ice pack to keep cold. 
5. Seal plate with cover and centrifuge. 
6. Load into instrument. Be sure to use “Erase” to denote empty wells. Setting 
on thermal cycler should be set to Standard Run Mode and Sample Volume 
of 20 μl. Thermal cycling conditions are below: 
 
STEP TIME TEMP 
Enzyme Activation Hold 10 min 95oC 
PCR (40 cycles) 
Denature 15 sec 95oC 
Anneal 60 sec 60oC 
 
Setting up RT-PCR Plate with Reference and Housekeeping Gene 
Investigating treatments A, B, and C 
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Looking at genes 1, 2, 3 
Common housekeeping genes: 18s, GAPDH, beta-2-microglobulin. 
 Housekeeping genes are primers that you use to test that the Ct values for all 
treatments of interest are the same (or very similar) 
 
References are samples that must be constant through every RT-PCR plate!  
 Can be anything, but must contain some quantity of the genes of interest.  
 Can either collect RNA and aliquot into many many tubes, or order an RNA 
sample from a company. Since miR’s are low in quantity, will order Mouse 
11-day Embryo Total RNA (Cat. No. 636608) from Clontech 
 
Sample plate setup: 
 A A A B B B C C C REF REF REF 
1 A1.1 A1.2 A1.3 B1.1 B1.2 B1.3 C1.1 C1.2 C1.3 REF1.1 REF1.2 REF1.3 
2 A2.1 A2.2 A2.3 B2.1 B2.2 B2.3 C2.1 C2.2 C2.3 REF2.1 REF2.2 REF2.3 
3 A3.1 A3.2 A3.3 B3.1 B3.2 B3.3 C3.1 C3.2 C3.3 REF3.1 REF3.2 REF3.3 
HS AH.1 AH.2 AH.3 BH.1 BH.2 BH.3 CH.1 CH.2 CH.3 REFH.1 REFH.2 REFH.3 
             
             
             
             
             
 
Note: HS = housekeeping gene; run samples in triplicate 
 
Once the plate is run and the raw data retrieved, average each triplicate set and use 
the Housekeeping gene to calculate ΔCt. Let A1 = average of A1.1 and A1.2 and 
A1.3, and so on. 
 
 ΔCtA1=A1-AH 
 ΔCtA2=A2-AH 
  : 
  : 
 ΔCtB2=B2-BH 
  : 
  : 
 ΔCtC3=C3-CH 
 
After finding ΔCt, use the Reference to find the ΔΔCt: 
 
 ΔΔCtA1= ΔCtA1 – REF1 
 ΔΔCtA2= ΔCtA2 – REF2 
  : 
  : 
 ΔΔCtC3= ΔCtC3 – REF3 
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Finally, calculate 2-ΔΔCt to find fold-difference of each sample from the 
Reference. 
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APPENDIX L. SYBR Green qRT-PCR Protocol 
3June2012 
 
Measuring RNA Concentration using Nanodrop (NOTE: Avoid rethaw cycles as RNA 
degrades quickly. Keep RNA samples in labtop cooler/on ice.) 
1. Place RNA samples (and REF sample) in cooler and grab nuclease-free water, P2 
pipette, and 10 μl filter tips. 
2. Log into computer (username: microarray, password: nanodrop) and select ND-
1000 V3.7.1 >> Nucleic Acids. 
3. Wipe down stage with Kimwipe. Add 1 μl of nuclease-free water onto the stage 
and click “ok” in the initialization window that pops up. 
4. Change DNA-50 (green) to RNA-40 (pink) using the pull-down menu in the 
upper-right corner. 
5. Click “Blank” in the upper-left corner. 
6. Wipe down stage with Kimwipe. Add 1μl of sample onto the stage and click 
“Measure” in the upper-left corner.  
7. Record the RNA concentration (ng/μl), A260/280, and A260/230 of the sample. The 
A260/280 purity level should be ~2; the A260/230 purity level should be ~2.5. 
8. Repeat steps 6-7 for each RNA sample. 
9. After measuring the last sample, wipe clean the stage.  
10. Exit out of the program and log off 
 
Making cDNA (NOTE: Complete RT on the same day that the RNA concentration 
measurements are made to avoid freezing and rethawing RNA samples.) 
1. Calculate the appropriate volume (μl) of RNA sample needed for a desired x ng 
of RNA. This is done by dividing x ng by RNA concentration in μg/μl.  
2. Calculate the volume (μl) of nuclease-free water such that the total amount of 
nuclease-free water + RNA sample is 18μl. 
3. Wipe down bench, pipettes, and gloves with RNAse Zap. Grab the 96-well 
freezer boxes in the -20°C freezer pull-out shelf and wipe down the lid with 
RNAse Zap. 
4. Add 5x iScript Reaction Mix (blue tube) and iScript Reverse Transcriptase 
(yellow tube) to ice bucket. 
5. Take a 0.2ml colored reaction tube for each sample and place in the 96-well 
freezer box.  
6. Add the calculated amount of nuclease-free water to the reaction tubes. 
7. Add the calculated amount of RNA to the reaction tubes. 
8. Add 5μl of the 5x iScript Reaction Mix (blue tube) to each reaction tube. 
9. Add 1.25μl of the iScript Reverse Transcriptase (yellow tube) to each tube 
(NOTE: This is the polymerase that initiates the reaction, so add this component 
last.). 
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10. Mix by gently pipetting up and down (NOTE: Do not vortex.). 
 
If thermocycler is available for use, continue through steps 11-17; if not, skip to step 
18.  
11. Turn the thermocycler on by switching the button on the power supply box first 
followed by switching on the unit. Place the tubes inside.  
12. Select Registered User >> Duke. 
13. Select F1 (Protocol Library) >> cDNA 
14. Select Run Protocol and set the sample volume to 25μl 
15. Select F5 (Begin Run) 
16. Sample will take about 45 minutes to run. Once the RT process is complete, you 
may choose to complete the PCR step or wait to complete the PCR a different 
day (PCR takes 2.5hr to complete) and store the cDNA in the -20°C freezer in a 
sample box.) 
17. If you choose to complete the PCR on a different day, turn the thermocycler off. 
 
If thermocycler is being used, you may use the MWG-Biotech thermocycler at the 
RNA station.   
 
18. Turn the thermocycler on (behind the machine above the plug) (NOTE: Be 
careful when moving the thermocycler to avoid unplugging the machine.). 
19. Select 2. Select Protocol >> 25-42.cyc. 
20. Continue selecting Run/Enter until the thermocycler begins. 
21. Sample will take about 45 minutes to run. Once the RT process is complete, you 
may choose to complete the PCR step or wait to complete the PCR a different 
day (PCR takes 2.5hr to complete) and store the cDNA in the -20°C freezer in a 
sample box.) 
22. If you choose to complete the PCR on a different day, turn the thermocylcer off. 
 
PCR (NOTE: Keep everything on ice or in freezer boxes during this process as this step is 
heat-sensitive; also, turn off the lights as this step is light-sensitive.) 
1. Wipe down bench, pipettes, and gloves with RNAse Zap. Grab cDNA samples 
and dilute with 20μl of RNA-ase/DNA-ase free water; mix gently by pipetting up 
and down (NOTE: Be sure to mark that the samples have been diluting to avoid 
confusion with undiluted cDNA samples.). 
2. Take two freezer boxes from the -20°C freezer. Wipe down the lids with RNAse 
Zap and place a 96-well PCR plate in the freezer box. (NOTE: Make sure that you 
do not touch the bottom of the 96-well PCR plate. Hold the plate by its sides to 
avoid initiating the reaction when samples have been aliquoted into the wells.)  
3. Let y be the number of genes of interest (2 in the case of gene of interest, 
PPARGC1A, and housekeeping gene, GAPDH). For x cDNA samples, obtain x*y 
0.2ml clear reaction tubes and place in the second freezer box.  
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4. Place iQ SYBR Green Supermix (orange tube) and primers (both 5’ and 3’ 
primers) in ice bucket. 
5. Let y be the number of genes of interest (2 in the case of gene of interest, 
PPARGC1A, and housekeeping gene, GAPDH). Label a 2.0ml colored microtube 
with the name of the gene for each gene of interest. 
6. Let z be the number of conditions (2 if conducting a study comparing static vs. 
stretch conditions; 2 if Plastic static vs. Bioflex static). Then, combine the 
following reagents in each 2.0ml tube: 
6.6*[(3.5*x*z)+3] μl nuclease-free water 
1.2*[(3.5*x*z)+3] μl 3’ primer for gene of interest 
1.2*[(3.5*x*z)+3] μl 5’ primer for gene of interest 
10*[(3.5*x*z)+3] μl iQ SYBER Green Supermix 
7. Mix solutions by pipetting up and down.  
8. Repeat steps 6-7 for each y 2.0ml tube labeled with the gene of interest.  
9. Add 66.5μl of the solution prepared in step 6 to each of the 0.2ml microtubes 
from step 3.  
10. Add 3.5μl of the cDNA sample from the RT step to each 0.2ml clear reaction 
tube. 
11. Mix the solution by pipetting up or down.  
12. Add 20μl of the mixed solution to each of 3 wells of the 96-well plate (NOTE: 
Add the mixed solution to the side of the well and let it drip down to the bottom. 
Make sure to avoid making air bubbles.). Repeat for the other microcentrifuge 
tubes in an order according to the determined plate set-up. 
13. Cover the 96-well PCR plate with optical tape and secure the cover. 
14. Centrifuge the PCR plate at 1400rpm for 2-3 minutes (NOTE: When transferring 
the PCR plate to the centrifuge, hold by the sides and avoid touching the bottom 
of the plate.). 
15. Place the 96-well PCR plate in the thermocycler. 
16. Open the MyiQ program and select the protocol 2StepAmp+Melt4ebd.tmo. 
17. Select the tab View Plate Setup and select Edit This Plate Setup. 
18. Label each triplicate set with a unite number and erase all blank wells.  
19. Save the plate setup and click Run with Selected Protocol. Enter in 20μl and double 
check that SYBR-40 has been selected in the lower right window. Select Begin 
Run. 
20. The thermocycler will run for about 2.5 hours; double check ~10 minutes into the 
process that the program has not exited out due to an error.  
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APPENDIX M. Western Blot Protocol 
Tracy Cheung 
April 2011 
Modified from CR and SW Protocols 
 
Materials 
 Lysis Buffer: CellLytic-M (Sigma C2978)+Protease inhibitor cocktail (Sigma 
P8340) 
 Mini Ready Gel 
 Laemmli’s Sample Buffer (Biorad #161-0737) 
 Beta-Mercaptoethanol (Biorad 161-0710) 
 TBST: Dilute 10x Tris-Buffered Saline (Biorad #170-6435) to 1X with DI water 
and add 0.1 % Tween 20 (Biorad 170-6531) (i.e. 50mL TBS, 450mL DI water, 
0.5mL Tween 20) 
 Transfer Buffer: 100 mL 10x Tris Glycine Buffer (Biorad #161-0771), 700mL 
distilled water, 200mL methanol (if using PVDF membrane, otherwise 900mL 
distilled water) 
 Running Buffer: 100mL 10x Tris/Glycine/SDS Buffer (Biorad #161-0772), 
900mL distilled water 
 PVDF membrane 
 Fiber pads 
 Filter paper 
 Kaleidoscope Ladder (Biorad 161-0375) 
 SuperSignal West Pico Stable Peroxide Solution 
 SuperSignal West Pico Luminal/Enhancer Solution 
 RESTORE Stripping Solution (21059) 
 Pierce BCA Assay Kit (Pierce 23227) 
 Film 
 Non-Fat Dry Milk Powder 
 Primary and Secondary Antibodies 
 Methanol 
 PBS -/- 
 Eppendorf tubes 
 Micropipettes 
 Pipettes 
 96-well plate for BSA 
 50mL and 15mL conical tubes 
 
DAY 1 
Buffer Preparation 
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1. Mix ingredients together for Transfer and Running Buffers and put into 
labeled 1L jars.  These can be stored in the fridge overnight. 
2. Mix ingredients together for TBST.  Tween 20 is very viscous.  Store in fridge 
overnight. 
 
DAY 2 
Protein Harvest (Can be done as cells are ready and stored in -20C) 
1. Prepare Lysis Buffer (KEEP ON ICE) 
 Cell-lytic M (Add 0.5mL protease/phosphatase inhibitor cocktail to 
every 5mL Cell-lytic M used) 
2. Carefully aspirate media from cells.  The whole process should be done on 
ice. 
3. Wash once with cold DPBS -/- 
4. Add DPBS to each flask or well (~400 μl /well). 
5. Scrape cells with cell scraper.  Keep plate tilted at all times in order to keep 
all the cellular debris in the PBS.  Pipette out all liquid and cells.  Add 
suspension to 2.0mL eppendorf tube. 
6. Spin down tubes with microcentrifuge at speed 3 for 5 minutse. 
7. Remove supernant and resuspend cells in ~70 μl of of lysis buffer. 
8. Shake for 30 minutes at 4C with lab quake. 
9. Spin down tubes at max speed for 15 minutes at 4C (place microcentrifuge in 
fridge). 
10. Remove supernatant (this is the protein soluble fraction) and place each into 
sterile vials.  Store in -20C. 
 
BSA Protein Concentration Determination Protocol 
1. Prepare BSA Standards as described in the manual that comes with the BSA 
kit, EXCEPT dilute in lysis buffer rather than PBS.  (Note: The standards can 
be prepared ahead of the time and aliquoted and stored at -20C.) 
2. Prepare BCA indicator solution (# samples + # of samples) * (number of 
replicates) * (volume of indicator solution per sample) = total volume of 
indicator solution needed.  Make the solution with 50 parts Reagent A with 1 
part Reagent B (example: 2500 μl Reagent A, 50uL Reagent B). 
3. Add 100 μl of BCA solution to each well of a 96-well plate. 
4. Add 2 μl of each BSA standard to the wells (do in duplicate in rows A and B 
of plate). 
5. Add 2 μl of each unknown sample to wells (do in duplicate, rows C and D). 
6. Shake for 30s on plate shaker. 
7. Incubate at 37C for 35 minutes. 
8. Read using plate reader in Yuan lab (ABS 590) or Bursac Lab (Mina_BSA). 
 
Prepare Proteins 
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1. Use Excel spreadsheet and BSA results to calculate volume of lysate needed 
to get desired amount of protein (usually, 10μg-30μg). 
2. In 1.5mL eppendorf tubes, add amount of DI water calculated on 
spreadsheet, then add protein lysate (amount specified on spreadsheet). 
3. Make Loading Buffer in a separate 1.5mL tube; solution should be 19 parts 
Laemmli’s Sample Buffer, 1 part BME (calculation on spreadsheet).  This 
should be added 1:1 with the rest of your protein solution (protein+water 
made in step 2), see spreadsheet for calculation.  ADD AND STORE BME in 
fume hood. 
4. Put samples on heat block set at 100C for 5 minutes.  Squirt DI H2O on set to 
help seal space between tube and set.  Make sure tubes are sealed and use 
forceps to poke holes in top of tube so that the pressure does not build up.  
DO NOT BOIL STANDARD. 
 
Run Gel 
1. During 5 minutes-Add gel to box 
a. Cut bottom film from ready gel (leave no black from cut line). 
b. Add gel to box with comb facing inward (push all the way down and 
lock).  The shorter plate faces the inside. 
c. Carefully remove comb. 
d. Add running buffer and then add to box (fill to top in inner and near 
top to outer). 
2. Add protein samples and ladder (15 μl for ladder, usually 30 μl for protein 
samples depending on gel lane size). 
3. Run the gel at 150 volts, max current and power for ~30-45 min (until visible 
bands reach bottom of gel, near wire). 
 
Transfer 
1. While the gel is running, soak the PVDF membrane in 100% methanol. 
2. Soak PVDF membrane, 2 fiber pads, 2 pieces of thin transfer/filter paper in 
transfer buffer right before the gel is done. 
3. Take the gel out of the cassette and gently break it open in transfer buffer.  
Pour out Running Buffer, but DO NOT wash gel box (need a small amount of 
SDS in transfer buffer). 
4. Cut off top and bottom parts of gel with green blade. 
5. Open up the cassette (black and clear parts) and lay the black part down. 
6. Put items in following order on the black part: fiber pad, filter paper, gel, 
PVDF membrane, filter paper, fiber pad.  Roll out air bubbles with pipette 
after you add membrane, paper, and pad. 
7. Cut one corner of the membrane so that you remember which side of the 
membrane is in contact with the gel. 
8. Close and clamp cassette. 
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9. Place the holder into the trans-blot, BLACK FACING BLACK. 
10. Put box in bin (like the small autoclave bin) on stir plate with magnetic stirrer 
set at a 9, add transblot, and BioIce (in freezer). 
11. Fill box to the top with transfer buffer. 
12.  Add ice to the bin to surround the box.  This is to keep the transfer cold. 
13. Set transfer for 200V, 500mA, 40W current for 3 hours for proteins above 
175kDa, 2.5 hours for proteins 100-175kDa, 1.5 hours for 45-100kDa, and 1 
hour for less than 45kDa (RT) and stir at Fast setting. 
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Probe with Antibodies 
14. While transferring, make 5% milk (1g non-fat milk with 20ml TBST) in 50mL 
conical tube and 1% milk (1g non-fat milk with 100mL TBST) in flask.  Add 
stir bar to flask and stir to mix. 
15.  Take apart trans-blot and remove the membrane and put into a tray with 5% 
milk, rock at RT for 1 hour (this can be extended if there is a lot of 
background). 
16. Rinse membrane quickly with 1% milk in TBST. 
17. Place the membrane in 1% milk and add the primary antibody (usually about 
5mL milk needed) at the proper dilution. 
18. Incubate overnight in the cold room using gentle tilting. 
 
DAY 3 
19. Rinse once quickly, then 3X for 10 minutes each in TBST using gentle tilting. 
20. Add secondary antibody to the membrane in 1% nonfat dry milk (usually 
about 1:5000 dilution). 
21. Incubate for 45 minutes at RT using gentle tilting. 
22. Rinse 3X, 10 minutes each in TBST using gentle tilting. 
 
Expose Membrane to Film 
1. In foil-wrapped 15mL conical tube, mix together 2.5mL of SuperSignal West 
Pico Stable Peroxide Solution and 2.5mL of SuperSignal West Pico 
Luminal/Enhancer Solution (1:1 ratio) (ECL Solution). 
2. Lay the membrane on Plastic Wrap and put ECL solution on the membrane 
(~5mL/membrane). 
3. Turn off the lights and let the solution sit on the membrane for 5 minutes. 
4. Transfer membrane with forceps over to new Plastic Wrap which is laid on 
top of a book or the film box. 
5. Add a new piece of Plastic Wrap over the top of the membrane and seal.  Roll 
out any air bubbles with pipette. 
6. Cut Plastic Wrap around membrane. 
7. Place and tape membrane into the cassette. 
8. Take cassette, film, scissors, pen, and timer to the dark room (2nd floor C wing 
of LSRC). 
9. Remove film and cut corner to match the cut corner on the membrane.  Place 
film on membrane, and close cassette.  The film can be cut in half if only one 
membrane is being used. 
10.  Set timer for exposure time (3 minutes is a good place to start). 
11.  Remove film from cassette at end of exposure time, flip over, and add to 
developing machine. 
12. Repeat film exposure with other pieces of film and adjust exposure time as 
necessary. 
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13. Analyze films using densitometry (see protocol below). 
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Strip Membrane (Only necessary if reprobing) 
1. Submerge membrane in RESTORE Stripping Solution (Pierce) and incubate 
at RT for 15 minutes with occasional agitation. 
2. Wash with TBST 3X for 5 minutes each.  Repeat steps 1 and 2 of this section. 
3. Re-block in 5% milk for 1 hour at RT, then can probe for a different primary 
antibody. 
 
Data Analysis – Densitometry Protocol (Using ImageJ Software) 
1. Scan films with scanner. 
2. Open ImageJ Software.  Go to File>Open and open the scanned image of your 
membrane. 
3. Select the rectangle tool and draw a box around your first lane.  Make sure 
that you do not overlap an y other lanes. 
4. Once first lane is selected, go to Analyze>Gels>Select First Lane, or type 
ctrl+1. 
5. Drag box onto the next land and go to Analyze>Gels>Select Next Lane, or 
type ctrl+2.  The box for each lane must be the same size.  Make sure that each 
box encloses only the desired lane and does not overlap with other bands … 
this will create error in your data. 
6. Repeat this until all lanes on your gel have been selected. 
7. Go to Analyze>Gels>Plot Lanes, or type ctrl+3. 
8. Select the line drawing tool and draw a horizontal line even with the baseline 
(no signal) part of the graph for each line.  Make sure that the curve 
corresponding to your band is completely closed in by this line (draw vertical 
lines if necessary to create a closed shape.  NOTE: Your procedure for this 
part isn’t as important as making sure you are consistent with what you do 
for all bands. 
9. Select the wand tool (to the left of the text tool).  Click inside each closed 
curve.  Another box will appear, containing the area of the enclosed area 
(arbitrary units). 
10. If you are using a loading control or standard (such as B-actin), divide the 
numbers you get by the corresponding number for that control for the same 
lane. 
11. Plot your results using excel. 
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APPENDIX N. Copyright Releases 
No permissions are required for reuse of material from American Journal of 
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